0000875320-23-000012.txt : 20230502 0000875320-23-000012.hdr.sgml : 20230502 20230502160733 ACCESSION NUMBER: 0000875320-23-000012 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230502 DATE AS OF CHANGE: 20230502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 23878944 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 10-Q 1 vrtx-20230331.htm 10-Q vrtx-20230331
VERTEX PHARMACEUTICALS INC / MA000087532012/312023Q1falseP1M00008753202023-01-012023-03-3100008753202023-04-25xbrli:sharesiso4217:USD00008753202022-01-012022-03-31iso4217:USDxbrli:shares00008753202023-03-3100008753202022-12-310000875320us-gaap:CommonStockMember2021-12-310000875320us-gaap:AdditionalPaidInCapitalMember2021-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000875320us-gaap:RetainedEarningsMember2021-12-3100008753202021-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000875320us-gaap:RetainedEarningsMember2022-01-012022-03-310000875320us-gaap:CommonStockMember2022-01-012022-03-310000875320us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000875320us-gaap:CommonStockMember2022-03-310000875320us-gaap:AdditionalPaidInCapitalMember2022-03-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000875320us-gaap:RetainedEarningsMember2022-03-3100008753202022-03-310000875320us-gaap:CommonStockMember2022-12-310000875320us-gaap:AdditionalPaidInCapitalMember2022-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000875320us-gaap:RetainedEarningsMember2022-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000875320us-gaap:RetainedEarningsMember2023-01-012023-03-310000875320us-gaap:CommonStockMember2023-01-012023-03-310000875320us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000875320us-gaap:CommonStockMember2023-03-310000875320us-gaap:AdditionalPaidInCapitalMember2023-03-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000875320us-gaap:RetainedEarningsMember2023-03-31vrtx:segment0000875320vrtx:TRIKAFTAKAFTRIOMember2023-01-012023-03-310000875320vrtx:TRIKAFTAKAFTRIOMember2022-01-012022-03-310000875320vrtx:KalydecoMember2023-01-012023-03-310000875320vrtx:KalydecoMember2022-01-012022-03-310000875320vrtx:ORKAMBIMember2023-01-012023-03-310000875320vrtx:ORKAMBIMember2022-01-012022-03-310000875320vrtx:SYMDEKOSYMKEVIMember2023-01-012023-03-310000875320vrtx:SYMDEKOSYMKEVIMember2022-01-012022-03-310000875320country:US2023-01-012023-03-310000875320country:US2022-01-012022-03-310000875320srt:EuropeMember2023-01-012023-03-310000875320srt:EuropeMember2022-01-012022-03-310000875320vrtx:OtherNonU.S.Member2023-01-012023-03-310000875320vrtx:OtherNonU.S.Member2022-01-012022-03-310000875320us-gaap:NonUsMember2023-01-012023-03-310000875320us-gaap:NonUsMember2022-01-012022-03-310000875320vrtx:CRISPRTherapeuticsAGMember2019-01-012019-12-31vrtx:target0000875320vrtx:CRSIPRJDCAMember2021-04-012021-06-300000875320vrtx:CRSIPRJDCAMember2021-07-01xbrli:pure0000875320vrtx:CRISPRMembervrtx:CRSIPRJDCAMember2021-07-010000875320vrtx:CRSIPRJDCAMember2023-01-012023-03-310000875320vrtx:CRSIPRJDCAMember2022-01-012022-03-310000875320vrtx:CRISPRT1DMember2023-03-012023-03-310000875320vrtx:EntradaTherapeuticsMember2023-02-012023-02-280000875320us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000875320us-gaap:EmployeeStockOptionMember2022-01-012022-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310000875320us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000875320us-gaap:EmployeeStockOptionMember2022-01-012022-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2023-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2023-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2023-03-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2023-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2022-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2022-12-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000875320us-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:EquitySecuritiesMember2023-03-310000875320us-gaap:FairValueInputsLevel3Member2023-03-310000875320us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Membersrt:MinimumMember2023-03-310000875320us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Member2023-03-310000875320us-gaap:MoneyMarketFundsMember2023-03-310000875320us-gaap:MoneyMarketFundsMember2022-12-310000875320us-gaap:BankTimeDepositsMember2023-03-310000875320us-gaap:BankTimeDepositsMember2022-12-310000875320us-gaap:USTreasurySecuritiesMember2023-03-310000875320us-gaap:USTreasurySecuritiesMember2022-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-03-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-12-310000875320us-gaap:CorporateDebtSecuritiesMember2023-03-310000875320us-gaap:CorporateDebtSecuritiesMember2022-12-310000875320us-gaap:CommercialPaperMember2023-03-310000875320us-gaap:CommercialPaperMember2022-12-310000875320us-gaap:AssetBackedSecuritiesMember2023-03-310000875320us-gaap:AssetBackedSecuritiesMember2022-12-310000875320us-gaap:CertificatesOfDepositMember2023-03-310000875320us-gaap:CertificatesOfDepositMember2022-12-310000875320us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2023-03-310000875320us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310000875320vrtx:MarketableSecuritiesAndOtherNoncurrentAssetsMember2023-03-310000875320vrtx:MarketableSecuritiesAndOtherNoncurrentAssetsMember2022-12-310000875320us-gaap:CashAndCashEquivalentsMember2023-03-310000875320us-gaap:CashAndCashEquivalentsMember2022-12-310000875320vrtx:MarketableSecuritiesMember2023-03-310000875320vrtx:MarketableSecuritiesMember2022-12-310000875320vrtx:MarketableSecuritiesNoncurrentMember2023-03-310000875320vrtx:MarketableSecuritiesNoncurrentMember2022-12-310000875320us-gaap:OtherAssetsMember2023-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMembersrt:MinimumMember2023-01-012023-03-310000875320srt:MaximumMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-03-310000875320currency:EURus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-03-310000875320currency:EURus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320currency:GBPus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-03-310000875320currency:GBPus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320currency:CADus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-03-310000875320currency:CADus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:CashFlowHedgingMembercurrency:AUDus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-03-310000875320us-gaap:CashFlowHedgingMembercurrency:AUDus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320currency:CHFus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-03-310000875320currency:CHFus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-03-310000875320us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-03-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-03-310000875320us-gaap:OtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-03-310000875320us-gaap:OtherAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-03-310000875320us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-03-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:OtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:OtherAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:RestrictedStockMember2023-01-012023-03-310000875320us-gaap:RestrictedStockMember2022-01-012022-03-310000875320us-gaap:EmployeeStockMember2023-01-012023-03-310000875320us-gaap:EmployeeStockMember2022-01-012022-03-310000875320us-gaap:CostOfSalesMember2023-01-012023-03-310000875320us-gaap:CostOfSalesMember2022-01-012022-03-310000875320us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310000875320us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-3100008753202023-02-280000875320us-gaap:RevolvingCreditFacilityMember2022-07-310000875320us-gaap:LetterOfCreditMember2022-07-310000875320us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MinimumMember2022-07-012022-07-310000875320us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:BaseRateMember2022-07-012022-07-310000875320us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MinimumMember2022-07-012022-07-310000875320srt:MaximumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-07-012022-07-310000875320us-gaap:RevolvingCreditFacilityMember2022-07-012022-07-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM    TO   
Commission file number 000-19319
____________________________________________
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction of incorporation or organization)

50 Northern Avenue, Boston, Massachusetts
(Address of principal executive offices)

04-3039129
(I.R.S. Employer Identification No.)

02210
(Zip Code)

Registrant’s telephone number, including area code (617) 341-6100
____________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Stock, par value $0.01 per share
257,551,600
Outstanding at April 25, 2023

VERTEX PHARMACEUTICALS INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2023

TABLE OF CONTENTS
Page
Condensed Consolidated Statements of Income - Three Months Ended March 31, 2023 and 2022
Condensed Consolidated Statements of Comprehensive Income - Three Months Ended March 31, 2023 and 2022
Condensed Consolidated Balance Sheets - March 31, 2023 and December 31, 2022
Condensed Consolidated Statements of Shareholders' Equity - Three Months Ended March 31, 2023 and 2022
Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2023 and 2022
Item 1A.

“Vertex,” “we,” “us,” and “our” as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex®,” “KALYDECO®,” “ORKAMBI®,” “SYMDEKO®,” “SYMKEVI®,” “TRIKAFTA®” and “KAFTRIO®” are registered trademarks of Vertex. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.
We use the brand name for our products when we refer to the product that has been approved and with respect to the indications on the approved label. Otherwise, including in discussions of our development programs, we refer to our compounds by their scientific (or generic) name or VX developmental designation.


Part I. Financial Information

Item 1.  Financial Statements
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Income
(in millions, except per share amounts)(unaudited)
Three Months Ended March 31,
20232022
Product revenues, net$2,374.8 $2,097.5 
Costs and expenses:
Cost of sales266.9 245.8 
Research and development expenses742.6 601.1 
Acquired in-process research and development expenses347.1 2.0 
Selling, general and administrative expenses241.1 215.2 
Change in fair value of contingent consideration(1.9)(7.5)
Total costs and expenses1,595.8 1,056.6 
Income from operations779.0 1,040.9 
Interest income122.6 1.6 
Interest expense(11.4)(14.9)
Other income (expense), net1.3 (72.8)
Income before provision for income taxes891.5 954.8 
Provision for income taxes191.7 192.7 
Net income$699.8 $762.1 
Net income per common share:
Basic$2.72 $2.99 
Diluted$2.69 $2.96 
Shares used in per share calculations:
Basic257.4 255.1 
Diluted260.3 257.9 
Please refer to Note A, “Basis of Presentation and Accounting Policies,” for an explanation of amounts reclassified from “Research and development expenses” to “Acquired in-process research and development expenses” for the three months ended March 31, 2022.
The accompanying notes are an integral part of these condensed consolidated financial statements.

2
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Comprehensive Income
(in millions)(unaudited)
Three Months Ended March 31,
20232022
Net income$699.8 $762.1 
Other comprehensive income:
Unrealized holding gains (losses) on marketable securities, net of tax of $(0.8) and zero, respectively
2.9 (2.3)
Unrealized (losses) gains on foreign currency forward contracts, net of tax of $7.4 and $(2.2), respectively
(26.8)10.1 
Foreign currency translation adjustment10.0 (12.4)
Total other comprehensive loss
(13.9)(4.6)
Comprehensive income$685.9 $757.5 
The accompanying notes are an integral part of these condensed consolidated financial statements.

3
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Balance Sheets
(in millions, except share data)(unaudited)
March 31,December 31,
20232022
Assets
Current assets:
Cash and cash equivalents$9,289.9 $10,504.0 
Marketable securities1,124.2 274.5 
Accounts receivable, net1,547.8 1,442.2 
Inventories535.1 460.6 
Prepaid expenses and other current assets
468.7 553.5 
Total current assets
12,965.7 13,234.8 
Property and equipment, net1,111.7 1,108.4 
Goodwill1,088.0 1,088.0 
Intangible assets
603.6 603.6 
Deferred tax assets
1,359.9 1,246.9 
Operating lease assets
336.3 347.4 
Long-term marketable securities1,081.5 112.2 
Other assets
427.5 409.6 
Total assets
$18,974.2 $18,150.9 
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable$323.2 $303.9 
Accrued expenses2,326.0 2,126.7 
Other current liabilities
377.0 311.5 
Total current liabilities
3,026.2 2,742.1 
Long-term finance lease liabilities417.6 430.8 
Long-term operating lease liabilities371.6 379.5 
Other long-term liabilities
726.5 685.8 
Total liabilities
4,541.9 4,238.2 
Commitments and contingencies— — 
Shareholders’ equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding
— — 
Common stock, $0.01 par value; 500,000,000 shares authorized, 257,509,761 and 257,011,628 shares issued and outstanding, respectively
2.6 2.6 
Additional paid-in capital7,220.2 7,386.5 
Accumulated other comprehensive (loss) income(13.1)0.8 
Retained earnings
7,222.6 6,522.8 
Total shareholders’ equity
14,432.3 13,912.7 
Total liabilities and shareholders’ equity
$18,974.2 $18,150.9 
The accompanying notes are an integral part of these condensed consolidated financial statements.

4
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Shareholders’ Equity
(in millions)(unaudited)
Three Months Ended
Common StockAdditional
Paid-in Capital		Accumulated Other Comprehensive Income (Loss)Retained EarningsTotal
Shareholders’ Equity
SharesAmount
Balance at December 31, 2021254.5 $2.5 $6,880.8 $15.9 $3,200.8 $10,100.0 
Other comprehensive loss, net of tax— — — (4.6)— (4.6)
Net income
— — — — 762.1 762.1 
Common stock withheld for employee tax obligations(0.5)(0.0)(117.5)— — (117.5)
Issuance of common stock under benefit plans1.6 0.1 36.4 — — 36.5 
Stock-based compensation expense
— — 130.5 — — 130.5 
Balance at March 31, 2022255.6 $2.6 $6,930.2 $11.3 $3,962.9 $10,907.0 
Balance at December 31, 2022257.0 $2.6 $7,386.5 $0.8 $6,522.8 $13,912.7 
Other comprehensive loss, net of tax— — — (13.9)— (13.9)
Net income
— — — — 699.8 699.8 
Repurchase of common stock(0.5)(0.0)(135.6)— — (135.6)
Common stock withheld for employee tax obligations(0.6)(0.0)(166.6)— — (166.6)
Issuance of common stock under benefit plans1.6 0.0 13.1 — — 13.1 
Stock-based compensation expense
— — 122.8 — — 122.8 
Balance at March 31, 2023257.5 $2.6 $7,220.2 $(13.1)$7,222.6 $14,432.3 
The accompanying notes are an integral part of these condensed consolidated financial statements.

5
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Cash Flows
(in millions)(unaudited)
Three Months Ended March 31,
20232022
Cash flows from operating activities:
Net income
$699.8 $762.1 
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense122.4 130.3 
Depreciation expense38.8 35.9 
Deferred income taxes(113.4)(12.3)
(Gains) losses on equity securities(6.4)75.6 
Decrease in fair value of contingent consideration(1.9)(7.5)
Other non-cash items, net21.7 4.9 
Changes in operating assets and liabilities:
Accounts receivable, net(90.5)(165.2)
Inventories(82.6)2.0 
Prepaid expenses and other assets46.2 67.6 
Accounts payable35.7 (14.5)
Accrued expenses140.7 61.6 
Other liabilities89.4 15.7 
Net cash provided by operating activities
899.9 956.2 
Cash flows from investing activities:
Purchases of available-for-sale debt securities(1,816.6)(117.1)
Maturities of available-for-sale debt securities50.0 129.7 
Purchases of property and equipment(42.1)(63.6)
Investment in equity securities(24.9)— 
Net cash used in investing activities
(1,833.6)(51.0)
Cash flows from financing activities:
Issuances of common stock under benefit plans14.2 33.7 
Repurchases of common stock
(132.8)— 
Payments in connection with common stock withheld for employee tax obligations
(166.6)(117.5)
Payments on finance leases
(10.6)(12.9)
Other financing activities1.1 1.3 
Net cash used in financing activities
(294.7)(95.4)
Effect of changes in exchange rates on cash
12.0 (5.9)
Net (decrease) increase in cash, cash equivalents and restricted cash(1,216.4)803.9 
Cash, cash equivalents and restricted cash—beginning of period
10,512.0 6,800.1 
Cash, cash equivalents and restricted cash—end of period
$9,295.6 $7,604.0 
Supplemental disclosure of cash flow information:
Cash paid for income taxes
$120.3 $85.0 
Cash paid for interest
$11.1 $13.7 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)

A.Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Beginning with the second quarter of 2022, we are separately classifying upfront, contingent milestone, and other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development expenses” in our condensed consolidated statements of income. To conform prior periods to current presentation, we reclassified $2.0 million from “Research and development expenses” to “Acquired in-process research and development expenses” for the three months ended March 31, 2022. Please refer to Note C, “Acquired In-Process Research and Development and Other Arrangements,” for further information on these transactions. We have reclassified certain items from the prior year’s condensed consolidated balance sheet to conform to the current year’s presentation.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended March 31, 2023 and 2022.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, which are contained in our 2022 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted and Issued Accounting Standards
For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2022 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.
Summary of Significant Accounting Policies
Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2022 Annual Report on Form 10-K.


7
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
B.Revenue Recognition
Disaggregation of Revenue
Revenues by Product
“Product revenues, net” consisted of the following:
Three Months Ended March 31,
20232022
(in millions)
TRIKAFTA/KAFTRIO$2,096.7 $1,761.6 
KALYDECO125.0 139.0 
ORKAMBI122.5 132.1 
SYMDEKO/SYMKEVI30.6 64.8 
Total product revenues, net$2,374.8 $2,097.5 
Product Revenues by Geographic Location
“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended March 31,
20232022
(in millions)
United States$1,403.8 $1,368.2 
Outside of the United States
Europe807.2 632.3 
Other
163.8 97.0 
Total product revenues outside of the United States971.0 729.3 
Total product revenues, net
$2,374.8 $2,097.5 
Contract Liabilities
We had contract liabilities of $236.4 million and $159.6 million as of March 31, 2023 and December 31, 2022, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.


8
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
C.Acquired In-Process Research and Development and Other Arrangements
We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. Our “Acquired in-process research and development expenses” included $347.1 million for the three months ended March 31, 2023, and $2.0 million, for the three months ended March 31, 2022, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions that qualify as in-process research and development.
Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three months ended March 31, 2023 and 2022, or were new or materially revised during the three months ended March 31, 2023, are described below. Additional agreements were described in Note B, “Acquired In-Process Research and Development and Other Arrangements,” of our 2022 Annual Report on Form 10-K.
In-license Agreements
We have entered into several in-license agreements to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.
Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.
We typically can terminate our in-license agreements by providing advance notice to our collaborators. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG - CRISPR-Cas9 Gene-editing Therapies
In 2015, we entered into a strategic collaboration, option, and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on resulting net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR (the “CRISPR JDCA”), which we amended and restated in 2021, pursuant to the terms of the CRISPR Agreement. Under the CRISPR JDCA, we and CRISPR are co-developing and preparing to co-commercialize exagamglogene autotemcel (“exa-cel”), for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia. Pursuant to the CRISPR JDCA, we lead global development, manufacturing, and commercialization of exa-cel, with support from CRISPR. We also conduct all research, development, manufacturing, and commercialization activities relating to other product candidates and products under the CRISPR JDCA throughout the world subject to CRISPR’s reserved right to conduct certain activities.
In connection with the CRISPR JDCA, CRISPR has the potential to receive a one-time $200.0 million milestone payment upon receipt of the first marketing approval of exa-cel from the U.S. Food and Drug Administration or the European Commission.
We account for the CRISPR JDCA as a cost-sharing arrangement, with costs incurred related to exa-cel allocated 60% to us and 40% to CRISPR, subject to certain adjustments. During the three months ended March 31, 2023 and 2022, we recognized the net impact of the CRISPR JDCA as “Research and development expenses” of $60.5 million and $36.2

9
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
million, respectively, and “Selling, general and administrative expenses” of $16.5 million and $9.8 million, respectively, within our condensed consolidated statements of income.
In March 2023, we entered into a non-exclusive license agreement (“the CRISPR T1D Agreement”) for the use of CRISPR’s CRISPR-Cas9 gene-editing technology to accelerate the development of our hypoimmune cell therapies for type 1 diabetes. Pursuant to the CRISPR T1D Agreement, we made a $100.0 million upfront payment to CRISPR. CRISPR is also eligible to receive up to an additional $230.0 million in research, development, regulatory and commercial milestones for any products that may result from the agreement, as well as royalties on resulting net product sales. We determined that substantially all the fair value of the collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses.”
Entrada Therapeutics, Inc.
In February 2023, we closed a strategic collaboration and license agreement (the “Entrada Agreement”) with Entrada Therapeutics, Inc. (“Entrada”) focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (“DM1”). Upon closing, we made an upfront payment of $225.1 million to Entrada, and purchased $24.9 million of Entrada’s common stock in connection with the Entrada Agreement. Entrada is eligible to receive up to an additional $485.0 million in research, development, regulatory and commercial milestones for any products that may result from the Entrada Agreement, as well as royalties on resulting net product sales. We determined that substantially all the fair value of the collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses.” We recorded the investment in Entrada’s common stock at fair value within our condensed consolidated balance sheet within “Marketable securities.”
Cystic Fibrosis Foundation
In 2004, we entered into a collaboration agreement with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc., to support research and development activities. Pursuant to the collaboration agreement, as amended, we have agreed to pay tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including ivacaftor, lumacaftor and tezacaftor and royalties ranging from low-single digits to mid-single digits on potential net sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor. We do not have any royalty obligations on compounds first synthesized and tested on or after September 1, 2016. For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO, sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”


10
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
D.Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended March 31,
20232022
(in millions, except per share amounts)
Net income$699.8 $762.1 
Basic weighted-average common shares outstanding257.4 255.1 
Effect of potentially dilutive securities:
Stock options1.3 1.3 
Restricted stock units (including PSUs)
1.6 1.4 
Employee stock purchase program
0.0 0.1 
Diluted weighted-average common shares outstanding260.3 257.9 
Basic net income per common share$2.72 $2.99 
Diluted net income per common share$2.69 $2.96 
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended March 31,
20232022
(in millions)
Stock options0.0 0.0 
Unvested restricted stock units (including PSUs)0.6 0.6 

E.Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic equity investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note F, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of income.

11
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $2.1 billion and $3.1 billion of cash as of March 31, 2023 and December 31, 2022, respectively):
As of March 31, 2023As of December 31, 2022
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds$4,954.1 $4,954.1 $— $— $5,162.6 $5,162.6 $— $— 
Time deposits1,600.0 — 1,600.0 — 2,000.0 — 2,000.0 — 
U.S. Treasury securities86.4 86.4 — — — — — — 
Government-sponsored enterprise securities129.3 129.3 — — — — — — 
Corporate debt securities1.7 — 1.7 — 5.8 — 5.8 — 
Commercial paper408.0 — 408.0 — 204.5 — 204.5 — 
Marketable securities:
Corporate equity securities148.1 127.2 20.9 — 116.8 88.8 28.0 — 
U.S. Treasury securities276.6 276.6 — — — — — — 
Government-sponsored enterprise securities532.4 532.4 — — 127.1 127.1 — — 
Asset-backed securities117.9 — 117.9 — — — — — 
Certificates of deposit44.9 — 44.9 — — — — — 
Corporate debt securities771.5 — 771.5 — 87.0 — 87.0 — 
Commercial paper314.3 — 314.3 — 55.8 — 55.8 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts19.5 — 19.5 — 47.5 — 47.5 — 
Other assets:
Foreign currency forward contracts0.3 — 0.3 — 0.8 — 0.8 — 
Total financial assets
$9,405.0 $6,106.0 $3,299.0 $— $7,807.9 $5,378.5 $2,429.4 $— 
:::::::
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(20.5)$— $(20.5)$— $(14.3)$— $(14.3)$— 
Contingent consideration(14.8)— — (14.8)(14.6)— — (14.6)
Other long-term liabilities:
Foreign currency forward contracts(0.5)— (0.5)— (0.9)— (0.9)— 
Contingent consideration(112.3)— — (112.3)(114.4)— — (114.4)
Total financial liabilities
$(148.1)$— $(21.0)$(127.1)$(144.2)$— $(15.2)$(129.0)
Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments.
As of March 31, 2023, several of our investments in publicly traded corporate equity securities were subject to contractual sales restrictions expiring in 2023, 2024 and 2025 with a total fair value of $42.8 million. We purchased these investments directly from these publicly traded companies in 2022 and the first quarter of 2023, and do not anticipate any circumstances that would cause these restrictions to lapse prior to the periods listed above.

12
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to former Exonics equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data attributable to rare diseases and our knowledge of the progress and viability of the programs. The discount rates used in the valuation model for contingent payments, which were between 4.7% and 5.8% as of March 31, 2023, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future, resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Three Months Ended March 31, 2023
(in millions)
Balance at December 31, 2022$129.0 
Decrease in fair value of contingent payments
(1.9)
Balance at March 31, 2023$127.1 


13
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
F.Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $2.1 billion and $3.1 billion of cash as of March 31, 2023 and December 31, 2022, respectively), is shown below:
As of March 31, 2023As of December 31, 2022
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$4,954.1 $— $— $4,954.1 $5,162.6 $— $— $5,162.6 
Time deposits1,600.0 — — 1,600.0 2,000.0 — — 2,000.0 
U.S. Treasury securities86.3 0.1 — 86.4 — — — — 
Government-sponsored enterprise securities
129.2 0.1 — 129.3 — — — — 
Corporate debt securities1.7 — — 1.7 5.8 — — 5.8 
Commercial paper408.0 — — 408.0 204.5 — — 204.5 
Total cash equivalents
$7,179.3 $0.2 $— $7,179.5 $7,372.9 $— $— $7,372.9 
Marketable securities:
U.S. Treasury securities$274.8 $1.8 $— $276.6 $— $— $— $— 
Government-sponsored enterprise securities
532.0 0.5 (0.1)532.4 127.0 0.2 (0.1)127.1 
Asset-backed securities118.1 — (0.2)117.9 — — — — 
Certificates of deposit44.9 — — 44.9 — — — — 
Corporate debt securities
770.0 2.9 (1.4)771.5 87.2 — (0.2)87.0 
Commercial paper
314.4 — (0.1)314.3 55.8 — — 55.8 
Total marketable debt securities
2,054.2 5.2 (1.8)2,057.6 270.0 0.2 (0.3)269.9 
Corporate equity securities
129.4 47.4 (28.7)148.1 104.4 30.9 (18.5)116.8 
Total marketable securities
$2,183.6 $52.6 $(30.5)$2,205.7 $374.4 $31.1 $(18.8)$386.7 
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of March 31, 2023As of December 31, 2022
(in millions)
Cash and cash equivalents$5,579.5 $5,372.9 
Marketable securities
976.1 157.7 
Long-term marketable securities1,081.5 112.2 
Total
$7,637.1 $5,642.8 
Available-for-sale debt securities by contractual maturity were as follows:
As of March 31, 2023As of December 31, 2022
(in millions)
Matures within one year$6,555.6 $5,530.6 
Matures after one year through five years
1,081.5 112.2 
Total
$7,637.1 $5,642.8 
We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three months ended March 31, 2023 and 2022. As of March 31, 2023, we held available-for-sale debt securities with a total fair value of $702.7 million that were in unrealized loss positions; however, none of these investments had been in an unrealized loss position for greater than twelve months.

14
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
We record changes in the fair value of our investments in corporate equity securities to “Other income (expense), net” in our condensed consolidated statements of income. During the three months ended March 31, 2023 and 2022, our net unrealized gains (losses) on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended March 31,
20232022
(in millions)
Net unrealized gains (losses)
$6.4 $(75.6)
        
As of March 31, 2023, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $98.6 million.

G.Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance at December 31, 2022$(25.0)$(0.1)$25.9 $0.8 
Other comprehensive income (loss) before reclassifications10.0 2.9 (9.6)3.3 
Amounts reclassified from accumulated other comprehensive income (loss)— — (17.2)(17.2)
Net current period other comprehensive income (loss)10.0 2.9 (26.8)(13.9)
Balance at March 31, 2023$(15.0)$2.8 $(0.9)$(13.1)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(12.4)(2.3)25.9 11.2 
Amounts reclassified from accumulated other comprehensive income (loss)— — (15.8)(15.8)
Net current period other comprehensive (loss) income(12.4)(2.3)10.1 (4.6)
Balance at March 31, 2022$(26.0)$(2.8)$40.1 $11.3 

H.Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our condensed consolidated statements of income in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging

15
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2023, all hedges were determined to be highly effective.
We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of March 31, 2023 and December 31, 2022, credit risk did not change the fair value of our foreign currency forward contracts.
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of March 31, 2023As of December 31, 2022
Foreign Currency(in millions)
Euro$1,325.9 $1,497.7 
British pound sterling
243.5 247.4 
Canadian dollar
231.1 216.3 
Australian dollar
180.3 174.9 
Swiss Franc65.9 65.2 
Total foreign currency forward contracts
$2,046.7 $2,201.5 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other income (expense), net” in our condensed consolidated statements of income each period. As of March 31, 2023, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $541.3 million.
During the three months ended March 31, 2023 and 2022, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:
Three Months Ended March 31,
20232022
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$22.0 $20.1 
Not designated as hedging instruments
Other income (expense), net$3.6 $(8.4)
Total reported in the Condensed Consolidated Statements of Income
Product revenues, net$2,374.8 $2,097.5 
Other income (expense), net$1.3 $(72.8)

16
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of March 31, 2023
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$19.5 Other current liabilities$(20.5)
Other assets0.3 Other long-term liabilities(0.5)
Total assets
$19.8 
Total liabilities
$(21.0)
As of December 31, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$47.5 Other current liabilities$(14.3)
Other assets0.8 Other long-term liabilities(0.9)
Total assets
$48.3 
Total liabilities
$(15.2)
As of March 31, 2023, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:
As of March 31, 2023
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$19.8 $— $19.8 $(19.8)$— 
Total liabilities(21.0)— (21.0)19.8 (1.2)
As of December 31, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$48.3 $— $48.3 $(15.2)$33.1 
Total liabilities(15.2)— (15.2)15.2 — 


17
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
I.Inventories
Inventories consisted of the following:
As of March 31, 2023As of December 31, 2022
(in millions)
Raw materials$58.1 $38.1 
Work-in-process341.1 260.7 
Finished goods
135.9 161.8 
Total
$535.1 $460.6 

J.Stock-based Compensation Expense and Share Repurchase Programs
Stock-based compensation expense
During the three months ended March 31, 2023 and 2022, we recognized the following stock-based compensation expense:
Three Months Ended March 31,
20232022
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$115.9 $118.2 
Stock options1.4 5.5 
ESPP share issuances5.5 6.8 
Stock-based compensation expense related to inventories
(0.4)(0.2)
Total stock-based compensation expense included in “Total costs and expenses”
$122.4 $130.3 
Stock-based compensation expense by line item:
Cost of sales$1.9 $2.2 
Research and development expenses76.3 80.4 
Selling, general and administrative expenses44.2 47.7 
Total stock-based compensation expense included in costs and expenses
122.4 130.3 
Income tax effect(40.6)(36.0)
Total stock-based compensation expense, net of tax
$81.8 $94.3 
Share repurchase program
In February 2023, our Board of Directors approved a share repurchase program (our “Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $3.0 billion of our common stock. Our Share Repurchase Program does not have an expiration date and can be discontinued at any time. During the three months ended March 31, 2023, we repurchased 459,017 shares of our common stock under our Share Repurchase Program for an aggregate of $135.6 million. As of March 31, 2023, a total of $2.9 billion remained authorized for future repurchases.


18
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
K.Income Taxes
We are subject to U.S. federal, state, and foreign income taxes. During the three months ended March 31, 2023 and 2022, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended March 31,
20232022
(in millions, except percentages)
Income before provision for income taxes$891.5 $954.8 
Provision for income taxes$191.7 $192.7 
Effective tax rate21.5 %20.2 %
Our effective tax rate for the three months ended March 31, 2023 was higher than the U.S. statutory rate primarily due to an increase in our unrecognized tax benefits partially offset by excess tax benefits related to stock-based compensation. Our effective tax rate for the three months ended March 31, 2022 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation.
We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of March 31, 2023 and December 31, 2022, we had $232.2 million and $208.5 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.
We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2014 in jurisdictions that have a material impact on our consolidated financial statements.

L.Commitments and Contingencies
2022 Credit Facility
In July 2022, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”), which matures on July 1, 2027. The Credit Agreement was not drawn upon at closing and we have not drawn upon it to date. Amounts drawn pursuant to the Credit Agreement, if any, will be used for general corporate purposes. Subject to satisfaction of certain conditions, we may request that the borrowing capacity for the Credit Agreement be increased by an additional $500.0 million. Additionally, the Credit Agreement provides a sublimit of $100.0 million for letters of credit.
Any amounts borrowed under the Credit Agreement will bear interest, at our option, at either a base rate or a Secured Overnight Financing Rate (“SOFR”), in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.000% to 0.500% and the applicable margins on SOFR loans range from 1.000% to 1.500%, in each case based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period).
Any amounts borrowed pursuant to the Credit Agreement are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.
The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including a financial covenant to maintain subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition. As of March 31, 2023, we were in compliance with the covenants described above. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Direct costs related to the Credit Agreement are recorded over its term and were not material to our financial statements.

19
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
Guaranties and Indemnifications
As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.
We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue for such contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note E, “Fair Value Measurements,” there were no material contingent liabilities accrued as of March 31, 2023 or December 31, 2022.

M.Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Three Months Ended March 31,
20232022
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$10,504.0 $9,289.9 $6,795.0 $7,600.1 
Prepaid expenses and other current assets
8.0 5.7 5.1 3.9 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$10,512.0 $9,295.6 $6,800.1 $7,604.0 


20
Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have four approved medicines that treat the underlying cause of cystic fibrosis (“CF”), a life-threatening genetic disease, and we continue to focus on developing additional treatments for CF. Beyond CF, we have a pipeline that includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies.
Our triple combination regimen, TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), was approved in 2019 in the United States (“U.S.”) and in 2020 in the European Union (“E.U.”). Collectively, our four medicines are being used to treat more than two-thirds of the approximately 88,000 people with CF in North America, Europe, and Australia. We are evaluating our medicines in additional patient populations, including younger children, with the goal of having small molecule treatments for all people who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (“CFTR”) gene that is responsive to our CFTR modulators. We also are pursuing messenger ribonucleic acid (“mRNA”) and genetic therapies for people with CF who do not make CFTR protein and, as a result, cannot benefit from our current CF medicines.
In addition, we are preparing for near-term launches of potential new products in sickle cell disease (“SCD”), beta thalassemia, CF and acute pain. We recently completed regulatory submissions in the U.S., E.U. and the United Kingdom (“U.K.”) for exagamglogene autotemcel (“exa-cel”) for the treatment of SCD and transfusion-dependent beta thalassemia (“TDT”).
Financial Highlights
Revenues
In the first quarter of 2023, our net product revenues increased to $2.4 billion as compared to $2.1 billion in the first quarter of 2022 primarily due to the strong uptake of TRIKAFTA/KAFTRIO in multiple countries internationally and continued performance of TRIKAFTA in the U.S.
Expenses
Our total research and development (“R&D”), acquired in-process research and development (“AIPR&D”), and selling, general and administrative (“SG&A”) expenses increased to $1.3 billion in the first quarter of 2023 as compared to $818.3 million in the first quarter of 2022. The increase was primarily due to increased AIPR&D and the progression of several product candidates in mid- to late-stage clinical development. Cost of sales was 11% and 12% of our net product revenues in the first quarter of 2023 and 2022, respectively.
Cash
Our total cash, cash equivalents and marketable securities increased to $11.5 billion as of March 31, 2023 as compared to $10.9 billion as of December 31, 2022 primarily due to our net product revenues and operating cash flows partially offset by our upfront payments to Entrada Therapeutics, Inc. (“Entrada”) and CRISPR Therapeutics AG (“CRISPR”), and repurchases of our common stock.
MDA chart.gif

21
Business Updates
Marketed Products
We expect to grow our CF business with (i) continued uptake by patients in countries where we are early in our launch, such as those with recently achieved reimbursement agreements, (ii) label expansions, including into younger patient groups, (iii) the development of mRNA therapies for people with CF who are not eligible for our approved CFTR modulators, and (iv) growth in the number of people living with CF. Recent progress in activities supporting continued uptake and label expansions is included below.
•The U.S. Food and Drug Administration (“FDA”) approved TRIKAFTA in children with CF 2 to 5 years of age with at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive to TRIKAFTA. We have completed regulatory submissions with the European Medicines Agency (“EMA”), the Medicines and Healthcare products Regulatory Agency (“MHRA”) in the U.K., Health Canada, and the Therapeutic Goods Administration in Australia for the use of KAFTRIO/TRIKAFTA in children with CF 2 to 5 years of age.
•We received a positive opinion from the EMA Committee for Medicinal Products for Human Use for the use of ORKAMBI in children with CF 1 year to less than 2 years of age with two copies of the F508del mutation in the CFTR gene.
•We have submitted a supplemental new drug application to the FDA and marketing authorization applications (“MAAs”) to the EMA, MHRA, and Health Canada for the use of KALYDECO in children with CF from 1 month to less than 4 months of age. KALYDECO has been granted Priority Review designation in the U.S.
•TRIKAFTA/KAFTRIO is approved and reimbursed or accessible in more than 30 countries outside the U.S.
Potential Near-Term Launch Opportunities
We are preparing for the following near-term launches of potential new products:
Exa-cel in SCD and TDT
•We recently completed rolling submissions of our biologics licensing applications (“BLAs”) for exa-cel in the U.S. Exa-cel has been granted Fast Track, Regenerative Medicine Advanced Therapy, Orphan Drug and Rare Pediatric Disease designations in the U.S.
•In the fourth quarter of 2022, we completed submissions for exa-cel with the EMA and MHRA in the E.U. and U.K., respectively. The EMA and MHRA have validated the MAAs, and exa-cel has been granted Priority Medicines and Orphan Drug designations in the E.U. In the U.K., exa-cel has been granted an Innovation Passport under the Innovative Licensing and Access Pathway from the MHRA.
Vanzacaftor/tezacaftor/deutivacaftor in CF
•In the fourth quarter of 2022, we completed enrollment in the pivotal SKYLINE 102 and SKYLINE 103 clinical trials, which evaluate the efficacy and safety of our new once-daily investigational triple combination vanzacaftor/tezacaftor/deutivacaftor relative to TRIKAFTA in people with CF 12 years of age and older. We expect to complete these clinical trials by the end of 2023. In parallel, we have initiated a study of vanzacaftor/tezacaftor/deutivacaftor in children with CF 6 to 11 years of age, known as the RIDGELINE clinical trial, and we expect to complete this clinical trial by the end of 2023.
VX-548 in Acute Pain
•We continue to enroll the Phase 3 pivotal program for our lead compound, VX-548, for the treatment of moderate to severe acute pain, and we expect to complete the pivotal program in late 2023 or early 2024. VX-548 has been granted Breakthrough Therapy and Fast Track designations in the U.S. for moderate to severe acute pain.

22
Pipeline
We continue to advance a pipeline of potentially transformative small molecule, mRNA, and cell and genetic therapies aimed at treating serious diseases. Recent and anticipated progress in activities supporting these efforts is included below.
Cystic Fibrosis
•In collaboration with Moderna, we are developing VX-522, a CFTR mRNA therapeutic for the treatment of people with CF who do not produce any CFTR protein. We have initiated a single-ascending dose clinical trial for VX-522 in people with CF, which is active and enrolling patients. We expect to complete this single-ascending dose clinical trial and initiate a multiple-ascending dose clinical trial in 2023. The FDA has granted Fast Track designation for VX-522.
Beta Thalassemia and Sickle Cell Disease
•We are evaluating the use of exa-cel, a non-viral ex vivo CRISPR gene-editing therapy, for the treatment of SCD and TDT.
•Dosing in the Phase 3 CLIMB-111 and CLIMB 121 clinical trials evaluating exa-cel continues, as does the CLIMB 131 long-term follow-up clinical trial in patients 12 years of age and older.
•Two additional Phase 3 clinical trials evaluating exa-cel in children with SCD or TDT 5 to 11 years of age are ongoing.
Neuropathic Pain
•We have discovered multiple selective small molecule inhibitors of NaV1.8, with the objective of creating a new class of pain medicines that provide effective non-opioid pain relief, without abuse potential.
•We continue to enroll and dose patients in a Phase 2 dose-ranging clinical trial evaluating VX-548 in diabetic peripheral neuropathy, a common form of chronic peripheral neuropathic pain. We expect to complete this clinical trial in late 2023 or early 2024.
APOL1-Mediated Kidney Disease
•Inaxaplin is our small molecule for the treatment of APOL1-mediated kidney disease (“AMKD”), including APOL1-mediated focal segmental glomerulosclerosis (“FSGS”). We continue to enroll and dose patients in the pivotal program for inaxaplin, a single Phase 2/3 clinical trial, and we expect to complete the Phase 2B dose-ranging portion of the trial in 2023.
•The FDA granted inaxaplin Breakthrough Therapy designation for APOL1-mediated FSGS and the EMA granted inaxaplin Orphan Drug and PRIME designations for AMKD.
Type 1 Diabetes
•VX-880 is a stem cell-derived, fully differentiated, insulin-producing islet cell replacement therapy, using standard immunosuppression to protect the implanted cells. A clinical trial is ongoing to evaluate VX-880 as a potential treatment for type 1 diabetes (“T1D”), and proof-of-concept has been achieved. We have completed enrollment and dosing in Part B of the Phase 1/2 clinical trial and we expect to begin Part C of the trial with concurrent dosing. The EMA granted VX-880 PRIME designation.
•We continue to advance additional programs in T1D, in which these same stem cell-derived, fully differentiated, insulin-producing islet cells are encapsulated and implanted in an immunoprotective device or are modified to produce hypoimmune cells with the goal of eliminating the need for immunosuppression. The Investigational New Drug Application in the U.S., and the Clinical Trial Application (“CTA”) in Canada for VX-264, the cells and device program, have been cleared, and we plan to begin enrollment and dosing in a Phase 1/2 clinical trial in the near term.
•Our hypoimmune cell research program continues to progress.

23
•A Phase 1/2 clinical trial evaluating VCTX-211, a hypoimmune cell program using ViaCyte cells that originated under the CRISPR and ViaCyte collaboration, is active and enrolling patients.
Alpha-1 Antitrypsin Deficiency
•We are working to address the underlying genetic cause of alpha-1 antitrypsin (“AAT”) deficiency (“AATD”). We are developing novel small molecule correctors of Z-AAT protein folding, with the goal of enabling the secretion of functional AAT into the blood and addressing both the lung and the liver aspects of AATD. We continue to enroll and dose healthy volunteers in a Phase 1 clinical trial for VX-634, which is the first in a series of next-wave investigational molecules with significantly improved potency and drug-like properties as compared to our previous AAT correctors.
•We initiated a second Phase 2 clinical trial of VX-864, a first-generation AAT corrector, to assess the impact of longer-term treatment on the liver, as well as the levels of functional AAT in the plasma. This Phase 2 clinical trial continues to enroll and dose patients.
Additional Earlier Stage R&D Programs
Consistent with our overall strategy, we are taking a portfolio approach to all of our programs, with additional assets in CF, SCD, TDT, pain, AMKD, T1D and AATD in earlier stages of development.
We are also advancing preclinical assets in new disease areas, such as DMD and myotonic dystrophy type 1 (“DM1”). Additionally, we are working on preclinical molecules with the potential to expand our leadership in existing disease areas, including assets targeting gentler conditioning for exa-cel and NaV1.7 inhibitors in pain.
Investments in External Innovation
Recent investments in external innovation are included below:
•We announced a new licensing agreement for the use of CRISPR’s gene-editing technology, known as CRISPR/Cas9, to accelerate the development of our hypoimmune cell therapies for T1D.
•We closed our previously announced strategic collaboration and licensing agreement with Entrada Therapeutics, Inc. (“Entrada”), focused on discovering and developing intracellular Endosomal Escape Vehicle (“EEV”) therapeutics for DM1.
Our Business Environment
Our net product revenues come from the sale of our medicines for the treatment of CF. Our CF strategy involves continuing to develop and obtain approval and reimbursement for treatment regimens that will provide benefits to all people with CF and increasing the number of people with CF eligible and able to receive our medicines, including through label expansions, expanded reimbursement, and the development of new medicines. We are advancing our pipeline of product candidates for the treatment of serious diseases outside of CF. Our strategy is to combine transformative advances in the understanding of causal human biology and the science of therapeutics to discover and develop innovative medicines. This approach includes advancing multiple compounds from each program, spanning multiple modalities, into early clinical trials to obtain patient data that can inform selection of the most promising compounds for later-stage development, and to inform discovery and development of additional compounds. We aim to rapidly follow our first-in-class therapies that achieve proof-of-concept with potential best-in-class candidates to provide durable clinical and commercial success.
In pursuit of new product candidates and therapies in specialty markets, we invest in research and development. We believe that pursuing research in diverse areas allows us to balance the risks inherent in product development and may provide product candidates that will form our pipeline in future years. To supplement our internal research programs, we acquire technologies and programs and collaborate with biopharmaceutical and technology companies, leading academic research institutions, government laboratories, foundations and other organizations, as needed, to advance research in our areas of therapeutic interest and to access technologies needed to execute on our strategy.
Discovery and development of a new pharmaceutical or biological product is a difficult and lengthy process that requires significant financial resources along with extensive technical and regulatory expertise. Across the industry, most potential drug or biological products never progress into development, and most products that do advance into development never

24
receive marketing approval. Our investments in product candidates are subject to considerable risks. We closely monitor the results of our discovery, research, clinical trials and nonclinical studies and frequently evaluate our product development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential. This process can result in rapid changes in focus and priorities as new information becomes available and as we gain additional understanding of our ongoing programs and potential new programs, as well as those of our competitors.
Our business also requires ensuring appropriate manufacturing and reimbursement of our products. As we advance our product candidates through clinical development toward commercialization and market and sell our approved products, we build and maintain our supply chain and quality assurance resources. We rely on a global network of third parties and our internal capabilities to manufacture and distribute our products for commercial sale and post-approval clinical trials and to manufacture and distribute our product candidates for clinical trials. In addition to establishing supply chains for each new approved product, we adapt our supply chain for existing products to include additional formulations or to increase scale of production for existing products as needed. The processes for cell and genetic therapies can be more complex than those required for small molecule drugs and require additional investments in different systems, equipment, facilities and expertise. We are focused on ensuring the stability of the supply chains for our current products, as well as for our pipeline programs.
Sales of our products depend, to a large degree, on the extent to which our products are reimbursed by third-party payors, such as government health programs, commercial insurance and managed health care organizations. Reimbursement for our products, including our potential pipeline therapies, cannot be assured and may take significant periods of time to obtain. We dedicate substantial management and other resources to obtain and maintain appropriate levels of reimbursement for our products from third-party payors, including governmental organizations in the U.S. and ex-U.S. markets.
In the U.S., we have worked successfully with third-party payors to promptly obtain appropriate levels of reimbursement for our CF medicines. We plan to continue to engage in discussions with numerous commercial insurers and managed health care organizations, along with government health programs that are typically managed by authorities in the individual states, to ensure that payors recognize the significant benefits that our medicines provide and provide patients with appropriate levels of access to our medicines now and in the future. We cannot, however, predict how recent changes in the law, including through the Inflation Reduction Act of 2022, will affect our ability to negotiate successfully with third-party payors in the future. In ex-U.S. markets, we seek government reimbursement for our medicines on a country-by-country or region-by-region basis, as required. This is necessary for each new medicine, as well as for label expansions for our current medicines. We expect to continue to focus significant resources to obtain expanded reimbursement for our CF medicines and, ultimately, pipeline therapies, in U.S. and ex-U.S. markets.
Strategic Transactions
Acquisitions
As part of our business strategy, we seek to acquire technologies, products, product candidates and other businesses that are aligned with our corporate and research and development strategies and complement and advance our ongoing research and development efforts.
In the second quarter of 2022, we acquired Catalyst Biosciences, Inc.’s, or Catalyst’s, portfolio of protease medicines that target the complement system and related intellectual property for $60.0 million. In the third quarter of 2022, we acquired ViaCyte, a privately held biotechnology company with intellectual property, tools, technologies and assets with potential to accelerate development of our T1D programs, for $315.0 million.
We expect to continue to identify and evaluate potential acquisitions and may include larger transactions or later-stage assets.
Collaboration and In-Licensing Arrangements
We enter into arrangements with third parties, including collaboration and licensing arrangements, for the development, manufacture and commercialization of products, product candidates and other technologies that have the potential to complement our ongoing research and development efforts. Over the last several years, we entered into collaboration agreements with a number of companies, including Arbor Biotechnologies, Inc., CRISPR, Entrada, ImmunoGen, Inc., Kymera Therapeutics, Inc., Mammoth Biosciences, Inc., Moderna, Inc., Obsidian Therapeutics, Inc., and Verve Therapeutics, Inc. Generally, when we in-license a technology or product candidate, we make upfront payments to the collaborator, assume the costs of the program and/or agree to make contingent payments, which could consist of milestone, royalty and option

25
payments. Most of these collaboration payments are expensed as AIPR&D; however, depending on many factors, including the structure of the collaboration, the stage of development of the acquired technology, the significance of the in-licensed product candidate to the collaborator’s operations and the other activities in which our collaborators are engaged, the accounting for these transactions can vary significantly. We expect to continue to identify and evaluate collaboration and licensing opportunities that may be similar to or different from the collaborations and licenses that we have engaged in previously.
In February 2023, we closed our strategic collaboration and licensing agreement with Entrada. Upon closing, we made an upfront payment of $225.1 million to Entrada, and purchased $24.9 million of Entrada’s common stock.
In March 2023, we entered into a non-exclusive license agreement for the use of CRISPR’s CRISPR-Cas9 gene-editing technology to accelerate the development of our hypoimmune cell therapies for T1D, and made a $100.0 million upfront payment to CRISPR.
Acquired In-Process Research and Development Expenses
In the first quarter of 2023 and 2022, our AIPR&D included $347.1 million, which primarily related to our upfront payments to Entrada and CRISPR, and $2.0 million, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including the collaborations, licenses of third-party technologies, and asset acquisitions described above.
Out-License Agreements
We also have out-licensed internally developed programs to collaborators who are leading the development of these programs. Pursuant to these out-licensing arrangements, our collaborators are responsible for the research, development, and commercialization costs associated with these programs, and we are entitled to receive contingent milestone and/or royalty payments. As a result, we do not expect to incur significant expenses in connection with these programs and have the potential for future collaborative and royalty revenues resulting from these programs. None of our out-license agreements had a significant impact on our condensed consolidated statement of income during the first quarter of 2023 and 2022.
Strategic Equity Investments
In connection with our business development activities, we have periodically made equity investments in our collaborators. As of March 31, 2023, we held strategic equity investments in certain public and private companies, and we expect to make additional strategic equity investments in the future. We invest the majority of our cash, cash equivalents and marketable securities in instruments that meet specific credit quality standards and limit our exposure to any one issue or type of instrument. Our strategic equity investments are maintained and managed separately from our other cash, cash equivalents and marketable securities. As discussed below in “Other Income (Expense), Net” in our Results of Operations, any changes in the fair value of equity investments with readily determinable fair values (including publicly traded securities) are recorded to other income (expense), net in our condensed consolidated statement of income.


26
RESULTS OF OPERATIONS
Three Months Ended March 31,
20232022Change
(in millions, except percentages and per share amounts)
Product revenues, net
$2,374.8 $2,097.5 13%
Operating costs and expenses1,595.8 1,056.6 51%
Income from operations
779.0 1,040.9 (25)%
Other non-operating income (expense), net112.5 (86.1)**
Provision for income taxes
191.7 192.7 (1)%
Net income
$699.8 $762.1 (8)%
Net income per diluted common share$2.69 $2.96 
Diluted shares used in per share calculations
260.3 257.9 
** Not meaningful
Product Revenues, net
Three Months Ended March 31,
20232022Change
(in millions, except percentages)
TRIKAFTA/KAFTRIO$2,096.7 $1,761.6 19%
KALYDECO125.0 139.0 (10)%
ORKAMBI122.5 132.1 (7)%
SYMDEKO/SYMKEVI30.6 64.8 (53)%
Product revenues, net$2,374.8 $2,097.5 13%
In the first quarter of 2023, our net product revenues increased by $277.3 million, or 13%, as compared to the first quarter of 2022, primarily due to the strong uptake of TRIKAFTA/KAFTRIO in multiple countries internationally and the continued performance of TRIKAFTA in the U.S. Decreases in revenues for our products other than TRIKAFTA/KAFTRIO were primarily the result of patients switching from these medicines to TRIKAFTA/KAFTRIO.
Our net product revenues from the U.S. and from ex-U.S. markets were as follows:
Three Months Ended March 31,
20232022Change
(in millions, except percentages)
United States$1,403.8 $1,368.2 3%
ex-U.S.971.0 729.3 33%
Product revenues, net$2,374.8 $2,097.5 13%

27
Operating Costs and Expenses

Three Months Ended March 31,
20232022Change
(in millions, except percentages)
Cost of sales$266.9 $245.8 9%
Research and development expenses742.6 601.1 24%
Acquired in-process research and development expenses347.1 2.0 **
Selling, general and administrative expenses241.1 215.2 12%
Change in fair value of contingent consideration(1.9)(7.5)**
Total costs and expenses$1,595.8 $1,056.6 51%
** Not meaningful
Cost of Sales
Our cost of sales primarily consists of third-party royalties payable on net sales of our products as well as the cost of producing inventories. Pursuant to our agreement with the Cystic Fibrosis Foundation our tiered third-party royalties on sales of TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, KALYDECO, and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens, with royalties on sales of TRIKAFTA/KAFTRIO lower than for our other products. Over the last several years, our cost of sales has been increasing due to increased net product revenues. Our cost of sales as a percentage of our net product revenues was 11% and 12% in the first quarter of 2023 and 2022, respectively.
Research and Development Expenses
Three Months Ended March 31,
20232022Change
(in millions, except percentages)
Research expenses$166.8 $143.8 16%
Development expenses
575.8 457.3 26%
Total research and development expenses
$742.6 $601.1 24%
Our research and development expenses include internal and external costs incurred for research and development of our products and product candidates. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual products or product candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. We assign external costs of services provided to us by clinical research organizations and other outsourced research by individual program. Our internal costs are significantly greater than our external costs. All research and development costs for our products and product candidates are expensed as incurred.
Since January 2021, we have incurred approximately $6.8 billion in total research and development and AIPR&D expenses associated with product discovery and development. The successful development of our product candidates is highly uncertain and subject to a number of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the product candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a project and are difficult to predict. Therefore, accurate and meaningful estimates of the ultimate costs to bring our product candidates to market are not available.

28
Any estimates regarding development and regulatory timelines for our product candidates are highly subjective and subject to change. Until we have data from Phase 3 clinical trials, we cannot make a meaningful estimate regarding when, or if, a clinical development program will generate revenues and cash flows.
Research Expenses
Three Months Ended March 31,
20232022Change
(in millions, except percentages)
Research Expenses:
Salary and benefits$45.5 $40.2 13%
Stock-based compensation expense20.2 22.9 (12)%
Outsourced services and other direct expenses53.6 39.5 36%
Infrastructure costs
47.5 41.2 15%
Total research expenses
$166.8 $143.8 16%
Our research expenses have been increasing over the last several years as we have invested in our pipeline and expanded our cell and genetic therapy capabilities, resulting in increased headcount, outside services and other direct expenses and infrastructure costs associated with our research facilities. We expect to continue to invest in our research programs with a focus on creating transformative medicines for serious diseases.
Development Expenses
Three Months Ended March 31,
20232022Change
(in millions, except percentages)
Development Expenses:
Salary and benefits$144.2 $109.9 31%
Stock-based compensation expense56.1 57.5 (2)%
Outsourced services and other direct expenses295.3 212.7 39%
Infrastructure costs
80.2 77.2 4%
Total development expenses
$575.8 $457.3 26%
Our development expenses increased by $118.5 million, or 26%, in the first quarter of 2023 as compared to the first quarter of 2022, primarily due to increased costs to support clinical trials associated with our advancing pipeline programs, including pain, our CF triple combination of vanzacaftor/tezacaftor/deutivacaftor, exa-cel and T1D. We are significantly investing in internal headcount, leveraging outsourced services, and investing in infrastructure to support these programs.
Acquired In-process Research and Development Expenses
Three Months Ended March 31,
20232022Change
(in millions, except percentages)
Acquired in-process research and development expenses$347.1 $2.0 **
** Not meaningful
AIPR&D in the first quarter of 2023 was primarily related to our upfront payments of $225.1 million to Entrada and $100.0 million to CRISPR. Our AIPR&D has historically fluctuated, and is expected to continue to fluctuate, from one period

29
to another due to upfront, contingent milestone, and other payments pursuant to our existing and future business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions.
Selling, General and Administrative Expenses
Three Months Ended March 31,
20232022Change
(in millions, except percentages)
Selling, general and administrative expenses$241.1 $215.2 12%
Selling, general and administrative expenses increased by 12% in the first quarter of 2023 as compared to the first quarter of 2022, primarily due to the continued investment to support the commercialization of our medicines and increased support for our pipeline product candidates.
Contingent Consideration
The fair value of our contingent consideration decreased by $1.9 million and $7.5 million in the first quarter of 2023 and 2022, respectively.
Other Non-Operating Income (Expense), Net
Interest Income
Interest income increased to $122.6 million in the first quarter of 2023, as compared to $1.6 million in the first quarter of 2022, primarily due to increased market interest rates and increased cash equivalents and available-for-sale debt securities. Our future interest income is dependent on the amount of, and prevailing market interest rates on, our outstanding cash equivalents and available-for-sale debt securities.
Interest Expense
Interest expense was $11.4 million and $14.9 million in the first quarter of 2023 and 2022, respectively. The majority of our interest expense in these periods was related to imputed interest expense associated with our leased corporate headquarters in Boston.
Other Income (Expense), Net
Other income (expense), net was income of $1.3 million and expense of $72.8 million in the first quarter of 2023 and 2022, respectively. The vast majority of these amounts relate to net unrealized gains or losses resulting from changes in the fair value of our strategic equity investments. As of March 31, 2023, the fair value of our investments in publicly traded companies was $148.1 million. To the extent that we continue to hold strategic equity investments in publicly traded companies, we will record other income (expense) related to these investments on a quarterly basis. We expect that due to the volatility of the stock price of biotechnology companies, our other income (expense), net will fluctuate in future periods based on increases or decreases in the fair value of our strategic equity investments.
Income Taxes
Our effective tax rate fluctuates from period to period due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, adjustments to the value of our uncertain tax positions, acquisitions and third-party collaboration and licensing transactions.
We recorded provisions for income taxes of $191.7 million and $192.7 million in the first quarter of 2023 and 2022, respectively. Our effective tax rate of 21.5% in the first quarter of 2023 was higher than the U.S. statutory rate primarily due to an increase in our unrecognized tax benefits partially offset by excess tax benefits related to stock-based compensation. Our effective tax rate of 20.2% in the first quarter of 2022 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation.

30

LIQUIDITY AND CAPITAL RESOURCES
The following table summarizes the components of our financial condition as of March 31, 2023 and December 31, 2022:
As of March 31, 2023As of December 31, 2022Change
(in millions, except percentages)
Total cash, cash equivalents and marketable securities$11,495.6 $10,890.7 6%
Working Capital:
Total current assets$12,965.7 $13,234.8 (2)%
Total current liabilities(3,026.2)(2,742.1)10%
Total working capital$9,939.5 $10,492.7 (5)%
Working Capital
As of March 31, 2023, total working capital was $9.9 billion, which represented a decrease of $553.2 million from $10.5 billion as of December 31, 2022. The decrease in total working capital in the first quarter of 2023 was primarily related to increased investment in long-term marketable securities and repurchases of our common stock partially offset by $899.9 million of cash provided by operations.
Cash Flows
Three Months Ended March 31,
20232022
(in millions)
Net cash provided by (used in):
Operating activities$899.9 $956.2 
Investing activities$(1,833.6)$(51.0)
Financing activities$(294.7)$(95.4)
Operating Activities
Cash provided by operating activities were $899.9 million in the first quarter of 2023 as compared to $956.2 million in the first quarter of 2022, primarily due to a $62.3 million decrease in net income resulting from increased AIPR&D partially offset by increased net product revenues.
Investing Activities
Cash used in investing activities were $1.8 billion and $51.0 million in the first quarter of 2023 and 2022, respectively. In the first quarter of 2023, the largest portion of our investing activities were purchases of marketable securities. In the first quarter of 2022, the largest portion of our investing activities were purchases of property and equipment.
Financing Activities
Cash used in financing activities were $294.7 million and $95.4 million in the first quarter of 2023 and 2022, respectively. In the first quarter of 2023, the largest portions of our financing activities were payments related to our employee stock benefit plans and repurchases of our common stock pursuant to our Share Repurchase Program. In the first quarter of 2022, the largest portion of our financing activities were payments related to our employee stock benefit plans.
Sources and Uses of Liquidity
As of March 31, 2023, we had total cash, cash equivalents and marketable securities of $11.5 billion, which represented an increase of $604.9 million from $10.9 billion as of December 31, 2022. We intend to rely on our existing cash, cash equivalents and marketable securities together with cash flows from product sales as our primary source of liquidity.

31
We expect that cash flows from our product sales together with our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including our future product sales, and the potential introduction of one or more of our other product candidates to the market, our business development activities, and the number, breadth, cost and prospects of our research and development programs.
Credit Facilities & Financing Strategy
We may borrow up to a total of $500.0 million pursuant to a revolving credit facility that we entered into in July 2022 and could repay and reborrow amounts under this revolving credit agreement without penalty. Subject to certain conditions, we could request that the borrowing capacity be increased by an additional $500.0 million, for a total of $1.0 billion. Negative covenants in our credit agreement could prohibit or limit our ability to access this source of liquidity. As of March 31, 2023, the facility was undrawn, and we were in compliance with these covenants.
We may also raise additional capital by borrowing under credit agreements, through public offerings or private placements of our securities or securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.
Future Capital Requirements
We have significant future capital requirements, including:
•Expected operating expenses to conduct research and development activities, manufacture and commercialize our existing and future products, and to operate our organization.
•Facility and finance lease obligations.
•Royalties we pay to the Cystic Fibrosis Foundation on sales of our CF products.
•Cash paid for income taxes.
In addition, we have significant potential future capital requirements including:
•We have entered into certain business development-related agreements with third parties that include the funding of certain research, development, and commercialization efforts. Certain of our transactions, including collaborations, licensing arrangements, and asset acquisitions, include the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental and regulatory targets and/or commercial targets. Our obligation to fund these research and development and commercialization efforts and to pay these potential milestone and royalties is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs associated with our collaborations, licensing arrangements and acquisitions. We may enter into additional business development transactions, including acquisitions, collaborations, licensing arrangements and equity investments, that require additional capital.
•To the extent we borrow amounts under our existing credit agreement, we would be required to repay any outstanding principal amounts in 2027.
•As of March 31, 2023, we had $2.9 billion remaining authorization available under our Share Repurchase Program.
There have not been any material changes to our future capital requirements disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission, or SEC, on February 10, 2023.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. The

32
preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate. During the three months ended March 31, 2023, there were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on February 10, 2023.

RECENT ACCOUNTING PRONOUNCEMENTS
For a discussion of recent accounting pronouncements, please refer to Note A, “Basis of Presentation and Accounting Policies.”

Item 3.    Quantitative and Qualitative Disclosures About Market Risk
Information required by this item is incorporated by reference from the discussion in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on February 10, 2023.

Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management (under the supervision and with the participation of our chief executive officer and chief financial officer), after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q, has concluded that, based on such evaluation, as of March 31, 2023 our disclosure controls and procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Controls Over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) occurred during the three months ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. Other Information

Item 1. Legal Proceedings
We are not currently subject to any material legal proceedings.


33
Item 1A. Risk Factors
Information regarding risk factors appears in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on February 10, 2023. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I, Item 2, contain a number of forward-looking statements. Forward-looking statements are not purely historical and may be accompanied by words such as “anticipates,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” and other words and terms of similar meaning. Such statements may relate to:
•our expectations regarding the amount of, timing of, and trends with respect to our financial performance, including revenues, costs and expenses, and other gains and losses;
•our expectations regarding clinical trials, including expectations for patient enrollment, development timelines, the expected timing of data from our ongoing and planned clinical trials, and regulatory authority filings and other submissions for our therapies;
•our ability to maintain and obtain adequate reimbursement for our products, our ability to launch, commercialize and market our products or any of our other therapies for which we obtain regulatory approval and our ability to obtain label expansions for existing therapies;
•our expectations regarding our ability to continue to grow our CF business by increasing the number of people with CF eligible and able to receive our medicines, providing improved treatment options for people who are already eligible for one of our medicines, and pursuing genetic therapies for people with CF who cannot currently benefit from our medicines;
•the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings;
•our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our therapies for further investigation, clinical trials or potential use as a treatment;
•our plans to continue investing in our research and development programs, including anticipated timelines for our programs, and our strategy to develop our pipeline programs, alone or with third party-collaborators;
•our beliefs regarding the approximate patient populations for the disease areas on which we focus;
•the potential benefits and therapeutic scope of our acquisitions and collaborations, including the expectation that the use of CRISPR/Cas9 gene editing technology will accelerate the development of our T1D hypoimmune cell therapy program;
•the establishment, development and maintenance of collaborative relationships, including potential milestone payments or other obligations;
•potential business development activities, including the identification of potential collaborative partners or acquisition targets;
•our ability to expand and protect our intellectual property portfolio and otherwise maintain exclusive rights to products;
•potential fluctuations in foreign currency exchange rates and the effectiveness of our foreign currency management program;
•our expectations regarding cash generated by operations, our cash balance and expected generation and interest income;

34
•our expectations regarding our provision for or benefit from income taxes and the utilization of our deferred tax assets;
•our ability to use our research programs to identify and develop new product candidates to address serious diseases and significant unmet medical needs;
•our plans to expand, strengthen, and invest in our global supply chains and manufacturing infrastructure and capabilities, including for cell and gene therapies; and
•our liquidity and our expectations regarding the possibility of raising additional capital.
Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements. These risks, uncertainties, and other factors include, but are not limited to, those described in our “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on February 10, 2023, and those described from time to time in our future reports filed with the Securities and Exchange Commission.
Any such forward-looking statements are made on the basis of our views and assumptions as of the date of the filing and are not estimates of future performance. Except as required by law, we undertake no obligation to publicly update any forward-looking statements. The reader is cautioned not to place undue reliance on any such statements.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Repurchases of Equity Securities
In February 2023, our Board of Directors approved a share repurchase program (our “Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $3.0 billion of our common stock. Our Share Repurchase Program does not have an expiration date and can be discontinued at any time. The table set forth below shows repurchases of securities by us during the three months ended March 31, 2023 under our Share Repurchase Program.
PeriodTotal Number
of Shares Purchased		Average Price
Paid per Share		Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs (1)		Approximate Dollar Value
 of Shares that May Yet be
Purchased Under the
Plans or Programs (1)
January 1, 2023 to January 31, 2023
N/AN/AN/AN/A
February 1, 2023 to February 28, 2023
172,784 $293.43 172,784 $2,949,299,420 
March 1, 2023 to March 31, 2023
286,233 $296.56 286,233 $2,864,413,554 
Total459,017 $295.38 459,017 $2,864,413,554 
(1) Under our Share Repurchase Program, we are authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases may be pursuant to Rule 10b5-1 plans or other means as determined by our management and in accordance with the requirements of the Securities and Exchange Commission.


35
Item 6.    Exhibits
Exhibit Number
Exhibit Description
10.1
Amendment No. 2 to Employment Agreement, between Jeffrey M. Leiden and Vertex Pharmaceuticals Incorporated, dated as of February 8, 2023. (incorporated by reference to Exhibit 10.23 to our Annual Report on Form 10-K filed on February 10, 2023).*
31.1
31.2
32.1
101.INSXBRL Instance - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema
101.CALXBRL Taxonomy Extension Calculation
101.LABXBRL Taxonomy Extension Labels
101.PREXBRL Taxonomy Extension Presentation
101.DEFXBRL Taxonomy Extension Definition
104Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
* Management contract, compensatory plan or agreement.

36

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Vertex Pharmaceuticals Incorporated
May 2, 2023
By:
/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President, Chief Financial Officer
(principal financial officer and
duly authorized officer)

37
 EX-31.1 2 a2023q110-qexhibit311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Reshma Kewalramani, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 2, 2023/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer and President


 EX-31.2 3 a2023q110-qexhibit312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Charles F. Wagner, Jr., certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 2, 2023/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer

 EX-32.1 4 a2023q110-qexhibit321.htm EX-32.1 Document

Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that the Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 2, 2023
/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer and President
Date: May 2, 2023
/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer



 EX-101.SCH 5 vrtx-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Basis of Presentation and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Acquired In-Process Research and Development and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Marketable Securities and Equity Investments link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Hedging link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Additional Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Basis of Presentation and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Marketable Securities and Equity Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Additional Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Basis of Presentation and Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Revenue Recognition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Earnings Per Share - Schedule of Computation (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Hedging - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Hedging - Notional Amount (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Hedging - Derivative Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Hedging - Offsetting Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Additional Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 vrtx-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 vrtx-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 vrtx-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Matures within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] British pound sterling United Kingdom, Pounds Deferred tax assets Deferred Income Tax Assets, Net Entity Address, Postal Zip Code Entity Address, Postal Zip Code Debt covenant, consolidated leverage ratio Debt Covenant, Consolidated Leverage Ratio Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants. Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Unrealized holding gains (losses) on marketable securities, net of tax of $(0.8) and zero, respectively Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Schedule of Cash Equivalents and Marketable Securities Cash, Cash Equivalents and Investments [Table Text Block] Gross Unrealized Gains Cash Equivalents And Debt Securities, Available for Sale, Gross Unrealized Gains Cash Equivalents And Debt Securities, Available for Sale, Gross Unrealized Gains Financial Instruments [Domain] Financial Instruments [Domain] Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Statistical Measurement [Domain] Statistical Measurement [Domain] Schedule of Fair Value of Our Contingent Consideration Liabilities Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Other non-cash items, net Other Noncash Income (Expense) Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Net income Net income Net income Net income Net Income (Loss) Attributable to Parent Measurement Input Type [Domain] Measurement Input Type [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Matures after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Collaborative Arrangements by Agreement [Domain] Collaborative Arrangements by Agreement [Domain] Collaborative Arrangements by Agreement [Domain] Equity Component [Domain] Equity Component [Domain] Discount Rate Measurement Input, Discount Rate [Member] Total financial assets Assets, Fair Value Disclosure Interest income Investment Income, Interest and Dividend Total stock-based compensation expense, net of tax Share-Based Payment Arrangement, Expense, after Tax Fair Value Debt securities Total Debt Securities, Available-for-Sale Hedging Designation [Domain] Hedging Designation [Domain] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Number of operating segments Number of Operating Segments Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Cash Flow Hedging Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] ESPP share issuances Employee Stock [Member] Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Award Type [Axis] Award Type [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Gross Amounts Presented Derivative Asset Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Currencies [Domain] All Currencies [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Costs and expenses: Costs and Expenses [Abstract] Legal Entity [Axis] Legal Entity [Axis] Certificates of deposit Certificates of Deposit [Member] Total liabilities Liabilities Time deposits Bank Time Deposits [Member] Share-based Compensation Arrangement by Share-based Payment Award Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Accrued expenses Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Other current liabilities, foreign currency forward contracts Derivative Liability, Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Australian dollar Australia, Dollars On Available-For-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Purchase of common stock Payment To Acquire Common Stock Payment To Acquire Common Stock Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type SOFR Loan Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Financial instruments carried at fair value (asset positions): Assets, Fair Value Disclosure [Abstract] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Schedule of Offsetting Liabilities Offsetting Liabilities [Table Text Block] Financial Instrument [Axis] Financial Instrument [Axis] SYMDEKO/SYMKEVI SYMDEKO/SYMKEVI [Member] SYMDEKO/SYMKEVI [Member] Document Period End Date Document Period End Date Deferred income taxes Increase (Decrease) in Other Deferred Liability Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Assets Net income per common share: Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Unrealized holding gains (losses) on marketable securities, tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Fair Value Equity Securities, FV-NI, Current Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accrued expenses Accrued Liabilities, Current Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Amortized Cost Cash Equivalents And Debt Securities, Available for Sale Cash Equivalents And Debt Securities, Available for Sale Accounting Policies [Abstract] Accounting Policies [Abstract] Number of shares authorized to be repurchased Stock Repurchase Program, Authorized Amount Amounts reclassified from accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Asset-backed securities Asset-Backed Securities [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Earnings Per Share Earnings Per Share [Text Block] Other long-term liabilities Other Noncurrent Liabilities [Member] Long-term finance lease liabilities Finance Lease, Liability, Noncurrent KALYDECO KALYDECO [Member] KALYDECO inventories, net Schedule of Provision for (Benefits from) Income Taxes and Effective Tax rates Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Award Type [Domain] Award Type [Domain] Gross Unrealized Gains Equity Securities, FV-NI, Unrealized Gain Derivative Contract [Domain] Derivative Contract [Domain] ORKAMBI ORKAMBI [Member] ORKAMBI [Member] Entity Registrant Name Entity Registrant Name Foreign Currency Translation Adjustment Foreign Currency Forward Contract Accumulated Foreign Currency Adjustment Attributable to Parent [Member] CRISPR T1D CRISPR T1D [Member] CRISPR T1D Entity Address, City or Town Entity Address, City or Town On Foreign Currency Forward Contracts Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Collaborative arrangement, development and regulatory potential milestone payments maximum Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized. Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Up-front payment Collaborative Arrangement Up-front License Fee Collaborative Arrangement Up-front License Fee Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Research and development expenses Research and Development Expense Prepaid expenses and other current assets Restricted Cash and Cash Equivalents Restricted stock units (including PSUs) Unvested restricted stock units (including PSUs) Restricted Stock Units (RSUs) [Member] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Accounts payable Increase (Decrease) in Accounts Payable Income Taxes Income Tax Disclosure [Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Credit Facility [Domain] Credit Facility [Domain] Unrealized loss position for greater than twelve months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Amortized Cost Debt and Equity Securities, Cost Debt and Equity Securities, Cost Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Basic (in dollars per share) Basic net income per common share (in dollars per share) Earnings Per Share, Basic Other Assets Other assets Other Assets [Member] Total shareholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Allowance for credit loss for available-for-sale debt securities Debt Securities, Available-for-Sale, Allowance for Credit Loss Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Government-sponsored enterprise securities Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Money market funds Money Market Funds [Member] Retained Earnings Retained Earnings [Member] Common Stock Common Stock [Member] Schedule of Stock-based Compensation Expense by Line Item Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total other comprehensive loss Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Repurchases of common stock Payments for Repurchase of Common Stock Balance at December 31, 2022 Balance at March 31, 2023 Business Combination, Contingent Consideration, Liability Statement [Table] Statement [Table] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Long-term marketable securities Marketable Securities, Noncurrent Document Quarterly Report Document Quarterly Report Letters of Credit Letter of Credit [Member] Current assets: Assets, Current [Abstract] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Additional Cash Flow Information Additional Financial Information Disclosure [Text Block] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Schedule of Additional Cash Flow Information Condensed Cash Flow Statement [Table Text Block] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Equity Components [Axis] Recurring Basis Fair Value, Recurring [Member] Remaining milestone payment Business Combination, Remaining Milestone Payment Business Combination, Remaining Milestone Payment Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement Statement [Line Items] Payments on finance leases Finance Lease, Principal Payments Other current liabilities, contingent consideration Business Combination, Contingent Consideration, Liability, Current Variable Rate [Domain] Variable Rate [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative expenses Selling, General and Administrative Expense Canadian dollar Canada, Dollars Change in fair value of contingent consideration Decrease in fair value of contingent consideration Decrease in fair value of contingent payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Operating lease assets Operating Lease, Right-of-Use Asset Repurchase of common stock Value of shares repurchased Stock Repurchased During Period, Value Accumulated Other Comprehensive Income (Loss) Total AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Income from operations Operating Income (Loss) Inventories Increase (Decrease) in Inventories Equity securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Effect of potentially dilutive securities: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill Other current liabilities Other Current Liabilities [Member] Gross Unrealized Losses Equity Securities, FV-NI, Unrealized Loss Repurchase of common stock (in shares) Shares repurchased (in shares) Stock Repurchased During Period, Shares Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Fair Value Cash Equivalents And Debt Securities, Available for Sale, Fair Value Disclosure Cash Equivalents And Debt Securities, Available for Sale, Fair Value Disclosure Income Statement [Abstract] Income Statement [Abstract] Hedging Relationship [Axis] Hedging Relationship [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Cost of sales Cost of Goods and Services Sold Derivative [Line Items] Derivative [Line Items] Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Gross Amounts Presented Derivative Liability Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Total liabilities Gross Amounts Recognized Derivative Liability, Subject to Master Netting Arrangement, before Offset Contingent liabilities Contingent Liabilities Contingent Liabilities Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Base Rate Base Rate [Member] Marketable securities: Marketable Securities Entrada Therapeutics Entrada Therapeutics [Member] Entrada Therapeutics Common stock, $0.01 par value; 500,000,000 shares authorized, 257,509,761 and 257,011,628 shares issued and outstanding, respectively Common Stock, Value, Issued Schedule of Potential Gross Common Equivalent Shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Financial Assets Subject to Fair Value Measurements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] CRISPR JDCA CRSIPR JDCA [Member] CRISPR Amended and restated the Original CTX001 JDCA Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cash, cash equivalents and restricted cash—beginning of period Cash, cash equivalents and restricted cash—end of period Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Foreign currency forward contracts Foreign Exchange Forward [Member] Common stock, shares issued (in shares) Common Stock, Shares, Issued Indemnification claims Indemnification Claims Amount of indemnification claims currently outstanding Schedule of Company's Net Unrealized Gains (Losses) on Corporate Equity Securities Unrealized Gain (Loss) on Investments [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Cash Flow Hedging Cash Flow Hedging [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Debt covenant, increase in consolidated leverage ratio Debt Covenant, Increase In Consolidated Leverage Ratio Debt Covenant, Increase In Consolidated Leverage Ratio Offsetting Derivative Liabilities [Abstract] Offsetting Derivative Liabilities [Abstract] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. Debt securities fair value, unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Legal Offset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Long-term marketable securities Marketable Securities, Noncurrent [Member] Marketable Securities, Noncurrent Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Issuances of common stock under benefit plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other current liabilities Other Liabilities, Current Other assets Other Assets, Noncurrent Unrealized gains (losses) on foreign currency forward contracts, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Depreciation expense Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Derivative [Table] Derivative [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Cash equivalents: Cash and Cash Equivalents [Abstract] Currency [Axis] Currency [Axis] Stock options Stock options Share-Based Payment Arrangement, Option [Member] Other income (expense), net Other income (expense), net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Basis of Presentation and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Common stock, shares authorized (in shares) Common Stock, Shares Authorized Swiss Franc Switzerland, Francs Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax CRISPR CRISPR [Member] CRISPR Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Designated as Hedging Instruments Designated as hedging instruments Designated as Hedging Instrument [Member] Cash paid for income taxes Income Taxes Paid, Net Entity Small Business Entity Small Business Unrealized (losses) gains on foreign currency forward contracts, net of tax of $7.4 and $(2.2), respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Measurement Frequency [Domain] Measurement Frequency [Domain] Revenues: Revenues [Abstract] Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Line of Credit Facility [Table] Line of Credit Facility [Table] Purchases of available-for-sale debt securities Payments to Acquire Debt Securities, Available-for-Sale Issuance of common stock under benefit plans (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Income tax effect Share-Based Payment Arrangement, Expense, Tax Benefit Accounts receivable, net Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Total costs and expenses Costs and Expenses Total marketable debt securities Marketable Securities And Other Noncurrent Assets [Member] Marketable Securities And Other Noncurrent Assets Other assets, foreign currency forward contracts Derivative Asset, Noncurrent Investments with restrictions Restricted Investments, at Fair Value Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent U.S. Treasury securities US Treasury Securities [Member] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Marketable Securities and Equity Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Inventories Total Inventory, Net CRISPR Therapeutics CRISPR Therapeutics AG [Member] CRISPR Therapeutics AG Accounts payable Accounts Payable, Current Allocation of net profits and net losses, percent Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent Gross Unrealized Gains Debt and Equity Securities, Unrealized Gain Debt and Equity Securities, Unrealized Gain Amortized Cost Equity Securities, FV-NI, Cost Hedging Relationship [Domain] Hedging Relationship [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Entity Filer Category Entity Filer Category Gross Amounts Offset Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic United States UNITED STATES Marketable securities Marketable Securities [Member] Marketable Securities [Member] Financial instruments carried at fair value (liability positions): Liabilities, Fair Value Disclosure [Abstract] Schedule of Foreign Exchange Contracts Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Total stock-based compensation expense included in costs and expenses Share-Based Payment Arrangement, Expense Commitments and contingencies Commitments and Contingencies Security Exchange Name Security Exchange Name Legal Offset Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Notional amount of foreign currency forward contract Derivative, Notional Amount Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Restricted stock units (including PSUs) Restricted Stock [Member] TRIKAFTA/KAFTRIO TRIKAFTA/KAFTRIO [Member] TRIKAFTA/KAFTRIO [Member] Gross Amounts Not Offset Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Product revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Cash equivalents: Cash and cash equivalents Cash and Cash Equivalents [Member] Cover [Abstract] Cover [Abstract] Level 3 Fair Value, Inputs, Level 3 [Member] Stock-based Compensation Expense and Share Repurchase Programs Share-Based Payment Arrangement [Text Block] Work-in-process Inventory, Work in Process, Net of Reserves Revenue Recognition Revenue from Contract with Customer [Text Block] Derivative asset current, foreign currency forward contracts Derivative Asset, Current Interest expense Interest Income (Expense), Net Payments in connection with common stock withheld for employee tax obligations Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and shareholders’ equity Liabilities and Equity Stock repurchase program, remaining amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Cash Cash Share-based payment arrangements (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Total product revenues outside of the United States Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Not Designated as Hedging Instrument Not designated as hedging instruments Not Designated as Hedging Instrument [Member] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Marketable securities Marketable Securities, Current Intangible assets Intangible Assets, Net (Excluding Goodwill) Diluted (in dollars per share) Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted Gross Amounts Not Offset Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Total stock-based compensation expense included in “Total costs and expenses” Share-Based Payment Arrangement, Expensed and Capitalized, Amount Other Other, Non U.S. [Member] Other, Non U.S. [Member] Corporate equity securities Equity Securities [Member] Net unrecognized tax benefits which would affect the tax rate if recognized Unrecognized Tax Benefits that Would Impact Effective Tax Rate Corporate debt securities Corporate Debt Securities [Member] Gross Amounts Offset Derivative Liability, Subject to Master Netting Arrangement, Asset Offset (Gains) losses on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Offsetting Derivative Assets [Abstract] Offsetting Derivative Assets [Abstract] Total assets Gross Amounts Recognized Derivative Asset, Subject to Master Netting Arrangement, before Offset Entity Address, Address Line One Entity Address, Address Line One Other financing activities Proceeds from (Payments for) Other Financing Activities Stock-based compensation expense related to inventories Share-Based Payment Arrangement, Amount Capitalized Contract liabilities Contract with Customer, Liability Net unrealized gains (losses) Unrealized Gain (Loss) on Investments Product and Service [Axis] Product and Service [Axis] Europe Europe [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Debt and Equity Securities, Fair Value Debt and Equity Securities, Fair Value Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Total marketable debt securities Debt Securities, Available-for-Sale [Abstract] Credit Facility [Axis] Credit Facility [Axis] Inventories Inventory Disclosure [Text Block] Equity [Abstract] Equity [Abstract] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Gross Unrealized Losses Debt and Equity Securities, Unrealized Loss Debt and Equity Securities, Unrealized Loss Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Investment in equity securities Payments to Acquire Equity Securities, FV-NI Common stock withheld for employee tax obligations (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Employee stock purchase program (in shares) Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Issuance of common stock under benefit plans Stock Issued During Period, Value, Employee Benefit Plan Contingent consideration, measurement input (as a percent) Business Combination, Contingent Consideration, Liability, Measurement Input Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Corporate equity securities Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Common stock withheld for employee tax obligations Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Acquired In-Process Research and Development and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Line of credit facility additional borrowing capacity Line Of Credit Facility Additional Borrowing Capacity Amount of increased borrowing capacity available in the future. Measurement Input Type [Axis] Measurement Input Type [Axis] Entity [Domain] Entity [Domain] City Area Code City Area Code Assets Assets [Abstract] Collaborative arrangement, right to exclusively license, number of targets Collaborative Arrangement, Right To License, Number Of Targets Collaborative Arrangement, Right To License, Number Of Targets Euro Euro Member Countries, Euro Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Maturities of available-for-sale debt securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Acquired in-process research and development expenses Research and Development in Process Total financial liabilities Financial Liabilities Fair Value Disclosure Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Variable Rate [Axis] Variable Rate [Axis] Other long-term liabilities Other Liabilities, Noncurrent Other liabilities Increase (Decrease) in Other Operating Liabilities Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Research and development expenses Research and Development Expense [Member] Derivative term Derivative, Term of Contract Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of sales Cost of Sales [Member] Schedule of Offsetting Assets Offsetting Assets [Table Text Block] Other long-term liabilities, foreign currency forward contracts Derivative Liability, Noncurrent EX-101.PRE 9 vrtx-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 vrtx-20230331_g1.gif GRAPHIC begin 644 vrtx-20230331_g1.gif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htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
 3 Months Ended
Mar. 31, 2023
Apr. 25, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 000-19319  
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA  
Entity Incorporation, State or Country Code MA  
Entity Tax Identification Number 04-3039129  
Entity Address, Address Line One 50 Northern Avenue  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02210  
City Area Code 617  
Local Phone Number 341-6100  
Title of 12(b) Security Common Stock, $0.01 Par Value Per Share  
Trading Symbol VRTX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   257,551,600
Entity Central Index Key 0000875320  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues:    
Product revenues, net $ 2,374.8 $ 2,097.5
Costs and expenses:    
Cost of sales 266.9 245.8
Research and development expenses 742.6 601.1
Acquired in-process research and development expenses 347.1 2.0
Selling, general and administrative expenses 241.1 215.2
Change in fair value of contingent consideration (1.9) (7.5)
Total costs and expenses 1,595.8 1,056.6
Income from operations 779.0 1,040.9
Interest income 122.6 1.6
Interest expense (11.4) (14.9)
Other income (expense), net 1.3 (72.8)
Income before provision for income taxes 891.5 954.8
Provision for income taxes 191.7 192.7
Net income $ 699.8 $ 762.1
Net income per common share:    
Basic (in dollars per share) $ 2.72 $ 2.99
Diluted (in dollars per share) $ 2.69 $ 2.96
Shares used in per share calculations:    
Basic (in shares) 257.4 255.1
Diluted (in shares) 260.3 257.9
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Statement of Comprehensive Income [Abstract]    
Net income $ 699.8 $ 762.1
Other comprehensive income:    
Unrealized holding gains (losses) on marketable securities, net of tax of $(0.8) and zero, respectively 2.9 (2.3)
Unrealized (losses) gains on foreign currency forward contracts, net of tax of $7.4 and $(2.2), respectively (26.8) 10.1
Foreign currency translation adjustment 10.0 (12.4)
Total other comprehensive loss (13.9) (4.6)
Comprehensive income $ 685.9 $ 757.5
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Statement of Comprehensive Income [Abstract]    
Unrealized holding gains (losses) on marketable securities, tax $ (0.8) $ 0.0
Unrealized gains (losses) on foreign currency forward contracts, tax $ 7.4 $ (2.2)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 9,289.9 $ 10,504.0
Marketable securities 1,124.2 274.5
Accounts receivable, net 1,547.8 1,442.2
Inventories 535.1 460.6
Prepaid expenses and other current assets 468.7 553.5
Total current assets 12,965.7 13,234.8
Property and equipment, net 1,111.7 1,108.4
Goodwill 1,088.0 1,088.0
Intangible assets 603.6 603.6
Deferred tax assets 1,359.9 1,246.9
Operating lease assets 336.3 347.4
Long-term marketable securities 1,081.5 112.2
Other assets 427.5 409.6
Total assets 18,974.2 18,150.9
Current liabilities:    
Accounts payable 323.2 303.9
Accrued expenses 2,326.0 2,126.7
Other current liabilities 377.0 311.5
Total current liabilities 3,026.2 2,742.1
Long-term finance lease liabilities 417.6 430.8
Long-term operating lease liabilities 371.6 379.5
Other long-term liabilities 726.5 685.8
Total liabilities 4,541.9 4,238.2
Commitments and contingencies 0.0 0.0
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding 0.0 0.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 257,509,761 and 257,011,628 shares issued and outstanding, respectively 2.6 2.6
Additional paid-in capital 7,220.2 7,386.5
Accumulated other comprehensive (loss) income (13.1) 0.8
Retained earnings 7,222.6 6,522.8
Total shareholders’ equity 14,432.3 13,912.7
Total liabilities and shareholders’ equity $ 18,974.2 $ 18,150.9
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 257,509,761 257,011,628
Common stock, shares outstanding (in shares) 257,509,761 257,011,628
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Beginning balance (in shares) at Dec. 31, 2021   254,500,000      
Beginning balance at Dec. 31, 2021 $ 10,100.0 $ 2.5 $ 6,880.8 $ 15.9 $ 3,200.8
Increase (Decrease) in Stockholders' Equity          
Other comprehensive loss, net of tax (4.6)     (4.6)  
Net income 762.1       762.1
Common stock withheld for employee tax obligations (in shares)   (500,000)      
Common stock withheld for employee tax obligations (117.5) $ (0.0) (117.5)    
Issuance of common stock under benefit plans (in shares)   1,600,000      
Issuance of common stock under benefit plans 36.5 $ 0.1 36.4    
Stock-based compensation expense 130.5   130.5    
Ending balance (in shares) at Mar. 31, 2022   255,600,000      
Ending balance at Mar. 31, 2022 $ 10,907.0 $ 2.6 6,930.2 11.3 3,962.9
Beginning balance (in shares) at Dec. 31, 2022 257,011,628 257,000,000.0      
Beginning balance at Dec. 31, 2022 $ 13,912.7 $ 2.6 7,386.5 0.8 6,522.8
Increase (Decrease) in Stockholders' Equity          
Other comprehensive loss, net of tax (13.9)     (13.9)  
Net income $ 699.8       699.8
Repurchase of common stock (in shares) (459,017) (500,000)      
Repurchase of common stock $ (135.6) $ (0.0) (135.6)    
Common stock withheld for employee tax obligations (in shares)   (600,000)      
Common stock withheld for employee tax obligations (166.6) $ (0.0) (166.6)    
Issuance of common stock under benefit plans (in shares)   1,600,000      
Issuance of common stock under benefit plans 13.1 $ 0.0 13.1    
Stock-based compensation expense $ 122.8   122.8    
Ending balance (in shares) at Mar. 31, 2023 257,509,761 257,500,000      
Ending balance at Mar. 31, 2023 $ 14,432.3 $ 2.6 $ 7,220.2 $ (13.1) $ 7,222.6
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net income $ 699.8 $ 762.1
Adjustments to reconcile net income to net cash provided by operating activities:    
Stock-based compensation expense 122.4 130.3
Depreciation expense 38.8 35.9
Deferred income taxes (113.4) (12.3)
(Gains) losses on equity securities (6.4) 75.6
Decrease in fair value of contingent consideration (1.9) (7.5)
Other non-cash items, net 21.7 4.9
Changes in operating assets and liabilities:    
Accounts receivable, net (90.5) (165.2)
Inventories (82.6) 2.0
Prepaid expenses and other assets 46.2 67.6
Accounts payable 35.7 (14.5)
Accrued expenses 140.7 61.6
Other liabilities 89.4 15.7
Net cash provided by operating activities 899.9 956.2
Cash flows from investing activities:    
Purchases of available-for-sale debt securities (1,816.6) (117.1)
Maturities of available-for-sale debt securities 50.0 129.7
Purchases of property and equipment (42.1) (63.6)
Investment in equity securities (24.9) 0.0
Net cash used in investing activities (1,833.6) (51.0)
Cash flows from financing activities:    
Issuances of common stock under benefit plans 14.2 33.7
Repurchases of common stock (132.8) 0.0
Payments in connection with common stock withheld for employee tax obligations (166.6) (117.5)
Payments on finance leases (10.6) (12.9)
Other financing activities 1.1 1.3
Net cash used in financing activities (294.7) (95.4)
Effect of changes in exchange rates on cash 12.0 (5.9)
Net (decrease) increase in cash, cash equivalents and restricted cash (1,216.4) 803.9
Cash, cash equivalents and restricted cash—beginning of period 10,512.0 6,800.1
Cash, cash equivalents and restricted cash—end of period 9,295.6 7,604.0
Supplemental disclosure of cash flow information:    
Cash paid for income taxes 120.3 85.0
Cash paid for interest $ 11.1 $ 13.7
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation and Accounting Policies
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Accounting Policies Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Beginning with the second quarter of 2022, we are separately classifying upfront, contingent milestone, and other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development expenses” in our condensed consolidated statements of income. To conform prior periods to current presentation, we reclassified $2.0 million from “Research and development expenses” to “Acquired in-process research and development expenses” for the three months ended March 31, 2022. Please refer to Note C, “Acquired In-Process Research and Development and Other Arrangements,” for further information on these transactions. We have reclassified certain items from the prior year’s condensed consolidated balance sheet to conform to the current year’s presentation.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended March 31, 2023 and 2022.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, which are contained in our 2022 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted and Issued Accounting Standards
For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2022 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.
Summary of Significant Accounting Policies
Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2022 Annual Report on Form 10-K.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Disaggregation of Revenue
Revenues by Product
“Product revenues, net” consisted of the following:
Three Months Ended March 31,
20232022
(in millions)
TRIKAFTA/KAFTRIO$2,096.7 $1,761.6 
KALYDECO125.0 139.0 
ORKAMBI122.5 132.1 
SYMDEKO/SYMKEVI30.6 64.8 
Total product revenues, net$2,374.8 $2,097.5 
Product Revenues by Geographic Location
“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended March 31,
20232022
(in millions)
United States$1,403.8 $1,368.2 
Outside of the United States
Europe807.2 632.3 
Other
163.8 97.0 
Total product revenues outside of the United States971.0 729.3 
Total product revenues, net
$2,374.8 $2,097.5 
Contract Liabilities
We had contract liabilities of $236.4 million and $159.6 million as of March 31, 2023 and December 31, 2022, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Acquired In-Process Research and Development and Other Arrangements
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Acquired In-Process Research and Development and Other Arrangements Acquired In-Process Research and Development and Other Arrangements
We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. Our “Acquired in-process research and development expenses” included $347.1 million for the three months ended March 31, 2023, and $2.0 million, for the three months ended March 31, 2022, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions that qualify as in-process research and development.
Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three months ended March 31, 2023 and 2022, or were new or materially revised during the three months ended March 31, 2023, are described below. Additional agreements were described in Note B, “Acquired In-Process Research and Development and Other Arrangements,” of our 2022 Annual Report on Form 10-K.
In-license Agreements
We have entered into several in-license agreements to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.
Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.
We typically can terminate our in-license agreements by providing advance notice to our collaborators. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG - CRISPR-Cas9 Gene-editing Therapies
In 2015, we entered into a strategic collaboration, option, and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on resulting net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR (the “CRISPR JDCA”), which we amended and restated in 2021, pursuant to the terms of the CRISPR Agreement. Under the CRISPR JDCA, we and CRISPR are co-developing and preparing to co-commercialize exagamglogene autotemcel (“exa-cel”), for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia. Pursuant to the CRISPR JDCA, we lead global development, manufacturing, and commercialization of exa-cel, with support from CRISPR. We also conduct all research, development, manufacturing, and commercialization activities relating to other product candidates and products under the CRISPR JDCA throughout the world subject to CRISPR’s reserved right to conduct certain activities.
In connection with the CRISPR JDCA, CRISPR has the potential to receive a one-time $200.0 million milestone payment upon receipt of the first marketing approval of exa-cel from the U.S. Food and Drug Administration or the European Commission.
We account for the CRISPR JDCA as a cost-sharing arrangement, with costs incurred related to exa-cel allocated 60% to us and 40% to CRISPR, subject to certain adjustments. During the three months ended March 31, 2023 and 2022, we recognized the net impact of the CRISPR JDCA as “Research and development expenses” of $60.5 million and $36.2
million, respectively, and “Selling, general and administrative expenses” of $16.5 million and $9.8 million, respectively, within our condensed consolidated statements of income.
In March 2023, we entered into a non-exclusive license agreement (“the CRISPR T1D Agreement”) for the use of CRISPR’s CRISPR-Cas9 gene-editing technology to accelerate the development of our hypoimmune cell therapies for type 1 diabetes. Pursuant to the CRISPR T1D Agreement, we made a $100.0 million upfront payment to CRISPR. CRISPR is also eligible to receive up to an additional $230.0 million in research, development, regulatory and commercial milestones for any products that may result from the agreement, as well as royalties on resulting net product sales. We determined that substantially all the fair value of the collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses.”
Entrada Therapeutics, Inc.
In February 2023, we closed a strategic collaboration and license agreement (the “Entrada Agreement”) with Entrada Therapeutics, Inc. (“Entrada”) focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (“DM1”). Upon closing, we made an upfront payment of $225.1 million to Entrada, and purchased $24.9 million of Entrada’s common stock in connection with the Entrada Agreement. Entrada is eligible to receive up to an additional $485.0 million in research, development, regulatory and commercial milestones for any products that may result from the Entrada Agreement, as well as royalties on resulting net product sales. We determined that substantially all the fair value of the collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses.” We recorded the investment in Entrada’s common stock at fair value within our condensed consolidated balance sheet within “Marketable securities.”
Cystic Fibrosis Foundation
In 2004, we entered into a collaboration agreement with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc., to support research and development activities. Pursuant to the collaboration agreement, as amended, we have agreed to pay tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including ivacaftor, lumacaftor and tezacaftor and royalties ranging from low-single digits to mid-single digits on potential net sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor. We do not have any royalty obligations on compounds first synthesized and tested on or after September 1, 2016. For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO, sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended March 31,
20232022
(in millions, except per share amounts)
Net income$699.8 $762.1 
Basic weighted-average common shares outstanding257.4 255.1 
Effect of potentially dilutive securities:
Stock options1.3 1.3 
Restricted stock units (including PSUs)
1.6 1.4 
Employee stock purchase program
0.0 0.1 
Diluted weighted-average common shares outstanding260.3 257.9 
Basic net income per common share$2.72 $2.99 
Diluted net income per common share$2.69 $2.96 
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended March 31,
20232022
(in millions)
Stock options0.0 0.0 
Unvested restricted stock units (including PSUs)0.6 0.6 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic equity investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note F, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of income.
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $2.1 billion and $3.1 billion of cash as of March 31, 2023 and December 31, 2022, respectively):
As of March 31, 2023As of December 31, 2022
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds$4,954.1 $4,954.1 $— $— $5,162.6 $5,162.6 $— $— 
Time deposits1,600.0 — 1,600.0 — 2,000.0 — 2,000.0 — 
U.S. Treasury securities86.4 86.4 — — — — — — 
Government-sponsored enterprise securities129.3 129.3 — — — — — — 
Corporate debt securities1.7 — 1.7 — 5.8 — 5.8 — 
Commercial paper408.0 — 408.0 — 204.5 — 204.5 — 
Marketable securities:
Corporate equity securities148.1 127.2 20.9 — 116.8 88.8 28.0 — 
U.S. Treasury securities276.6 276.6 — — — — — — 
Government-sponsored enterprise securities532.4 532.4 — — 127.1 127.1 — — 
Asset-backed securities117.9 — 117.9 — — — — — 
Certificates of deposit44.9 — 44.9 — — — — — 
Corporate debt securities771.5 — 771.5 — 87.0 — 87.0 — 
Commercial paper314.3 — 314.3 — 55.8 — 55.8 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts19.5 — 19.5 — 47.5 — 47.5 — 
Other assets:
Foreign currency forward contracts0.3 — 0.3 — 0.8 — 0.8 — 
Total financial assets
$9,405.0 $6,106.0 $3,299.0 $— $7,807.9 $5,378.5 $2,429.4 $— 
:::::::
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(20.5)$— $(20.5)$— $(14.3)$— $(14.3)$— 
Contingent consideration(14.8)— — (14.8)(14.6)— — (14.6)
Other long-term liabilities:
Foreign currency forward contracts(0.5)— (0.5)— (0.9)— (0.9)— 
Contingent consideration(112.3)— — (112.3)(114.4)— — (114.4)
Total financial liabilities
$(148.1)$— $(21.0)$(127.1)$(144.2)$— $(15.2)$(129.0)
Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments.
As of March 31, 2023, several of our investments in publicly traded corporate equity securities were subject to contractual sales restrictions expiring in 2023, 2024 and 2025 with a total fair value of $42.8 million. We purchased these investments directly from these publicly traded companies in 2022 and the first quarter of 2023, and do not anticipate any circumstances that would cause these restrictions to lapse prior to the periods listed above.
Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to former Exonics equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data attributable to rare diseases and our knowledge of the progress and viability of the programs. The discount rates used in the valuation model for contingent payments, which were between 4.7% and 5.8% as of March 31, 2023, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future, resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Three Months Ended March 31, 2023
(in millions)
Balance at December 31, 2022$129.0 
Decrease in fair value of contingent payments
(1.9)
Balance at March 31, 2023$127.1 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities and Equity Investments
 3 Months Ended
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities and Equity Investments Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $2.1 billion and $3.1 billion of cash as of March 31, 2023 and December 31, 2022, respectively), is shown below:
As of March 31, 2023As of December 31, 2022
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$4,954.1 $— $— $4,954.1 $5,162.6 $— $— $5,162.6 
Time deposits1,600.0 — — 1,600.0 2,000.0 — — 2,000.0 
U.S. Treasury securities86.3 0.1 — 86.4 — — — — 
Government-sponsored enterprise securities
129.2 0.1 — 129.3 — — — — 
Corporate debt securities1.7 — — 1.7 5.8 — — 5.8 
Commercial paper408.0 — — 408.0 204.5 — — 204.5 
Total cash equivalents
$7,179.3 $0.2 $— $7,179.5 $7,372.9 $— $— $7,372.9 
Marketable securities:
U.S. Treasury securities$274.8 $1.8 $— $276.6 $— $— $— $— 
Government-sponsored enterprise securities
532.0 0.5 (0.1)532.4 127.0 0.2 (0.1)127.1 
Asset-backed securities118.1 — (0.2)117.9 — — — — 
Certificates of deposit44.9 — — 44.9 — — — — 
Corporate debt securities
770.0 2.9 (1.4)771.5 87.2 — (0.2)87.0 
Commercial paper
314.4 — (0.1)314.3 55.8 — — 55.8 
Total marketable debt securities
2,054.2 5.2 (1.8)2,057.6 270.0 0.2 (0.3)269.9 
Corporate equity securities
129.4 47.4 (28.7)148.1 104.4 30.9 (18.5)116.8 
Total marketable securities
$2,183.6 $52.6 $(30.5)$2,205.7 $374.4 $31.1 $(18.8)$386.7 
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of March 31, 2023As of December 31, 2022
(in millions)
Cash and cash equivalents$5,579.5 $5,372.9 
Marketable securities
976.1 157.7 
Long-term marketable securities1,081.5 112.2 
Total
$7,637.1 $5,642.8 
Available-for-sale debt securities by contractual maturity were as follows:
As of March 31, 2023As of December 31, 2022
(in millions)
Matures within one year$6,555.6 $5,530.6 
Matures after one year through five years
1,081.5 112.2 
Total
$7,637.1 $5,642.8 
We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three months ended March 31, 2023 and 2022. As of March 31, 2023, we held available-for-sale debt securities with a total fair value of $702.7 million that were in unrealized loss positions; however, none of these investments had been in an unrealized loss position for greater than twelve months.
We record changes in the fair value of our investments in corporate equity securities to “Other income (expense), net” in our condensed consolidated statements of income. During the three months ended March 31, 2023 and 2022, our net unrealized gains (losses) on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended March 31,
20232022
(in millions)
Net unrealized gains (losses)
$6.4 $(75.6)
        
As of March 31, 2023, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $98.6 million.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Accumulated Other Comprehensive Income (Loss)
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance at December 31, 2022$(25.0)$(0.1)$25.9 $0.8 
Other comprehensive income (loss) before reclassifications10.0 2.9 (9.6)3.3 
Amounts reclassified from accumulated other comprehensive income (loss)— — (17.2)(17.2)
Net current period other comprehensive income (loss)10.0 2.9 (26.8)(13.9)
Balance at March 31, 2023$(15.0)$2.8 $(0.9)$(13.1)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(12.4)(2.3)25.9 11.2 
Amounts reclassified from accumulated other comprehensive income (loss)— — (15.8)(15.8)
Net current period other comprehensive (loss) income(12.4)(2.3)10.1 (4.6)
Balance at March 31, 2022$(26.0)$(2.8)$40.1 $11.3 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Hedging
 3 Months Ended
Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our condensed consolidated statements of income in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging
activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2023, all hedges were determined to be highly effective.
We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of March 31, 2023 and December 31, 2022, credit risk did not change the fair value of our foreign currency forward contracts.
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of March 31, 2023As of December 31, 2022
Foreign Currency(in millions)
Euro$1,325.9 $1,497.7 
British pound sterling
243.5 247.4 
Canadian dollar
231.1 216.3 
Australian dollar
180.3 174.9 
Swiss Franc65.9 65.2 
Total foreign currency forward contracts
$2,046.7 $2,201.5 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other income (expense), net” in our condensed consolidated statements of income each period. As of March 31, 2023, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $541.3 million.
During the three months ended March 31, 2023 and 2022, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:
Three Months Ended March 31,
20232022
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$22.0 $20.1 
Not designated as hedging instruments
Other income (expense), net$3.6 $(8.4)
Total reported in the Condensed Consolidated Statements of Income
Product revenues, net$2,374.8 $2,097.5 
Other income (expense), net$1.3 $(72.8)
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of March 31, 2023
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$19.5 Other current liabilities$(20.5)
Other assets0.3 Other long-term liabilities(0.5)
Total assets
$19.8 
Total liabilities
$(21.0)
As of December 31, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$47.5 Other current liabilities$(14.3)
Other assets0.8 Other long-term liabilities(0.9)
Total assets
$48.3 
Total liabilities
$(15.2)
As of March 31, 2023, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:
As of March 31, 2023
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$19.8 $— $19.8 $(19.8)$— 
Total liabilities(21.0)— (21.0)19.8 (1.2)
As of December 31, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$48.3 $— $48.3 $(15.2)$33.1 
Total liabilities(15.2)— (15.2)15.2 — 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories
 3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of the following:
As of March 31, 2023As of December 31, 2022
(in millions)
Raw materials$58.1 $38.1 
Work-in-process341.1 260.7 
Finished goods
135.9 161.8 
Total
$535.1 $460.6 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-based Compensation Expense and Share Repurchase Programs
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Expense and Share Repurchase Programs Stock-based Compensation Expense and Share Repurchase Programs
Stock-based compensation expense
During the three months ended March 31, 2023 and 2022, we recognized the following stock-based compensation expense:
Three Months Ended March 31,
20232022
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$115.9 $118.2 
Stock options1.4 5.5 
ESPP share issuances5.5 6.8 
Stock-based compensation expense related to inventories
(0.4)(0.2)
Total stock-based compensation expense included in “Total costs and expenses”
$122.4 $130.3 
Stock-based compensation expense by line item:
Cost of sales$1.9 $2.2 
Research and development expenses76.3 80.4 
Selling, general and administrative expenses44.2 47.7 
Total stock-based compensation expense included in costs and expenses
122.4 130.3 
Income tax effect(40.6)(36.0)
Total stock-based compensation expense, net of tax
$81.8 $94.3 
Share repurchase program
In February 2023, our Board of Directors approved a share repurchase program (our “Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $3.0 billion of our common stock. Our Share Repurchase Program does not have an expiration date and can be discontinued at any time. During the three months ended March 31, 2023, we repurchased 459,017 shares of our common stock under our Share Repurchase Program for an aggregate of $135.6 million. As of March 31, 2023, a total of $2.9 billion remained authorized for future repurchases.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
 3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
We are subject to U.S. federal, state, and foreign income taxes. During the three months ended March 31, 2023 and 2022, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended March 31,
20232022
(in millions, except percentages)
Income before provision for income taxes$891.5 $954.8 
Provision for income taxes$191.7 $192.7 
Effective tax rate21.5 %20.2 %
Our effective tax rate for the three months ended March 31, 2023 was higher than the U.S. statutory rate primarily due to an increase in our unrecognized tax benefits partially offset by excess tax benefits related to stock-based compensation. Our effective tax rate for the three months ended March 31, 2022 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation.
We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of March 31, 2023 and December 31, 2022, we had $232.2 million and $208.5 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.
We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2014 in jurisdictions that have a material impact on our consolidated financial statements.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
2022 Credit Facility
In July 2022, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”), which matures on July 1, 2027. The Credit Agreement was not drawn upon at closing and we have not drawn upon it to date. Amounts drawn pursuant to the Credit Agreement, if any, will be used for general corporate purposes. Subject to satisfaction of certain conditions, we may request that the borrowing capacity for the Credit Agreement be increased by an additional $500.0 million. Additionally, the Credit Agreement provides a sublimit of $100.0 million for letters of credit.
Any amounts borrowed under the Credit Agreement will bear interest, at our option, at either a base rate or a Secured Overnight Financing Rate (“SOFR”), in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.000% to 0.500% and the applicable margins on SOFR loans range from 1.000% to 1.500%, in each case based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period).
Any amounts borrowed pursuant to the Credit Agreement are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.
The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including a financial covenant to maintain subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition. As of March 31, 2023, we were in compliance with the covenants described above. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Direct costs related to the Credit Agreement are recorded over its term and were not material to our financial statements.
Guaranties and Indemnifications
As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.
We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue for such contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note E, “Fair Value Measurements,” there were no material contingent liabilities accrued as of March 31, 2023 or December 31, 2022.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Additional Cash Flow Information
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Additional Cash Flow Information Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Three Months Ended March 31,
20232022
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$10,504.0 $9,289.9 $6,795.0 $7,600.1 
Prepaid expenses and other current assets
8.0 5.7 5.1 3.9 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$10,512.0 $9,295.6 $6,800.1 $7,604.0 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation and Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Beginning with the second quarter of 2022, we are separately classifying upfront, contingent milestone, and other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development expenses” in our condensed consolidated statements of income. To conform prior periods to current presentation, we reclassified $2.0 million from “Research and development expenses” to “Acquired in-process research and development expenses” for the three months ended March 31, 2022. Please refer to Note C, “Acquired In-Process Research and Development and Other Arrangements,” for further information on these transactions. We have reclassified certain items from the prior year’s condensed consolidated balance sheet to conform to the current year’s presentation.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended March 31, 2023 and 2022.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, which are contained in our 2022 Annual Report on Form 10-K.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition (Tables)
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
“Product revenues, net” consisted of the following:
Three Months Ended March 31,
20232022
(in millions)
TRIKAFTA/KAFTRIO$2,096.7 $1,761.6 
KALYDECO125.0 139.0 
ORKAMBI122.5 132.1 
SYMDEKO/SYMKEVI30.6 64.8 
Total product revenues, net$2,374.8 $2,097.5 
“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended March 31,
20232022
(in millions)
United States$1,403.8 $1,368.2 
Outside of the United States
Europe807.2 632.3 
Other
163.8 97.0 
Total product revenues outside of the United States971.0 729.3 
Total product revenues, net
$2,374.8 $2,097.5 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share (Tables)
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended March 31,
20232022
(in millions, except per share amounts)
Net income$699.8 $762.1 
Basic weighted-average common shares outstanding257.4 255.1 
Effect of potentially dilutive securities:
Stock options1.3 1.3 
Restricted stock units (including PSUs)
1.6 1.4 
Employee stock purchase program
0.0 0.1 
Diluted weighted-average common shares outstanding260.3 257.9 
Basic net income per common share$2.72 $2.99 
Diluted net income per common share$2.69 $2.96 
Schedule of Potential Gross Common Equivalent Shares
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended March 31,
20232022
(in millions)
Stock options0.0 0.0 
Unvested restricted stock units (including PSUs)0.6 0.6 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets Subject to Fair Value Measurements
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $2.1 billion and $3.1 billion of cash as of March 31, 2023 and December 31, 2022, respectively):
As of March 31, 2023As of December 31, 2022
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds$4,954.1 $4,954.1 $— $— $5,162.6 $5,162.6 $— $— 
Time deposits1,600.0 — 1,600.0 — 2,000.0 — 2,000.0 — 
U.S. Treasury securities86.4 86.4 — — — — — — 
Government-sponsored enterprise securities129.3 129.3 — — — — — — 
Corporate debt securities1.7 — 1.7 — 5.8 — 5.8 — 
Commercial paper408.0 — 408.0 — 204.5 — 204.5 — 
Marketable securities:
Corporate equity securities148.1 127.2 20.9 — 116.8 88.8 28.0 — 
U.S. Treasury securities276.6 276.6 — — — — — — 
Government-sponsored enterprise securities532.4 532.4 — — 127.1 127.1 — — 
Asset-backed securities117.9 — 117.9 — — — — — 
Certificates of deposit44.9 — 44.9 — — — — — 
Corporate debt securities771.5 — 771.5 — 87.0 — 87.0 — 
Commercial paper314.3 — 314.3 — 55.8 — 55.8 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts19.5 — 19.5 — 47.5 — 47.5 — 
Other assets:
Foreign currency forward contracts0.3 — 0.3 — 0.8 — 0.8 — 
Total financial assets
$9,405.0 $6,106.0 $3,299.0 $— $7,807.9 $5,378.5 $2,429.4 $— 
:::::::
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(20.5)$— $(20.5)$— $(14.3)$— $(14.3)$— 
Contingent consideration(14.8)— — (14.8)(14.6)— — (14.6)
Other long-term liabilities:
Foreign currency forward contracts(0.5)— (0.5)— (0.9)— (0.9)— 
Contingent consideration(112.3)— — (112.3)(114.4)— — (114.4)
Total financial liabilities
$(148.1)$— $(21.0)$(127.1)$(144.2)$— $(15.2)$(129.0)
Schedule of Fair Value of Our Contingent Consideration Liabilities
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Three Months Ended March 31, 2023
(in millions)
Balance at December 31, 2022$129.0 
Decrease in fair value of contingent payments
(1.9)
Balance at March 31, 2023$127.1 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities and Equity Investments (Tables)
 3 Months Ended
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash Equivalents and Marketable Securities
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $2.1 billion and $3.1 billion of cash as of March 31, 2023 and December 31, 2022, respectively), is shown below:
As of March 31, 2023As of December 31, 2022
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$4,954.1 $— $— $4,954.1 $5,162.6 $— $— $5,162.6 
Time deposits1,600.0 — — 1,600.0 2,000.0 — — 2,000.0 
U.S. Treasury securities86.3 0.1 — 86.4 — — — — 
Government-sponsored enterprise securities
129.2 0.1 — 129.3 — — — — 
Corporate debt securities1.7 — — 1.7 5.8 — — 5.8 
Commercial paper408.0 — — 408.0 204.5 — — 204.5 
Total cash equivalents
$7,179.3 $0.2 $— $7,179.5 $7,372.9 $— $— $7,372.9 
Marketable securities:
U.S. Treasury securities$274.8 $1.8 $— $276.6 $— $— $— $— 
Government-sponsored enterprise securities
532.0 0.5 (0.1)532.4 127.0 0.2 (0.1)127.1 
Asset-backed securities118.1 — (0.2)117.9 — — — — 
Certificates of deposit44.9 — — 44.9 — — — — 
Corporate debt securities
770.0 2.9 (1.4)771.5 87.2 — (0.2)87.0 
Commercial paper
314.4 — (0.1)314.3 55.8 — — 55.8 
Total marketable debt securities
2,054.2 5.2 (1.8)2,057.6 270.0 0.2 (0.3)269.9 
Corporate equity securities
129.4 47.4 (28.7)148.1 104.4 30.9 (18.5)116.8 
Total marketable securities
$2,183.6 $52.6 $(30.5)$2,205.7 $374.4 $31.1 $(18.8)$386.7 
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of March 31, 2023As of December 31, 2022
(in millions)
Cash and cash equivalents$5,579.5 $5,372.9 
Marketable securities
976.1 157.7 
Long-term marketable securities1,081.5 112.2 
Total
$7,637.1 $5,642.8 
Available-for-sale debt securities by contractual maturity were as follows:
As of March 31, 2023As of December 31, 2022
(in millions)
Matures within one year$6,555.6 $5,530.6 
Matures after one year through five years
1,081.5 112.2 
Total
$7,637.1 $5,642.8 
Schedule of Company's Net Unrealized Gains (Losses) on Corporate Equity Securities During the three months ended March 31, 2023 and 2022, our net unrealized gains (losses) on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended March 31,
20232022
(in millions)
Net unrealized gains (losses)
$6.4 $(75.6)
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Accumulated Other Comprehensive Income (Loss) (Tables)
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance at December 31, 2022$(25.0)$(0.1)$25.9 $0.8 
Other comprehensive income (loss) before reclassifications10.0 2.9 (9.6)3.3 
Amounts reclassified from accumulated other comprehensive income (loss)— — (17.2)(17.2)
Net current period other comprehensive income (loss)10.0 2.9 (26.8)(13.9)
Balance at March 31, 2023$(15.0)$2.8 $(0.9)$(13.1)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(12.4)(2.3)25.9 11.2 
Amounts reclassified from accumulated other comprehensive income (loss)— — (15.8)(15.8)
Net current period other comprehensive (loss) income(12.4)(2.3)10.1 (4.6)
Balance at March 31, 2022$(26.0)$(2.8)$40.1 $11.3 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Hedging (Tables)
 3 Months Ended
Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedging Instruments
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of March 31, 2023As of December 31, 2022
Foreign Currency(in millions)
Euro$1,325.9 $1,497.7 
British pound sterling
243.5 247.4 
Canadian dollar
231.1 216.3 
Australian dollar
180.3 174.9 
Swiss Franc65.9 65.2 
Total foreign currency forward contracts
$2,046.7 $2,201.5 
Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations
During the three months ended March 31, 2023 and 2022, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:
Three Months Ended March 31,
20232022
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$22.0 $20.1 
Not designated as hedging instruments
Other income (expense), net$3.6 $(8.4)
Total reported in the Condensed Consolidated Statements of Income
Product revenues, net$2,374.8 $2,097.5 
Other income (expense), net$1.3 $(72.8)
Schedule of Foreign Exchange Contracts
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of March 31, 2023
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$19.5 Other current liabilities$(20.5)
Other assets0.3 Other long-term liabilities(0.5)
Total assets
$19.8 
Total liabilities
$(21.0)
As of December 31, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$47.5 Other current liabilities$(14.3)
Other assets0.8 Other long-term liabilities(0.9)
Total assets
$48.3 
Total liabilities
$(15.2)
Schedule of Offsetting Liabilities The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:
As of March 31, 2023
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$19.8 $— $19.8 $(19.8)$— 
Total liabilities(21.0)— (21.0)19.8 (1.2)
As of December 31, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$48.3 $— $48.3 $(15.2)$33.1 
Total liabilities(15.2)— (15.2)15.2 — 
Schedule of Offsetting Assets The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:
As of March 31, 2023
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$19.8 $— $19.8 $(19.8)$— 
Total liabilities(21.0)— (21.0)19.8 (1.2)
As of December 31, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$48.3 $— $48.3 $(15.2)$33.1 
Total liabilities(15.2)— (15.2)15.2 — 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories (Tables)
 3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
Inventories consisted of the following:
As of March 31, 2023As of December 31, 2022
(in millions)
Raw materials$58.1 $38.1 
Work-in-process341.1 260.7 
Finished goods
135.9 161.8 
Total
$535.1 $460.6 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-based Compensation Expense and Share Repurchase Programs (Tables)
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expense by Line Item
During the three months ended March 31, 2023 and 2022, we recognized the following stock-based compensation expense:
Three Months Ended March 31,
20232022
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$115.9 $118.2 
Stock options1.4 5.5 
ESPP share issuances5.5 6.8 
Stock-based compensation expense related to inventories
(0.4)(0.2)
Total stock-based compensation expense included in “Total costs and expenses”
$122.4 $130.3 
Stock-based compensation expense by line item:
Cost of sales$1.9 $2.2 
Research and development expenses76.3 80.4 
Selling, general and administrative expenses44.2 47.7 
Total stock-based compensation expense included in costs and expenses
122.4 130.3 
Income tax effect(40.6)(36.0)
Total stock-based compensation expense, net of tax
$81.8 $94.3 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Tables)
 3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Provision for (Benefits from) Income Taxes and Effective Tax rates During the three months ended March 31, 2023 and 2022, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended March 31,
20232022
(in millions, except percentages)
Income before provision for income taxes$891.5 $954.8 
Provision for income taxes$191.7 $192.7 
Effective tax rate21.5 %20.2 %
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Additional Cash Flow Information (Tables)
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Three Months Ended March 31,
20232022
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$10,504.0 $9,289.9 $6,795.0 $7,600.1 
Prepaid expenses and other current assets
8.0 5.7 5.1 3.9 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$10,512.0 $9,295.6 $6,800.1 $7,604.0 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation and Accounting Policies (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2023
USD ($)
segment
Mar. 31, 2022
USD ($)
Accounting Policies [Abstract]    
Number of operating segments | segment 1  
Acquired in-process research and development expenses | $ $ 347.1 $ 2.0
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Product revenues, net $ 2,374.8 $ 2,097.5
United States    
Disaggregation of Revenue [Line Items]    
Product revenues, net 1,403.8 1,368.2
Europe    
Disaggregation of Revenue [Line Items]    
Product revenues, net 807.2 632.3
Other    
Disaggregation of Revenue [Line Items]    
Product revenues, net 163.8 97.0
Total product revenues outside of the United States    
Disaggregation of Revenue [Line Items]    
Product revenues, net 971.0 729.3
TRIKAFTA/KAFTRIO    
Disaggregation of Revenue [Line Items]    
Product revenues, net 2,096.7 1,761.6
KALYDECO    
Disaggregation of Revenue [Line Items]    
Product revenues, net 125.0 139.0
ORKAMBI    
Disaggregation of Revenue [Line Items]    
Product revenues, net 122.5 132.1
SYMDEKO/SYMKEVI    
Disaggregation of Revenue [Line Items]    
Product revenues, net $ 30.6 $ 64.8
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Additional Information (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]    
Contract liabilities $ 236.4 $ 159.6
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
Feb. 28, 2023
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2019
USD ($)
target
Jul. 01, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Acquired in-process research and development expenses     $ 347,100,000 $ 2,000,000      
Selling, general and administrative expenses     241,100,000 215,200,000      
CRISPR Therapeutics              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaborative arrangement, right to exclusively license, number of targets | target           3  
Collaborative arrangement, development and regulatory potential milestone payments maximum           $ 410,000,000  
CRISPR JDCA              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaborative arrangement, development and regulatory potential milestone payments maximum         $ 200,000,000    
Allocation of net profits and net losses, percent             60.00%
Research and development expenses     60,500,000 36,200,000      
Selling, general and administrative expenses     $ 16,500,000 $ 9,800,000      
CRISPR JDCA | CRISPR              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Allocation of net profits and net losses, percent             40.00%
CRISPR T1D              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaborative arrangement, development and regulatory potential milestone payments maximum $ 230,000,000            
Up-front payment $ 100,000,000            
Entrada Therapeutics              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaborative arrangement, development and regulatory potential milestone payments maximum   $ 485,000,000          
Up-front payment   225,100,000          
Purchase of common stock   $ 24,900,000          
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share - Schedule of Computation (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Net income $ 699.8 $ 762.1
Basic weighted-average common shares outstanding (in shares) 257.4 255.1
Effect of potentially dilutive securities:    
Employee stock purchase program (in shares) 0.0 0.1
Diluted weighted-average common shares outstanding (in shares) 260.3 257.9
Basic net income per common share (in dollars per share) $ 2.72 $ 2.99
Diluted net income per common share (in dollars per share) $ 2.69 $ 2.96
Stock options    
Effect of potentially dilutive securities:    
Share-based payment arrangements (in shares) 1.3 1.3
Restricted stock units (including PSUs)    
Effect of potentially dilutive securities:    
Share-based payment arrangements (in shares) 1.6 1.4
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share - Anti-dilutive Securities (Details) - shares
shares in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 0.0 0.0
Unvested restricted stock units (including PSUs)    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 0.6 0.6
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements - Additional Information (Details)
$ in Millions
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash $ 2,100.0 $ 3,100.0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Remaining milestone payment $ 678.3  
Level 3 | Minimum | Discount Rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, measurement input (as a percent) 0.047  
Level 3 | Maximum | Discount Rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, measurement input (as a percent) 0.058  
Corporate equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments with restrictions $ 42.8  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) - Recurring Basis - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Financial instruments carried at fair value (asset positions):    
Derivative asset current, foreign currency forward contracts $ 19.5 $ 47.5
Other assets, foreign currency forward contracts 0.3 0.8
Total financial assets 9,405.0 7,807.9
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts (20.5) (14.3)
Other current liabilities, contingent consideration (14.8) (14.6)
Other long-term liabilities, foreign currency forward contracts (0.5) (0.9)
Contingent consideration (112.3) (114.4)
Total financial liabilities (148.1) (144.2)
Level 1    
Financial instruments carried at fair value (asset positions):    
Derivative asset current, foreign currency forward contracts 0.0 0.0
Other assets, foreign currency forward contracts 0.0 0.0
Total financial assets 6,106.0 5,378.5
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts 0.0 0.0
Other current liabilities, contingent consideration 0.0 0.0
Other long-term liabilities, foreign currency forward contracts 0.0 0.0
Contingent consideration 0.0 0.0
Total financial liabilities 0.0 0.0
Level 2    
Financial instruments carried at fair value (asset positions):    
Derivative asset current, foreign currency forward contracts 19.5 47.5
Other assets, foreign currency forward contracts 0.3 0.8
Total financial assets 3,299.0 2,429.4
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts (20.5) (14.3)
Other current liabilities, contingent consideration 0.0 0.0
Other long-term liabilities, foreign currency forward contracts (0.5) (0.9)
Contingent consideration 0.0 0.0
Total financial liabilities (21.0) (15.2)
Level 3    
Financial instruments carried at fair value (asset positions):    
Derivative asset current, foreign currency forward contracts 0.0 0.0
Other assets, foreign currency forward contracts 0.0 0.0
Total financial assets 0.0 0.0
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts 0.0 0.0
Other current liabilities, contingent consideration (14.8) (14.6)
Other long-term liabilities, foreign currency forward contracts 0.0 0.0
Contingent consideration (112.3) (114.4)
Total financial liabilities (127.1) (129.0)
Money market funds    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 4,954.1 5,162.6
Money market funds | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 4,954.1 5,162.6
Money market funds | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Money market funds | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Time deposits    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 1,600.0 2,000.0
Time deposits | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Time deposits | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 1,600.0 2,000.0
Time deposits | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Corporate equity securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 148.1 116.8
Corporate equity securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 127.2 88.8
Corporate equity securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 20.9 28.0
Corporate equity securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
U.S. Treasury securities    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 86.4 0.0
Marketable securities: 276.6 0.0
U.S. Treasury securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 86.4 0.0
Marketable securities: 276.6 0.0
U.S. Treasury securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
U.S. Treasury securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
Government-sponsored enterprise securities    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 129.3 0.0
Marketable securities: 532.4 127.1
Government-sponsored enterprise securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 129.3 0.0
Marketable securities: 532.4 127.1
Government-sponsored enterprise securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
Government-sponsored enterprise securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
Asset-backed securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 117.9 0.0
Asset-backed securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Asset-backed securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 117.9 0.0
Asset-backed securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Certificates of deposit    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 44.9 0.0
Certificates of deposit | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Certificates of deposit | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 44.9 0.0
Certificates of deposit | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Corporate debt securities    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 1.7 5.8
Marketable securities: 771.5 87.0
Corporate debt securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
Corporate debt securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 1.7 5.8
Marketable securities: 771.5 87.0
Corporate debt securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
Commercial paper    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 408.0 204.5
Marketable securities: 314.3 55.8
Commercial paper | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
Commercial paper | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 408.0 204.5
Marketable securities: 314.3 55.8
Commercial paper | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: $ 0.0 $ 0.0
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance at December 31, 2022 $ 129.0  
Decrease in fair value of contingent payments (1.9) $ (7.5)
Balance at March 31, 2023 $ 127.1  
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities and Equity Investments - Additional Information (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Summary of cash, cash equivalents and marketable securities      
Cash $ 2,100,000,000 $ 3,100,000,000  
Allowance for credit loss for available-for-sale debt securities 0   $ 0
Debt securities fair value, unrealized loss position 702,700,000    
Unrealized loss position for greater than twelve months 0    
Other Assets      
Summary of cash, cash equivalents and marketable securities      
Equity securities without readily determinable fair value, amount $ 98,600,000    
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Cash equivalents:      
Amortized Cost $ 7,179.3   $ 7,372.9
Gross Unrealized Gains 0.2    
Fair Value 7,179.5   7,372.9
Total marketable debt securities      
Fair Value 7,637.1   5,642.8
Corporate equity securities      
Amortized Cost 129.4   104.4
Gross Unrealized Gains 47.4 $ 30.9  
Gross Unrealized Losses (28.7) $ (18.5)  
Fair Value 148.1   116.8
Amortized Cost 2,183.6   374.4
Gross Unrealized Gains 52.6   31.1
Gross Unrealized Losses (30.5)   (18.8)
Fair Value 2,205.7   386.7
Money market funds      
Cash equivalents:      
Amortized Cost 4,954.1   5,162.6
Fair Value 4,954.1   5,162.6
Time deposits      
Cash equivalents:      
Amortized Cost 1,600.0   2,000.0
Fair Value 1,600.0   2,000.0
U.S. Treasury securities      
Cash equivalents:      
Amortized Cost 86.3   0.0
Gross Unrealized Gains 0.1    
Fair Value 86.4   0.0
Total marketable debt securities      
Amortized Cost 274.8   0.0
Gross Unrealized Gains 1.8   0.0
Gross Unrealized Losses 0.0   0.0
Fair Value 276.6   0.0
Government-sponsored enterprise securities      
Cash equivalents:      
Amortized Cost 129.2   0.0
Gross Unrealized Gains 0.1    
Fair Value 129.3   0.0
Total marketable debt securities      
Amortized Cost 532.0   127.0
Gross Unrealized Gains 0.5   0.2
Gross Unrealized Losses (0.1)   (0.1)
Fair Value 532.4   127.1
Asset-backed securities      
Total marketable debt securities      
Amortized Cost 118.1   0.0
Gross Unrealized Gains 0.0   0.0
Gross Unrealized Losses (0.2)   0.0
Fair Value 117.9   0.0
Certificates of deposit      
Total marketable debt securities      
Amortized Cost 44.9   0.0
Gross Unrealized Gains 0.0   0.0
Gross Unrealized Losses 0.0   0.0
Fair Value 44.9   0.0
Corporate debt securities      
Cash equivalents:      
Amortized Cost 1.7   5.8
Fair Value 1.7   5.8
Total marketable debt securities      
Amortized Cost 770.0   87.2
Gross Unrealized Gains 2.9   0.0
Gross Unrealized Losses (1.4)   (0.2)
Fair Value 771.5   87.0
Commercial paper      
Cash equivalents:      
Amortized Cost 408.0   204.5
Fair Value 408.0   204.5
Commercial paper      
Total marketable debt securities      
Amortized Cost 314.4   55.8
Gross Unrealized Gains 0.0   0.0
Gross Unrealized Losses (0.1)   0.0
Fair Value 314.3   55.8
Cash equivalents:      
Total marketable debt securities      
Fair Value 5,579.5   5,372.9
Marketable securities      
Total marketable debt securities      
Fair Value 976.1   157.7
Long-term marketable securities      
Total marketable debt securities      
Fair Value 1,081.5   112.2
Total marketable debt securities      
Total marketable debt securities      
Amortized Cost 2,054.2   270.0
Gross Unrealized Gains 5.2   0.2
Gross Unrealized Losses (1.8)   (0.3)
Fair Value $ 2,057.6   $ 269.9
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Debt securities $ 7,637.1 $ 5,642.8
Cash and cash equivalents    
Debt Securities, Available-for-sale [Line Items]    
Debt securities 5,579.5 5,372.9
Marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Debt securities $ 976.1 $ 157.7
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]    
Matures within one year $ 6,555.6 $ 5,530.6
Matures after one year through five years 1,081.5 112.2
Total $ 7,637.1 $ 5,642.8
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]    
Net unrealized gains (losses) $ 6.4 $ (75.6)
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance $ 13,912.7 $ 10,100.0
Other comprehensive income (loss) before reclassifications 3.3 11.2
Amounts reclassified from accumulated other comprehensive income (loss) (17.2) (15.8)
Total other comprehensive loss (13.9) (4.6)
Ending balance 14,432.3 10,907.0
Foreign Currency Translation Adjustment    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (25.0) (13.6)
Other comprehensive income (loss) before reclassifications 10.0 (12.4)
Amounts reclassified from accumulated other comprehensive income (loss) 0.0 0.0
Total other comprehensive loss 10.0 (12.4)
Ending balance (15.0) (26.0)
On Available-For-Sale Debt Securities    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (0.1) (0.5)
Other comprehensive income (loss) before reclassifications 2.9 (2.3)
Amounts reclassified from accumulated other comprehensive income (loss) 0.0 0.0
Total other comprehensive loss 2.9 (2.3)
Ending balance 2.8 (2.8)
On Foreign Currency Forward Contracts    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 25.9 30.0
Other comprehensive income (loss) before reclassifications (9.6) 25.9
Amounts reclassified from accumulated other comprehensive income (loss) (17.2) (15.8)
Total other comprehensive loss (26.8) 10.1
Ending balance (0.9) 40.1
Total    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 0.8 15.9
Total other comprehensive loss (13.9) (4.6)
Ending balance $ (13.1) $ 11.3
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Hedging - Additional Information (Details) - Foreign currency forward contracts
$ in Millions
 3 Months Ended
Mar. 31, 2023
USD ($)
Not Designated as Hedging Instrument  
Derivative [Line Items]  
Derivative term 1 month
Notional amount of foreign currency forward contract $ 541.3
Cash Flow Hedging | Minimum  
Derivative [Line Items]  
Derivative term 1 month
Cash Flow Hedging | Maximum  
Derivative [Line Items]  
Derivative term 18 months
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Hedging - Notional Amount (Details) - Foreign currency forward contracts - Designated as Hedging Instruments - Cash Flow Hedging - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 2,046.7 $ 2,201.5
Euro    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 1,325.9 1,497.7
British pound sterling    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 243.5 247.4
Canadian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 231.1 216.3
Australian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 180.3 174.9
Swiss Franc    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 65.9 $ 65.2
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Hedging - Cash Flow Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]    
Product revenues, net $ 2,374.8 $ 2,097.5
Other income (expense), net 1.3 (72.8)
Foreign Currency Forward Contract | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts | Designated as hedging instruments    
Derivative Instruments, Gain (Loss) [Line Items]    
Product revenues, net 22.0 20.1
Foreign Currency Forward Contract | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts | Not designated as hedging instruments    
Derivative Instruments, Gain (Loss) [Line Items]    
Other income (expense), net $ 3.6 $ (8.4)
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Hedging - Derivative Fair Value (Details) - Designated as Hedging Instruments - Foreign currency forward contracts - Cash Flow Hedging - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Derivative [Line Items]    
Total assets $ 19.8 $ 48.3
Total liabilities (21.0) (15.2)
Prepaid expenses and other current assets    
Derivative [Line Items]    
Total assets 19.5 47.5
Other assets    
Derivative [Line Items]    
Total assets 0.3 0.8
Other current liabilities    
Derivative [Line Items]    
Total liabilities (20.5) (14.3)
Other long-term liabilities    
Derivative [Line Items]    
Total liabilities $ (0.5) $ (0.9)
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Hedging - Offsetting Derivatives (Details) - Cash Flow Hedging - Designated as Hedging Instruments - Foreign currency forward contracts - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Offsetting Derivative Assets [Abstract]    
Gross Amounts Recognized $ 19.8 $ 48.3
Gross Amounts Offset 0.0 0.0
Gross Amounts Presented 19.8 48.3
Gross Amounts Not Offset (19.8) (15.2)
Legal Offset 0.0 33.1
Offsetting Derivative Liabilities [Abstract]    
Gross Amounts Recognized (21.0) (15.2)
Gross Amounts Offset 0.0 0.0
Gross Amounts Presented (21.0) (15.2)
Gross Amounts Not Offset 19.8 15.2
Legal Offset $ (1.2) $ 0.0
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 58.1 $ 38.1
Work-in-process 341.1 260.7
Finished goods 135.9 161.8
Total $ 535.1 $ 460.6
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses $ 122.4 $ 130.3
Stock-based compensation expense related to inventories (0.4) (0.2)
Total stock-based compensation expense included in “Total costs and expenses” 122.4 130.3
Income tax effect (40.6) (36.0)
Total stock-based compensation expense, net of tax 81.8 94.3
Cost of sales    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 1.9 2.2
Research and development expenses    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 76.3 80.4
Selling, general and administrative expenses    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 44.2 47.7
Restricted stock units (including PSUs)    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 115.9 118.2
Stock options    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 1.4 5.5
ESPP share issuances    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses $ 5.5 $ 6.8
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Feb. 28, 2023
Share-Based Payment Arrangement [Abstract]    
Number of shares authorized to be repurchased   $ 3,000,000,000
Shares repurchased (in shares) 459,017  
Value of shares repurchased $ 135,600,000  
Stock repurchase program, remaining amount $ 2,900,000,000  
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
Income before provision for income taxes $ 891.5 $ 954.8  
Provision for income taxes $ 191.7 $ 192.7  
Effective tax rate 21.50% 20.20%  
Net unrecognized tax benefits which would affect the tax rate if recognized $ 232.2   $ 208.5
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Details) - USD ($)
 1 Months Ended
Jul. 31, 2022
Mar. 31, 2023
Dec. 31, 2022
Line of Credit Facility [Line Items]      
Indemnification claims   $ 0  
Contingent liabilities   $ 0 $ 0
SOFR Loan | Minimum      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (as a percent) 1.00%    
SOFR Loan | Maximum      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (as a percent) 1.50%    
Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Line of credit facility, maximum borrowing capacity $ 500,000,000    
Line of credit facility additional borrowing capacity $ 500,000,000    
Debt covenant, consolidated leverage ratio 3.50    
Debt covenant, increase in consolidated leverage ratio 4.00    
Revolving Credit Facility | Base Rate | Minimum      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (as a percent) 0.00%    
Revolving Credit Facility | Base Rate | Maximum      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (as a percent) 0.50%    
Letters of Credit      
Line of Credit Facility [Line Items]      
Line of credit facility, maximum borrowing capacity $ 100,000,000    
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Additional Cash Flow Information (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Cash and cash equivalents $ 9,289.9 $ 10,504.0 $ 7,600.1 $ 6,795.0
Prepaid expenses and other current assets 5.7 8.0 3.9 5.1
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows $ 9,295.6 $ 10,512.0 $ 7,604.0 $ 6,800.1
XML 69 vrtx-20230331_htm.xml IDEA: XBRL DOCUMENT 0000875320 2023-01-01 2023-03-31 0000875320 2023-04-25 0000875320 2022-01-01 2022-03-31 0000875320 2023-03-31 0000875320 2022-12-31 0000875320 us-gaap:CommonStockMember 2021-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000875320 us-gaap:RetainedEarningsMember 2021-12-31 0000875320 2021-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000875320 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000875320 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000875320 us-gaap:CommonStockMember 2022-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000875320 us-gaap:RetainedEarningsMember 2022-03-31 0000875320 2022-03-31 0000875320 us-gaap:CommonStockMember 2022-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000875320 us-gaap:RetainedEarningsMember 2022-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000875320 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000875320 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000875320 us-gaap:CommonStockMember 2023-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000875320 us-gaap:RetainedEarningsMember 2023-03-31 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2023-01-01 2023-03-31 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2022-01-01 2022-03-31 0000875320 vrtx:KalydecoMember 2023-01-01 2023-03-31 0000875320 vrtx:KalydecoMember 2022-01-01 2022-03-31 0000875320 vrtx:ORKAMBIMember 2023-01-01 2023-03-31 0000875320 vrtx:ORKAMBIMember 2022-01-01 2022-03-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2023-01-01 2023-03-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2022-01-01 2022-03-31 0000875320 country:US 2023-01-01 2023-03-31 0000875320 country:US 2022-01-01 2022-03-31 0000875320 srt:EuropeMember 2023-01-01 2023-03-31 0000875320 srt:EuropeMember 2022-01-01 2022-03-31 0000875320 vrtx:OtherNonU.S.Member 2023-01-01 2023-03-31 0000875320 vrtx:OtherNonU.S.Member 2022-01-01 2022-03-31 0000875320 us-gaap:NonUsMember 2023-01-01 2023-03-31 0000875320 us-gaap:NonUsMember 2022-01-01 2022-03-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-01-01 2019-12-31 0000875320 vrtx:CRSIPRJDCAMember 2021-04-01 2021-06-30 0000875320 vrtx:CRSIPRJDCAMember 2021-07-01 0000875320 vrtx:CRSIPRJDCAMember vrtx:CRISPRMember 2021-07-01 0000875320 vrtx:CRSIPRJDCAMember 2023-01-01 2023-03-31 0000875320 vrtx:CRSIPRJDCAMember 2022-01-01 2022-03-31 0000875320 vrtx:CRISPRT1DMember 2023-03-01 2023-03-31 0000875320 vrtx:EntradaTherapeuticsMember 2023-02-01 2023-02-28 0000875320 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2023-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000875320 us-gaap:EquitySecuritiesMember 2023-03-31 0000875320 us-gaap:FairValueInputsLevel3Member 2023-03-31 0000875320 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2023-03-31 0000875320 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2023-03-31 0000875320 us-gaap:MoneyMarketFundsMember 2023-03-31 0000875320 us-gaap:MoneyMarketFundsMember 2022-12-31 0000875320 us-gaap:BankTimeDepositsMember 2023-03-31 0000875320 us-gaap:BankTimeDepositsMember 2022-12-31 0000875320 us-gaap:USTreasurySecuritiesMember 2023-03-31 0000875320 us-gaap:USTreasurySecuritiesMember 2022-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-03-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000875320 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:CommercialPaperMember 2023-03-31 0000875320 us-gaap:CommercialPaperMember 2022-12-31 0000875320 us-gaap:AssetBackedSecuritiesMember 2023-03-31 0000875320 us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000875320 us-gaap:CertificatesOfDepositMember 2023-03-31 0000875320 us-gaap:CertificatesOfDepositMember 2022-12-31 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-03-31 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0000875320 vrtx:MarketableSecuritiesAndOtherNoncurrentAssetsMember 2023-03-31 0000875320 vrtx:MarketableSecuritiesAndOtherNoncurrentAssetsMember 2022-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2023-03-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2022-12-31 0000875320 vrtx:MarketableSecuritiesMember 2023-03-31 0000875320 vrtx:MarketableSecuritiesMember 2022-12-31 0000875320 vrtx:MarketableSecuritiesNoncurrentMember 2023-03-31 0000875320 vrtx:MarketableSecuritiesNoncurrentMember 2022-12-31 0000875320 us-gaap:OtherAssetsMember 2023-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-03-31 0000875320 srt:MinimumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-03-31 0000875320 srt:MaximumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-03-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 currency:CHF us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000875320 currency:CHF us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-01-01 2023-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000875320 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0000875320 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0000875320 us-gaap:EmployeeStockMember 2022-01-01 2022-03-31 0000875320 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0000875320 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0000875320 2023-02-28 0000875320 us-gaap:RevolvingCreditFacilityMember 2022-07-31 0000875320 us-gaap:LetterOfCreditMember 2022-07-31 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2022-07-01 2022-07-31 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2022-07-01 2022-07-31 0000875320 srt:MinimumMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-07-01 2022-07-31 0000875320 srt:MaximumMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-07-01 2022-07-31 0000875320 us-gaap:RevolvingCreditFacilityMember 2022-07-01 2022-07-31 shares iso4217:USD iso4217:USD shares vrtx:segment vrtx:target pure VERTEX PHARMACEUTICALS INC / MA 0000875320 --12-31 2023 Q1 false P1M 10-Q true 2023-03-31 false 000-19319 MA 50 Northern Avenue Boston MA 04-3039129 02210 617 341-6100 Common Stock, $0.01 Par Value Per Share VRTX NASDAQ Yes Yes Large Accelerated Filer false false false 257551600 2374800000 2097500000 266900000 245800000 742600000 601100000 347100000 2000000.0 241100000 215200000 -1900000 -7500000 1595800000 1056600000 779000000.0 1040900000 122600000 1600000 -11400000 -14900000 1300000 -72800000 891500000 954800000 191700000 192700000 699800000 762100000 2.72 2.99 2.69 2.96 257400000 255100000 260300000 257900000 699800000 762100000 -800000 0 2900000 -2300000 7400000 -2200000 -26800000 10100000 10000000.0 -12400000 -13900000 -4600000 685900000 757500000 9289900000 10504000000 1124200000 274500000 1547800000 1442200000 535100000 460600000 468700000 553500000 12965700000 13234800000 1111700000 1108400000 1088000000 1088000000 603600000 603600000 1359900000 1246900000 336300000 347400000 1081500000 112200000 427500000 409600000 18974200000 18150900000 323200000 303900000 2326000000 2126700000 377000000.0 311500000 3026200000 2742100000 417600000 430800000 371600000 379500000 726500000 685800000 4541900000 4238200000 0 0 0.01 0.01 1000000 1000000 0 0 0 0 0 0 0.01 0.01 500000000 500000000 257509761 257509761 257011628 257011628 2600000 2600000 7220200000 7386500000 -13100000 800000 7222600000 6522800000 14432300000 13912700000 18974200000 18150900000 254500000 2500000 6880800000 15900000 3200800000 10100000000 -4600000 -4600000 762100000 762100000 500000 0.0 117500000 117500000 1600000 100000 36400000 36500000 130500000 130500000 255600000 2600000 6930200000 11300000 3962900000 10907000000 257000000.0 2600000 7386500000 800000 6522800000 13912700000 -13900000 -13900000 699800000 699800000 500000 0.0 135600000 135600000 600000 0.0 166600000 166600000 1600000 0.0 13100000 13100000 122800000 122800000 257500000 2600000 7220200000 -13100000 7222600000 14432300000 699800000 762100000 122400000 130300000 38800000 35900000 -113400000 -12300000 6400000 -75600000 -1900000 -7500000 -21700000 -4900000 90500000 165200000 82600000 -2000000.0 -46200000 -67600000 35700000 -14500000 140700000 61600000 89400000 15700000 899900000 956200000 1816600000 117100000 50000000.0 129700000 42100000 63600000 24900000 0 -1833600000 -51000000.0 14200000 33700000 132800000 0 166600000 117500000 10600000 12900000 1100000 1300000 -294700000 -95400000 12000000.0 -5900000 -1216400000 803900000 10512000000 6800100000 9295600000 7604000000 120300000 85000000.0 11100000 13700000 Basis of Presentation and Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning with the second quarter of 2022, we are separately classifying upfront, contingent milestone, and other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development expenses” in our condensed consolidated statements of income. To conform prior periods to current presentation, we reclassified $2.0 million from “Research and development expenses” to “Acquired in-process research and development expenses” for the three months ended March 31, 2022. Please refer to Note C, “Acquired In-Process Research and Development and Other Arrangements,” for further information on these transactions. We have reclassified certain items from the prior year’s condensed consolidated balance sheet to conform to the current year’s presentation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended March 31, 2023 and 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, which are contained in our 2022 Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted and Issued Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2022 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2022 Annual Report on Form 10-K.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning with the second quarter of 2022, we are separately classifying upfront, contingent milestone, and other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development expenses” in our condensed consolidated statements of income. To conform prior periods to current presentation, we reclassified $2.0 million from “Research and development expenses” to “Acquired in-process research and development expenses” for the three months ended March 31, 2022. Please refer to Note C, “Acquired In-Process Research and Development and Other Arrangements,” for further information on these transactions. We have reclassified certain items from the prior year’s condensed consolidated balance sheet to conform to the current year’s presentation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended March 31, 2023 and 2022.</span></div>The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, which are contained in our 2022 Annual Report on Form 10-K. 1 2000000 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div> Revenue Recognition <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenues by Product</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Product revenues, net” consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:64.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA/KAFTRIO</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KALYDECO</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORKAMBI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYMDEKO/SYMKEVI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues by Geographic Location</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:64.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues outside of the United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had contract liabilities of $236.4 million and $159.6 million as of March 31, 2023 and December 31, 2022, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Product revenues, net” consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:64.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA/KAFTRIO</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KALYDECO</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORKAMBI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYMDEKO/SYMKEVI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:64.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues outside of the United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2096700000 1761600000 125000000.0 139000000.0 122500000 132100000 30600000 64800000 2374800000 2097500000 1403800000 1368200000 807200000 632300000 163800000 97000000.0 971000000.0 729300000 2374800000 2097500000 236400000 159600000 Acquired In-Process Research and Development and Other Arrangements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. Our “Acquired in-process research and development expenses” included $347.1 million for the three months ended March 31, 2023, and $2.0 million, for the three months ended March 31, 2022, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions that qualify as in-process research and development.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three months ended March 31, 2023 and 2022, or were new or materially revised during the three months ended March 31, 2023, are described below. Additional agreements were described in Note B, “Acquired In-Process Research and Development and Other Arrangements,” of our 2022 Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-license Agreements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into several in-license agreements to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically can terminate our in-license agreements by providing advance notice to our collaborators. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CRISPR Therapeutics AG - CRISPR-Cas9 Gene-editing Therapies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a strategic collaboration, option, and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on resulting net product sales. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into a joint development and commercialization agreement with CRISPR (the “CRISPR JDCA”), which we amended and restated in 2021, pursuant to the terms of the CRISPR Agreement. Under the CRISPR JDCA, we and CRISPR are co-developing and preparing to co-commercialize exagamglogene autotemcel (“exa-cel”), for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia. Pursuant to the CRISPR JDCA, we lead global development, manufacturing, and commercialization of exa-cel, with support from CRISPR. We also conduct all research, development, manufacturing, and commercialization activities relating to other product candidates and products under the CRISPR JDCA throughout the world subject to CRISPR’s reserved right to conduct certain activities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the CRISPR JDCA, CRISPR has the potential to receive a one-time $200.0 million milestone payment upon receipt of the first marketing approval of exa-cel from the U.S. Food and Drug Administration or the European Commission.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the CRISPR JDCA as a cost-sharing arrangement, with costs incurred related to exa-cel allocated 60% to us and 40% to CRISPR, subject to certain adjustments. During the three months ended March 31, 2023 and 2022, we recognized the net impact of the CRISPR JDCA as “Research and development expenses” of $60.5 million and $36.2 </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million, respectively, and “Selling, general and administrative expenses” of $16.5 million and $9.8 million, respectively, within our condensed consolidated statements of income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into a non-exclusive license agreement (“the CRISPR T1D Agreement”) for the use of CRISPR’s CRISPR-Cas9 gene-editing technology to accelerate the development of our hypoimmune cell therapies for type 1 diabetes. Pursuant to the CRISPR T1D Agreement, we made a $100.0 million upfront payment to CRISPR. CRISPR is also eligible to receive up to an additional $230.0 million in research, development, regulatory and commercial milestones for any products that may result from the agreement, as well as royalties on resulting net product sales. We determined that substantially all the fair value of the collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses.” </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Entrada Therapeutics, Inc.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we closed a strategic collaboration and license agreement (the “Entrada Agreement”) with Entrada Therapeutics, Inc. (“Entrada”) focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (“DM1”). Upon closing, we made an upfront payment of $225.1 million to Entrada, and purchased $24.9 million of Entrada’s common stock in connection with the Entrada Agreement. Entrada is eligible to receive up to an additional $485.0 million in research, development, regulatory and commercial milestones for any products that may result from the Entrada Agreement, as well as royalties on resulting net product sales. We determined that substantially all the fair value of the collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses.” We recorded the investment in Entrada’s common stock at fair value within our condensed consolidated balance sheet within “Marketable securities.”</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cystic Fibrosis Foundation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2004, we entered into a collaboration agreement with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc., to support research and development activities. Pursuant to the collaboration agreement, as amended, we have agreed to pay tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including ivacaftor, lumacaftor and tezacaftor and royalties ranging from low-single digits to mid-single digits on potential net sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor. We do not have any royalty obligations on compounds first synthesized and tested on or after September 1, 2016. For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO, sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”</span></div> 347100000 2000000 3 3 410000000 200000000 0.60 0.40 60500000 36200000 16500000 9800000 100000000 230000000 225100000 24900000 485000000 Earnings Per Share<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:64.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase program</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:64.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units (including PSUs)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:64.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase program</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 699800000 762100000 257400000 255100000 1300000 1300000 1600000 1400000 0.0 100000 260300000 257900000 2.72 2.99 2.69 2.96 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:64.159%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units (including PSUs)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.0 0.0 600000 600000 Fair Value Measurements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.392%"><tr><td style="width:1.0%"/><td style="width:11.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.611%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic equity investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note F, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $2.1 billion and $3.1 billion of cash as of March 31, 2023 and December 31, 2022, respectively):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (asset positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,954.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,954.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,600.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,600.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">771.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">771.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,405.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,106.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,299.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,807.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,378.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,429.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (liability positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(129.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Corporate Equity Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, several of our investments in publicly traded corporate equity securities were subject to contractual sales restrictions expiring in 2023, 2024 and 2025 with a total fair value of $42.8 million. We purchased these investments directly from these publicly traded companies in 2022 and the first quarter of 2023, and do not anticipate any circumstances that would cause these restrictions to lapse prior to the periods listed above.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Contingent Consideration</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to former Exonics equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data attributable to rare diseases and our knowledge of the progress and viability of the programs. The discount rates used in the valuation model for contingent payments, which were between 4.7% and 5.8% as of March 31, 2023, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future, resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a rollforward of the fair value of our contingent consideration liabilities:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"/><td style="width:73.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.854%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $2.1 billion and $3.1 billion of cash as of March 31, 2023 and December 31, 2022, respectively):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (asset positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,954.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,954.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,600.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,600.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">771.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">771.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,405.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,106.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,299.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,807.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,378.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,429.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (liability positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(129.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2100000000 3100000000 4954100000 4954100000 0 0 5162600000 5162600000 0 0 1600000000 0 1600000000 0 2000000000 0 2000000000 0 86400000 86400000 0 0 0 0 0 0 129300000 129300000 0 0 0 0 0 0 1700000 0 1700000 0 5800000 0 5800000 0 408000000.0 0 408000000.0 0 204500000 0 204500000 0 148100000 127200000 20900000 0 116800000 88800000 28000000.0 0 276600000 276600000 0 0 0 0 0 0 532400000 532400000 0 0 127100000 127100000 0 0 117900000 0 117900000 0 0 0 0 0 44900000 0 44900000 0 0 0 0 0 771500000 0 771500000 0 87000000.0 0 87000000.0 0 314300000 0 314300000 0 55800000 0 55800000 0 19500000 0 19500000 0 47500000 0 47500000 0 300000 0 300000 0 800000 0 800000 0 9405000000 6106000000 3299000000 0 7807900000 5378500000 2429400000 0 20500000 0 20500000 0 14300000 0 14300000 0 14800000 0 0 14800000 14600000 0 0 14600000 500000 0 500000 0 900000 0 900000 0 112300000 0 0 112300000 114400000 0 0 114400000 148100000 0 21000000.0 127100000 144200000 0 15200000 129000000.0 42800000 678300000 0.047 0.058 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a rollforward of the fair value of our contingent consideration liabilities:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"/><td style="width:73.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.854%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 129000000.0 -1900000 127100000 Marketable Securities and Equity Investments<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $2.1 billion and $3.1 billion of cash as of March 31, 2023 and December 31, 2022, respectively), is shown below:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:25.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,954.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,954.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,600.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,600.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,179.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,179.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,372.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,372.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">770.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">771.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,054.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,057.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,183.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">386.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,579.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,372.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,637.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,555.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after one year through five years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,637.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three months ended March 31, 2023 and 2022. As of March 31, 2023, we held available-for-sale debt securities with a total fair value of $702.7 million that were in unrealized loss positions; however, none of these investments had been in an unrealized loss position for greater than twelve months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record changes in the fair value of our investments in corporate equity securities to “Other income (expense), net” in our condensed consolidated statements of income. During the three months ended March 31, 2023 and 2022, our net unrealized gains (losses) on corporate equity securities held at the conclusion of each period were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.482%"><tr><td style="width:1.0%"/><td style="width:60.753%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $98.6 million.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $2.1 billion and $3.1 billion of cash as of March 31, 2023 and December 31, 2022, respectively), is shown below:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:25.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,954.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,954.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,600.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,600.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,179.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,179.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,372.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,372.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">770.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">771.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,054.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,057.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,183.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">386.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,579.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,372.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,637.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,555.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after one year through five years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,637.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2100000000 3100000000 4954100000 4954100000 5162600000 5162600000 1600000000 1600000000 2000000000 2000000000 86300000 100000 86400000 0 0 129200000 100000 129300000 0 0 1700000 1700000 5800000 5800000 408000000.0 408000000.0 204500000 204500000 7179300000 200000 7179500000 7372900000 7372900000 274800000 1800000 0 276600000 0 0 0 0 532000000.0 500000 100000 532400000 127000000.0 200000 100000 127100000 118100000 0 200000 117900000 0 0 0 0 44900000 0 0 44900000 0 0 0 0 770000000.0 2900000 1400000 771500000 87200000 0 200000 87000000.0 314400000 0 100000 314300000 55800000 0 0 55800000 2054200000 5200000 1800000 2057600000 270000000.0 200000 300000 269900000 129400000 47400000 28700000 148100000 104400000 30900000 18500000 116800000 2183600000 52600000 30500000 2205700000 374400000 31100000 18800000 386700000 5579500000 5372900000 976100000 157700000 1081500000 112200000 7637100000 5642800000 6555600000 5530600000 1081500000 112200000 7637100000 5642800000 0 0 702700000 0 During the three months ended March 31, 2023 and 2022, our net unrealized gains (losses) on corporate equity securities held at the conclusion of each period were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.482%"><tr><td style="width:1.0%"/><td style="width:60.753%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 6400000 -75600000 98600000 Accumulated Other Comprehensive Income (Loss)<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses), Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Available-For-Sale Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Foreign Currency Forward Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses), Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Available-For-Sale Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Foreign Currency Forward Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -25000000.0 -100000 25900000 800000 10000000.0 2900000 -9600000 3300000 0 0 17200000 17200000 10000000.0 2900000 -26800000 -13900000 -15000000.0 2800000 -900000 -13100000 -13600000 -500000 30000000.0 15900000 -12400000 -2300000 25900000 11200000 0 0 15800000 15800000 -12400000 -2300000 10100000 -4600000 -26000000.0 -2800000 40100000 11300000 Hedging <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency forward contracts - Designated as hedging instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxMDhjZTFhYzYyZTQzYjNiMGZkNjg2OWI5NjI3YjFmL3NlYzpjMTA4Y2UxYWM2MmU0M2IzYjBmZDY4NjliOTYyN2IxZl81OC9mcmFnOjBhMzllYTA2ZWE4MzQ5YTViMTJkNTI1MTMxMjA3MjY2L3RleHRyZWdpb246MGEzOWVhMDZlYTgzNDlhNWIxMmQ1MjUxMzEyMDcyNjZfNDE4_d1c0c737-93ce-41cb-b05c-df6e20f05e94">one</span> to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our condensed consolidated statements of income in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2023, all hedges were determined to be highly effective.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of March 31, 2023 and December 31, 2022, credit risk did not change the fair value of our foreign currency forward contracts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pound sterling</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollar</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss Franc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency forward contracts - Not designated as hedging instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other income (expense), net” in our condensed consolidated statements of income each period. As of March 31, 2023, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $541.3 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"/><td style="width:65.670%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designated as hedging instruments - Reclassified from AOCI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Not designated as hedging instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total reported in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> P18M <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pound sterling</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollar</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss Franc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1325900000 1497700000 243500000 247400000 231100000 216300000 180300000 174900000 65900000 65200000 2046700000 2201500000 P1M 541300000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"/><td style="width:65.670%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designated as hedging instruments - Reclassified from AOCI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Not designated as hedging instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total reported in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 22000000.0 20100000 3600000 -8400000 2374800000 2097500000 1300000 -72800000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 19500000 20500000 300000 500000 19800000 21000000.0 47500000 14300000 800000 900000 48300000 15200000 The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:<div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:<div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 19800000 0 19800000 19800000 0 21000000.0 0 21000000.0 19800000 1200000 48300000 0 48300000 15200000 33100000 15200000 0 15200000 15200000 0 Inventories<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 58100000 38100000 341100000 260700000 135900000 161800000 535100000 460600000 Stock-based Compensation Expense and Share Repurchase Programs<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation expense </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, we recognized the following stock-based compensation expense:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.482%"><tr><td style="width:1.0%"/><td style="width:60.753%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type of award:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to inventories</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in “Total costs and expenses”</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by line item:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchase program</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, our Board of Directors approved a share repurchase program (our “Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $3.0 billion of our common stock. Our Share Repurchase Program does not have an expiration date and can be discontinued at any time. During the three months ended March 31, 2023, we repurchased 459,017 shares of our common stock under our Share Repurchase Program for an aggregate of $135.6 million. As of March 31, 2023, a total of $2.9 billion remained authorized for future repurchases.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, we recognized the following stock-based compensation expense:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.482%"><tr><td style="width:1.0%"/><td style="width:60.753%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type of award:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to inventories</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in “Total costs and expenses”</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by line item:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 115900000 118200000 1400000 5500000 5500000 6800000 400000 200000 122400000 130300000 1900000 2200000 76300000 80400000 44200000 47700000 122400000 130300000 40600000 36000000.0 81800000 94300000 3000000000 459017 135600000 2900000000 Income Taxes<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and foreign income taxes. During the three months ended March 31, 2023 and 2022, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.482%"><tr><td style="width:1.0%"/><td style="width:60.753%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.482%"><tr><td style="width:1.0%"/><td style="width:60.753%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for the three months ended March 31, 2023 was higher than the U.S. statutory rate primarily due to an increase in our unrecognized tax benefits partially offset by excess tax benefits related to stock-based compensation. Our effective tax rate for the three months ended March 31, 2022 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of March 31, 2023 and December 31, 2022, we had $232.2 million and $208.5 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.</span></div>We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2014 in jurisdictions that have a material impact on our consolidated financial statements. During the three months ended March 31, 2023 and 2022, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.482%"><tr><td style="width:1.0%"/><td style="width:60.753%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.482%"><tr><td style="width:1.0%"/><td style="width:60.753%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table> 891500000 954800000 191700000 192700000 0.215 0.202 232200000 208500000 Commitments and Contingencies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Facility</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”), which matures on July 1, 2027. The Credit Agreement was not drawn upon at closing and we have not drawn upon it to date. Amounts drawn pursuant to the Credit Agreement, if any, will be used for general corporate purposes. Subject to satisfaction of certain conditions, we may request that the borrowing capacity for the Credit Agreement be increased by an additional $500.0 million. Additionally, the Credit Agreement provides a sublimit of $100.0 million for letters of credit.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amounts borrowed under the Credit Agreement will bear interest, at our option, at either a base rate or a Secured Overnight Financing Rate (“SOFR”), in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.000% to 0.500% and the applicable margins on SOFR loans range from 1.000% to 1.500%, in each case based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amounts borrowed pursuant to the Credit Agreement are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including a financial covenant to maintain subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition. As of March 31, 2023, we were in compliance with the covenants described above. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct costs related to the Credit Agreement are recorded over its term and were not material to our financial statements. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guaranties and Indemnifications</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue for such contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note E, “Fair Value Measurements,” there were no material contingent liabilities accrued as of March 31, 2023 or December 31, 2022.</span></div> 500000000 500000000 100000000 0.00000 0.00500 0.01000 0.01500 3.50 4.00 0 0 0 Additional Cash Flow Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,504.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,289.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,795.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,600.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,604.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,504.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,289.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,795.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,600.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,604.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10504000000 9289900000 6795000000 7600100000 8000000.0 5700000 5100000 3900000 10512000000 9295600000 6800100000 7604000000 EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .V HE8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #M@*)6S?R-Y^X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VU1(71S43PI""XHWD(RNQML_I",M/OVIG6WB^@#"+EDYI=O MOH'T.@H=$CZG$#&1Q7PUN<%GH>.&'8BB ,CZ@$[ENB1\:>Y"TA*OVA M]@@MYS?@D)11I& &5G$E,MD;+71"12&=\$:O^/B9A@5F-." #CUE:.H&F)PG MQN,T]' !S##"Y/)W -8C]V2*SLT\/;T^+*L6UF? M27F-Y56V@HX1-^P\^;6[N]\^,-GRMJOX=<7;;621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M .V HE;5TCU!T 4 - > 8 >&PO=V]R:W-H965T&UL MM9EK;]LV%(;_"N$-PP;$L4C%N72) 45UUF!)ZMANUV[8!UJB;:&2Z%%4+O]^ MAY(M)1EU[ GUET2W\YH/#R\OR?-'J;YE2R$T>4KB-+OH++5>O>OULF I$IX= MRI5(XI9W!>?%LI ;G,M=QE(J1(EF> M)%P]7XI8/EYT:&?S8!PMEMH\Z W.5WPA)D)_6HT4W/4JE3!*1)I%,B5*S"\Z M'GWGN\P$%%]\CL1C]N*:&)29E-_,S75XT7%,B40L FTD./Q[$+Z(8Z,$Y?AG M+=JI?M,$OKS>J%\5\ SXYGP9?Q'%.KE1>>T0T(QYWFLQ_+Q@U@#]8U>(..L M^$L>RV^/CCHDR#,MDW4PE"")TO(_?UI7Q,L IR& K0/8FP#:] ON.L M0,N2 M%5CON>:#&OBN-6]>,6>BY:/W]YLTPK:')_VVJH5#BR*YA^^"Y;\4!< M=*"C94(]B,[@IQ_HL?.K#>\[B;V"/:I@CS#UP7L9Y-!%-9D^KX2-% ^G3O?> MAH1&M43J5TC]W9#NC6N(=5WC'N^&-A(ID M:'HA@7' FCQIWC1T/C6_)>5)QGNS8,A6'*:28 9KSB&O->9Q9$XF&M00\ MK0!/T4(-4QWI9W(5Q8+>N?3,!H>&MH0[J^#.=H$;BT5D MAE%(XQU/K&T4U_D\'$^'7\CH@S>^]?SAI^FU[]U,R/6=3WKDUK-AHX(ML:E3 M3Z[.+N#7:2 5-%9NVNT!F6CHH40JXLL\U>H9_H?6VMBB;B?&@]HBO_ 3=!?D M*7\BUR'TV&@>!04WTJRW2#I'7==QSRBS-FP\N"TOJWG9+KQ>&()Z=K"Y(#?P M'?F8VO.*2_8=<@@HX@ M(SPF?T:KYO$)5W08HXZ5=!^6B=:>B>)6IVBJ'BQZF\%P@6-Z8L7:AT.BM46B MN*^YD0'D:[24*68AMHBX1[1[3!U[VO9AD&CMD"AN;Z:1!G,DYX2RGV>_D(D( M<@69M$+B2KY,$IB0)EH&WP[(C\ZA0\F(*_*9Q[DP5II,S'+86@?[\%&T-E(4 M=T!@?\,H79#)\^Z"L4#VQ+6OHCMY(O\7"FSCBD7+T4J84+)K3LO6Q2_6O=K?#RJ+6?M MA]A.?N@ZA<5VN4=G%J1\ V[EQ!6;./?A?UCM?]A._LUY:O M-D!L)P,T3(1:F([Y&RCH)7B$9,53>VIQP6;0??@?5OL?AMN732*7 A*)X>$R MS7C[\$&L]D$,MS";D?;5)%],Z!GYF&MPM:F90ZW$W\GAK.NA5.L7:N8\Y6' M^B?]/GP/_NK!!EF;(;;3?I$/0ZH"UW>=AN*)_"[L>=RZ;>2'#; M9-:&A^%^93-?7D69<;=?!=@T;)-SBURW2UG7I5;0?3@@MW9 +FYR,4=RUO&]:9U,R4N=V_-(Q[4EK'V/R[N5CP #$O( MF%L'F2T"C<,J'O=_P7HOS@S-C%<_7EYUGO+ MS829D5C,(=0Y/($13Y7'I^6-EJOB!'(FM99)<;D4/!3*? #OYU+JS8WY@>H0 M>_ O4$L#!!0 ( .V HE:-XXMN# 4 " 4 8 >&PO=V]R:W-H965T M&ULK5AM5:R)X'DH2BH^.>>Y?RT<+#S=N,YV^Z4OC%=SO=TR]9,?=L_"5A-VRAI5K!2 M9KQ$@FT6SAV^71%?.U06?V7L)'O72%-YX?R[7GQ-%XZK$;&<)4J'H/!U9"N6 MYSH2X/C1!'7:_]2._>NWZ%\J\D#FA4JVXOG?6:IV"V?FH)1MZ"%7S_ST&VL( M!3I>PG-9?:)38^LZ*#E(Q8O&&1 465E_T]5-[#)2EW&M1+P:P9^:KGB90I%82F"*\GS M+*4*%FL%7U M)1'?H*]EP@N&;M"W]0.Z^O09R1T53**L1(]9GD,YY#7ZU%_. MIPK Z;^8)@V0^QH(&0'BH4=>JIU$OP*@]-Q_"J1:9N2-V3VQ!GRD8H(\?(V( M2SP#GM5_=R<6.%Z;:*^*YXW$>V9'5AZ8O#6EIG;US:YZ)]_*/4W8PH&M*IDX M,F?Y\T\X='\Q\?J@8&-<_N2K!1U;E@X*= M\0U;OJ&U*IJOWL>2YLRX-6OWJ)_F,)S$%\4P6/E!KV1GV*(66V3%]@QLJ4AV M53E2:)N<[_7@:4MCPAL-D$0^F807>(=6H8LGV(QWUN*=6?'>)3\.F8 1F94W M>\$3)B42_X?#;(#.\Z,>NII#;17TR#M:;ID6F@W-!#K2_,!T8R<@ M'4!*IQPN998RS8271AER!]AN\*#735:C\+_)<&*8S$;SV&DBMHMBBZ^IMA&@;^A*//$O M 9K,_-$4=H*(K?JS_$/MF&CRAZX:G)]'U;N)=IXG[Q+KT.@F(F-Z@3LQPW8U M:]KRA<%+#$,P@X]9]5(!RS<&BKZ.[*FAALUBW-O7#?2A61SXH] [K<-VL7MZ M']BA@&$ &UV"-9F1GMDYV$[HL%WI?F?6'34;/)J%<3P<3D.S*"1C(HP[%<.Q M]1&N X=@,L%$+0K(:O5>8GR6PU95?._#W$=%.W^QZ620V&7PGLHL05<@@RG/ M@18FVL=?UJ>Y#5(UZ'%"4T3PYYK8'&%B-6-7UOBWU4M/,T=)I* M[)K:M5C]KF\NU% N21 -1,MH%HS- -+I*K'K:K^S;"B'FDE"=R!7)C,@<]G_ MT]Y92\'$MCJ"DC" #J6J#R?:N^TQUUUUN'-Q_Q[?KNK#JBY,?7;V2,4V*R7* MV09"NI,(A%34QU'U0O%]=:+SPI7B176Y8Q0>>K4!_+[A7+TM]!^TAX++?P%0 M2P,$% @ [8"B5@S5_]V" P L H !@ !X;"]W;W)KJ"EL:6& M(EV2MI/]]1U2CM:V:'G43!*JH MH*'*%RO@^&4A9$,U+N4R4"L)M+1.#0OB,$R#AM;23%5W"(^BGU8/$5="AE'4#7-6"$PF+J7<; MW\.U.O^ MTSCNS]_0/UGQ*&9.%B ;(!_+T^)%<7ER1"U)S%#L*=RV% M^ 2%A-P+KBM%?D8JY:%_@'(Z3?&;IKOX+. ]E3Y)HFL2AW'BX#/[?O?X#)VD M"W%B\9(3>%TL3X;RK]NYTA)/]-^NZ+7H S>ZN>8W:D4+F'H(K$!NP,M__"%* MPY]\ M\)5@9A M/[HBE)?D*TAQC15>K<"6:/;JBF%++-O+8^R/CW+=M_D0^XD[U5DG.?M>R9W( M5C-*Q5<1RS['NBLE\.+5;&RI+/%H<'L_^[HS?V!57US&?GSU_[HSAZ:T=\K[ M5E%XZI"/.N6CL\H_'8M#15PQVKZFY3_XUI@BY2+= @\/Z!PQ'O5U1;$_<%,> M=Y3'9RG_+C1E1#ANITF=B^G802/I'2R'UR]_0W(I6V)%(9KS77[9':[7=MU:YN-H_T[TX[9GN(; M3-O+X8.X-#>$P0(A0S_#DR#;]JA=:+&R'<9<:.Q7[+3"EA*D,<#O"R'TV\+\ M0=>DYO\!4$L#!!0 ( .V HE;S*BQOO0( -0& 8 >&PO=V]R:W-H M965T&ULK55=3]LP%/TK5QF:0((F35I@K(U$RZ;Q@%11L3U, M>W"3V\;"L3O;;6"_?M=.FI72(A[V$G_=>WS.M7TRJ)1^- 6BA:=22#,,"FN7 M5V%HL@)+9CIJB9)6YDJ7S-)0+T*SU,ARGU2*,(ZB\[!D7 ;IP,]-=#I0*RNX MQ(D&LRI+II]'*%0U#+K!9N*>+PKK)L)TL&0+G*)]6$XTC<(6)>J^H;-GH\P4P)X[]0-;%1 M -G*6%4VR<2@Y+)NV5-3AZT$PMF?$#<)\6Y"[T!"TB0D7FC-S,NZ89:E ZTJ MT"Z:T%S'U\9GDQHNW2E.K:953GDV'2N9TYE@#M0S2O"<61I,+35T6-: FM-2 M25>D<&>W1KB5F2H1CB=,4T"!EF=,G, 9/$QOX/CH!(Z 2[CC0M YF4%HB:;; M+,P:2J.:4GR 4@)WBG -?"%J^GQ&W22MN2)QTL.X+6U/5C:G]C]_:CNU=_998LPV% P ;U M&H/TXX?N>?1YG_3_!/:B$+VV$+VWT-,'2;XC^!^Z;X42.9<+6)#O&#@6RA@T M)T#OG+SE$2V;"02#V4ISR]&<@F5/^VI3;WCN-W0&MD[/HL[E(%QO:ZZ#/FT% M16W$"R']5DC_O4)>"R"G)2^1])@UO9?LV4U43.>0T2UWAWQ83?^5FHM.;T?, MZYBSN!/OZ FW#*)$O?"^:8C!2MKZ';6SK35?>T?:F1^19=<.^P^F]GMZ)0LG M7>"<(*/.!1'3M8?6 ZN6WH9FRI*I^6Y!OQW4+H#6YTK9S>B_WE!$^>'_S([M=*/YBOEAMVSV^X^KFYKN!NWO:29@4O929* M5/&[R\E'?'Y%?=V@MO@GXWO9NT;:E5LA'O3-U_1RXFE%/.>)TETP^+/C5SS/ M=4^@X]>ATTG[3MVP?_W<^Q^U\^#,+9/\2N3_9JE:7T[B"4KY'=OFZH?8_\D/ M#@6ZOT3DLOX?[0^VW@0E6ZE$<6@,"HJL;/ZRQ\- ]!I@?Z0!.30@+VU #PUH M[6BCK';K,U-LM:S$'E7:&GK3%_78U*W!FZS4TWBC*O@U@W9J=27*%":%IPBN MI,BSE"FX^<1R5B8B.)3I#/V\^H_=O/Z"W*"O1MRS/80[D M]ZEY'1EYW3=6S1#%4T0\0BW-K]S-/_.D;4Z&S>?@>.L]:;TG=7]TS/MM5?%2 M(28EN'EN\Z?IP+=WH!?9N=RPA%].8!5)7NWX9/7N#0Z]"YMWK]39P%?:^DI= MO:^NF%PC5J8HT1?\US;;L1R>W5@.A?BO4=PJ%&'G@BMWF'$F>;*M,9=PJLNDFZK\=$W]&CD2:9B3R9X%= M9-"*#)PB/R:)V,+@02I+.(PDJ)VBDBN;SL#4&?C1+#[2:3'S?=)S9R T;(6& M3J%?RQU,LJA&QC T7AK08(:/I)E6?NC-0KNRJ%46.95=5WS#LA3QQXW.0+(. M3J'6O(+$UU^7-MV115$\BXYTFU9!0,>F/FYUQT[=?PO%\A=(C,WY)(LP,$1: M["BA?B\^!C(7K$%UE?JJ1Y6O=PW0%\U&J0+RV+"V!!K,_/BV/FPOD(/&4V5!C1S'L! =@\8Y#-*9(L4>72F*)M,#,ZC8[XH<]NZ'.CD#8C:#O M$)!,9>4]RCF47BZIU)! :3BCQTHM9I!9QZ*Q(Q!V(^@O4=Z?*5X54&J]$$;8 M0B,OQKUD18S;S$:HAV%L!M#3=)T MR#,1@^-%9-+<:H@#;S0Z.QSAZ$7%8)ZQVRRO)]I:$6(GUGZW)'RMWH9.=RS# M;IBU=DHMSIL$@H 9Y(:[B(Y>Q$VO[X.JI1= UAV%"2H:'7/V8#083(S'2A?2X8RX<38L M7DXI-7E%/1BOXYFWV$&)37IEY%!M;WOF!EN7A^^RLMZ0-N XI=L$F(\C \\82-P,A(WHH7Z62B0/4_36FWD8B%BA'=Y^A^2 M>IQ@*K=J#7OJ_WAZ@4I1(85IM@Y=?'J"729#)SN*$C=% M=2"*QA/0Q(_F]M'8(K@MPVO#VOS)^MX M6*!LICRWT?! K,,V=6/[8YIF^C 9\H@^B3C+2I2P309YQ7HF9B(Y(L0S:&BS MHW$XEI]IQV[J9C<40MMBF]<'M(=S$E' BECK4_4=1^]S(>4'E)7PV%K(49/3 M9Y@:IST6LU$JTH[EU,WR'["-@D=0Q[&JA,BPGSN:2(8Q-N/!8A<&8#>FLG=( MZF9W0Q4YF@VMHDT>8]^GQ-BNV@SI G9_(P4H[=!-W>@V8%BOP]]TPS<.?>U; M,*NA;0LV[WV7T!^%OK'J/BLE%$-WT-*;19#AJN8[2W.CQ*;^5'$KE!)%?;GF M#.1K _C]3@CU?*._?K1?NU;_ U!+ P04 " #M@*)6C/0 M !U$:JFJ[6$2*MKV,.W!)!=BU8DSVT"W7[_K),V@3?GHQ@/XXY[CYU"F#(0R9R/7928XI+U]5Q"AG3'5E CC,+J3)FL*N6KBX4L*0$9<+U*0W= MC/',[CP!U?IL8.N-&H8$N8@?E2 M3!7VW(8EX1GDFLN<*%B,G2OO9U MM:;_PIJ?F>J0KG=!?.IW6^"3_? ;B!NXOPMWT7V3 K])@5_R=5_@FQFTC)5I MB%R06YZC<EHUJB4&YA/T'64>T0[V1N]YV>2!H1WVO4=\[37U5G(2M3"H5_XT3 MUD4UVBJ]X@^V5'FT_#Q1?SANQT#0& A>98!KO3HL/G@FZJGL?1$[@L-&RH[C>J^WM53V26X9G^AQ+O'U/B!X)VI \:Z8,3 MI)]I<(SF5!\:^R)N/R?7(D2.B&8VYA(C$GT>ZHEDFD<0XOC:@HV-, MZ=B]_HX>UI,7DWF(*KIBV;]IPK?7H_D()70=[3-^QYY^I\V$/(D7LZRJ_T=/ MC:TS0O&^XBQOG,4(\K0X_(V>FT1T'+![PH$T#N1E>P)E=):H,F+FJ[:6R0X+>3* MNN>E^#85?GRY8D4BU@E-D+BJ6)8F$1KJ@L#?&B'OZ-<[! ".XC*(BTV MO11/!.-'VLF1=E)C3D]@?J";M)!@HBRSJ(C%Z$0&*LES=8$BCFYH/$8N?HN( M0[")4RN^W _?5;LHIMAD'3NXG_'5PJSH-OY\ M[HSGJEF@FV%OO%"-0MW(%8_)#I:2H>DQ0]/:SSV1(5&#XL%;B74NTE)?7CN;*553R-4."78#"19 @H5 8 K=WI%NSUH0AVTX5K;A3&R_;U$A3FOB MD<:C9Q//!]199_%=3L=^KR*LH8?R!PD6G#/\$"BBPHM_Y,6W\O*GR'Y:/PY- MV?>UX<]\,L:]]%LC#$T_)%@ "1:^E PE_[-C_F?6_#>'IDIN>^*DR;=;FB5( M-"B(YKN,?:-45@9B#UFZB>3YJ.H>#$R<6>,-W1EGVCG@TG@*@ P:0(*%0& * MN?,CN7-@N[U>QV#E+L0Q>F$^1N-6 M3L#6]G68@&9.VM2P6F<.QCZ9]Q-G-C4N;% ] !0MA$)3*6LE 6S7!%X4R;IHY2XP&6NK6SW]O%L\99$>$7B_ZFL;+'&$P#)%H BA9B78!0$Z+2T+;YV-[GW]'= MOHRWH]N@@KLXQ_\\^-K=.FD[=*)O4N'%Y;M 0?_ MPHSUBC)VAJ!A U"T$ I-Y;CSSH"]V8?1EYL@:GGXOEYIY.5*.P\JL,]K, NO MT9^3MC\G]OX<4F:VAQI<8^Z90C-HV 4+81"4]EM=05BUQ7^K];TC4I/,NKGPW M6\QZDXHG<4;7PM$9S\2Z*@^O.Q]N.-O5K^<^,,Y97E]N:20V>VD@OE\SQK_? MR#=^CR^=+_\#4$L#!!0 ( .V HE9=O((';@< (,@ 8 >&PO=V]R M:W-H965T&ULK5I1<]HX$/XK&MKIM#,%+ D;2!-FDK2]ZT-Z MF69Z]RQL$70U%I4$2?[]K6S'-I&LD+GP$&RSDK]=[>ZW*^7T3JI?>LVY0?>; MO-!G@[4QVY/Q6*=KOF%Z)+>\@%]64FV8@5MU.]9;Q5E6#MKD8Q)%R7C#1#%8 MG);/KM7B5.Y,+@I^K9#>;39,/5SP7-Z=#?#@\<$/<;LV]L%X<;IEM_R&FY_; M:P5WXV:63&QXH84LD.*KL\$Y/KFDIL5,P^-KS2Y[G=B; \;N>=-"\TP[L7C_._K54'I19,LTO9?Z/R,SZ;# ; MH(ROV"XW/^3=G[Q6*+;SI3+7Y5]T5\M& Y3NM)&;>C @V(BB^F;WM2$Z V > M_P!2#R!/!TQZ!M!Z "T5K9"5:GUFABU.E;Q#RDK#;/:BM$TY&K01A5W&&Z/@ M5P'CS.)2%ADL"L\07&F9BXP9N+DQ\ 6K9322*W3)]!I]A177:(A^WGQ&[]]^ M0&^1*-"5R'-8#7TZ-@#&3CE.ZQ=?5"\F/2^FZ$H69JW1%P"0'8X?@Q*-)N11 MDPL2G/"*J1&B^",B$:$>/)?'#RV:MJ)?UH;U2=ZRU)^-H"PU5SM^6#Q[@U.HD\^G5]IL@,+3!H+ M3$*S+[Y#$A)%*C?WOM7=QJQFEGV3 AH\F3Q?5(T6A$ M_8L[;>!.@W _<[!!*IZ%.'5>3F>.^WF$XM'<#W#6 )P] W#%E0)C/GH:N^?> M_#ES7C[$F#I6](F1/BO.&Y#S(,CW?T %H#^@7&K-@0/ E+]WPCP@S=.=*KW> M!WGN8DD%#B_CH I_F357J)#%L,Q! NA8?[0Y MR8L4.Q@('DV?(G6E)GW>C$D+E(2);LW GMJ:NI,IW%E>@1S$Q9XM<]Z_:-1UG'G4\9Q:(X\83N(1 MZ5FXEIYQF)^_%7L( ZEZ8KD>??#>&>D+U!IK-2;N^F$/S):L<9#=%M>*;YG( M'G-YY52RC([*R[S@8]?5DX[):KBN5#(]+A6U[(G#]-EXQ)8]6'?PHG69$'C& M"5]7:H@GO9FF)4P<9DQ J':\-; 7H!*Y$%VQ!(^2'H0M8^(P95:YL)-( MO!!=(IS-1Y.H\\%/X;I#<-?NAW!;[L1A\OQ^;.'H5<.EQQD4QDZDN6+S..E+ M"J1E3A*]J&T1D"3T,?4N"3+R2]/X:\UV:(66?$F8?*]W*EVSLO)9(;9G(K>A M.UQ)-=0,&H6,+\TSI1!QR7:(9SCI1$.MJD\03_N:'-(2,PER'72TIL;W/[0@ M3D*/HZ<*$$^U/^\+(])R*0ESZ<$B0"A! $$!:K._K46WMG_S0O;PY:3;,]:H M/6()[UTV9%X MX]V+V:5.<&]*7?>.'=3#N,^W6U8ER8O2U$H4#'KX(])4D*U?G*9>:;9#*[3, M3<+,_4WK':A=10@TDQOHT[1MU]&N@,8&+7G!5\*@;<[\6W3$1^M.F>21@H7N MB^^6U4F8U7_P;3?"N_B]6'V-+B5.SU[+'1,F+:.3,*-?LX=JNP@B!-K&HMZ# MOA-F?6AW^V3-\PQ!DD5\L\WE R];?"27N;@M6TW_2GA:9YQXV,(GAWO[3=H2 M/PVWS(V*H$L531SEMH?VPJ6^UCART'K%2%_/25M^IL=Q7]AYJT=G*#C/QE]4*/+X,TK;9 MY_?5#8*RMMHBLHIZ=:%.1.*G.89ZZ+AWJXVV;$R?WX-^G]6[01_LEENS+V31 M?JP6Q[+T'BJBHMZR@%QME$CM04BO3A[.Q@2[NUT>P5E$>S5KF9N&F?OR:/CO MWLP()I^6_%84A?4\6TYQ)63F5YU#M5;48^ M5C'@C]6)+-"#_U H6 B\^%3HE68[M$A+_#1,_&7Q5N[I6)9\;AN<>IITTCTF MJ'5R:7_61XHM[],P[S]%:KCU02_*N7-2A3TDXY%R*ZEQYSAWP]5M>WTU3'\U=,03;0P/ KF#(:3<%NJCKQKFZ, MW):'QDMIC-R4EVO.H*BT O#[2DKS>&-?T/S?P>(_4$L#!!0 ( .V HE8F MQ>A%0P< $D3 8 >&PO=V]R:W-H965T&ULO5A=;]O& M$OTK"_6B: %9DF4W#1+;@)RTO<%%6B-.VH>B#ZOE2-R$W&5VEU;\[^^969*F M6LEMT*(O-DGMSIXY<^:#O-CY\"&61$E]JBL7+R=E2LVS^3R:DFH=9[XAAU\V M/M0ZX39LY[$)I O95%?SY6+Q9%YKZR97%_+L)EQ=^#95UM%-4+&M:QWNKZGR MN\O)Z:1_\,9NR\0/YE<7C=[2+:5WS4W W7RP4MB:7+3>J4";R\GJ]-GU.:^7 M!3];VL71M6)/UMY_X)M7Q>5DP8"H(I/8@L:_.WI!5<6& .-C9W,R',D;Q]>] M]>_%=_BRUI%>^.H76Z3R[_7R48.O=9BIL].I6BZ6 M9X_8.QO\/Q-[9T?L'?!2_;I:QQ2@E]\..9SMG1^VQSGT+#;:T.6D84;#'4VN MOOSB],GB^2-HSP>TYX]9__O1^@?-J\.KWY:$5#.^;K2[Y_7&(_0N4L%7$9L+ MG7"SL4X[8W6E(G82\CQ%I0.IUNFVL+R$#R[U':DUD5.@L\'OA5K?JY\I)/JD M;DJ-Q#34)FMT%=4K9WQH?) #OOKRBZ?+Y>)Y7CN5N]/GJGNZH]\_:6/_P(?^ MF6]#]_!K99WX%0K )F1I*N6^8Z4)%MXT%7C9DJ.@J^J>?Z>&L6!O B_OG/AU MRPX+MPT<43!;!B]Z-808ZXJ$T^X"%0 M5%D4*D8X4[_T((@Y\(Y4I"T#G:IF/W@S=4U;ZQR3*>2R Y'8=?6QU8 >V FD M_7*J=B12B:P(V ;5IM(QVHTHKFTVP?,1V,S!P7$HG0A- H!I)@#6@VKT?2:M M:4-L-98E+]RLVXC4B!'U_0Y]J^%5>^Y.X8ZIH%,1>%7IM>^8GBJD!P=+.$^E M#<4)4*9[ED"=XP'$XT'4PI MN\?8Z%,C9_829K+AQQ'AC.0"C/#$UP2E>5[%?9[5C"1 X*PO(I-BVA#XG&:4 MZA*&0!WS%G;_LYPMF.F*"P%B4/>^O/FKN''4/^$^G!#]I#(0J3JW(.(6I%Z+ M@:Z#+&?JIB(T=4X;" +'_^BAU1?3/\!XY4YN.AA[WKP

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end XML 71 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 238 241 1 false 68 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://www.vrtx.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statements of Income Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - Basis of Presentation and Accounting Policies Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies Basis of Presentation and Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Revenue Recognition Sheet http://www.vrtx.com/role/RevenueRecognition Revenue Recognition Notes 10 false false R11.htm 0000011 - Disclosure - Acquired In-Process Research and Development and Other Arrangements Sheet http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangements Acquired In-Process Research and Development and Other Arrangements Notes 11 false false R12.htm 0000012 - Disclosure - Earnings Per Share Sheet http://www.vrtx.com/role/EarningsPerShare Earnings Per Share Notes 12 false false R13.htm 0000013 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 0000014 - Disclosure - Marketable Securities and Equity Investments Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments Marketable Securities and Equity Investments Notes 14 false false R15.htm 0000015 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 15 false false R16.htm 0000016 - Disclosure - Hedging Sheet http://www.vrtx.com/role/Hedging Hedging Notes 16 false false R17.htm 0000017 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories Notes 17 false false R18.htm 0000018 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms Stock-based Compensation Expense and Share Repurchase Programs Notes 18 false false R19.htm 0000019 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 0000020 - Disclosure - Commitments and Contingencies Sheet http://www.vrtx.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 20 false false R21.htm 0000021 - Disclosure - Additional Cash Flow Information Sheet http://www.vrtx.com/role/AdditionalCashFlowInformation Additional Cash Flow Information Notes 21 false false R22.htm 0000022 - Disclosure - Basis of Presentation and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies Basis of Presentation and Accounting Policies (Policies) Policies http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies 22 false false R23.htm 0000023 - Disclosure - Revenue Recognition (Tables) Sheet http://www.vrtx.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.vrtx.com/role/RevenueRecognition 23 false false R24.htm 0000024 - Disclosure - Earnings Per Share (Tables) Sheet http://www.vrtx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.vrtx.com/role/EarningsPerShare 24 false false R25.htm 0000025 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vrtx.com/role/FairValueMeasurements 25 false false R26.htm 0000026 - Disclosure - Marketable Securities and Equity Investments (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables Marketable Securities and Equity Investments (Tables) Tables http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments 26 false false R27.htm 0000027 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss 27 false false R28.htm 0000028 - Disclosure - Hedging (Tables) Sheet http://www.vrtx.com/role/HedgingTables Hedging (Tables) Tables http://www.vrtx.com/role/Hedging 28 false false R29.htm 0000029 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) Tables http://www.vrtx.com/role/Inventories 29 false false R30.htm 0000030 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables Stock-based Compensation Expense and Share Repurchase Programs (Tables) Tables http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms 30 false false R31.htm 0000031 - Disclosure - Income Taxes (Tables) Sheet http://www.vrtx.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.vrtx.com/role/IncomeTaxes 31 false false R32.htm 0000032 - Disclosure - Additional Cash Flow Information (Tables) Sheet http://www.vrtx.com/role/AdditionalCashFlowInformationTables Additional Cash Flow Information (Tables) Tables http://www.vrtx.com/role/AdditionalCashFlowInformation 32 false false R33.htm 0000033 - Disclosure - Basis of Presentation and Accounting Policies (Details) Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails Basis of Presentation and Accounting Policies (Details) Details http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies 33 false false R34.htm 0000034 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails Revenue Recognition - Disaggregation of Revenue (Details) Details 34 false false R35.htm 0000035 - Disclosure - Revenue Recognition - Additional Information (Details) Sheet http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails Revenue Recognition - Additional Information (Details) Details 35 false false R36.htm 0000036 - Disclosure - Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details) Sheet http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details) Details 36 false false R37.htm 0000037 - Disclosure - Earnings Per Share - Schedule of Computation (Details) Sheet http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails Earnings Per Share - Schedule of Computation (Details) Details 37 false false R38.htm 0000038 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) Sheet http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails Earnings Per Share - Anti-dilutive Securities (Details) Details 38 false false R39.htm 0000039 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 39 false false R40.htm 0000040 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Details 40 false false R41.htm 0000041 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Details 41 false false R42.htm 0000042 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails Marketable Securities and Equity Investments - Additional Information (Details) Details 42 false false R43.htm 0000043 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Details 43 false false R44.htm 0000044 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Details 44 false false R45.htm 0000045 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Details 45 false false R46.htm 0000046 - Disclosure - Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsNetUnrealizedGainsLossesDetails Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details) Details 46 false false R47.htm 0000047 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables 47 false false R48.htm 0000048 - Disclosure - Hedging - Additional Information (Details) Sheet http://www.vrtx.com/role/HedgingAdditionalInformationDetails Hedging - Additional Information (Details) Details 48 false false R49.htm 0000049 - Disclosure - Hedging - Notional Amount (Details) Sheet http://www.vrtx.com/role/HedgingNotionalAmountDetails Hedging - Notional Amount (Details) Details 49 false false R50.htm 0000050 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) Sheet http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails Hedging - Cash Flow Hedging Instruments (Details) Details 50 false false R51.htm 0000051 - Disclosure - Hedging - Derivative Fair Value (Details) Sheet http://www.vrtx.com/role/HedgingDerivativeFairValueDetails Hedging - Derivative Fair Value (Details) Details 51 false false R52.htm 0000052 - Disclosure - Hedging - Offsetting Derivatives (Details) Sheet http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails Hedging - Offsetting Derivatives (Details) Details 52 false false R53.htm 0000053 - Disclosure - Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesDetails Inventories (Details) Details http://www.vrtx.com/role/InventoriesTables 53 false false R54.htm 0000054 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) Details 54 false false R55.htm 0000055 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) Details 55 false false R56.htm 0000056 - Disclosure - Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.vrtx.com/role/IncomeTaxesTables 56 false false R57.htm 0000057 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.vrtx.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.vrtx.com/role/CommitmentsandContingencies 57 false false R58.htm 0000058 - Disclosure - Additional Cash Flow Information (Details) Sheet http://www.vrtx.com/role/AdditionalCashFlowInformationDetails Additional Cash Flow Information (Details) Details http://www.vrtx.com/role/AdditionalCashFlowInformationTables 58 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept ResearchAndDevelopmentInProcess in us-gaap/2022 used in 5 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. vrtx-20230331.htm 4 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, us-gaap:DerivativeTermOfContract - vrtx-20230331.htm 4 vrtx-20230331.htm a2023q110-qexhibit311.htm a2023q110-qexhibit312.htm a2023q110-qexhibit321.htm vrtx-20230331.xsd vrtx-20230331_cal.xml vrtx-20230331_def.xml vrtx-20230331_lab.xml vrtx-20230331_pre.xml vrtx-20230331_g1.gif http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vrtx-20230331.htm": { "axisCustom": 1, "axisStandard": 20, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 746, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 238, "dts": { "calculationLink": { "local": [ "vrtx-20230331_cal.xml" ] }, "definitionLink": { "local": [ "vrtx-20230331_def.xml" ] }, "inline": { "local": [ "vrtx-20230331.htm" ] }, "labelLink": { "local": [ "vrtx-20230331_lab.xml" ] }, "presentationLink": { "local": [ "vrtx-20230331_pre.xml" ] }, "schema": { "local": [ "vrtx-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 418, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 1, "http://xbrl.sec.gov/dei/2022": 6, "total": 7 }, "keyCustom": 18, "keyStandard": 223, "memberCustom": 13, "memberStandard": 53, "nsprefix": "vrtx", "nsuri": "http://www.vrtx.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.vrtx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Revenue Recognition", "menuCat": "Notes", "order": "10", "role": "http://www.vrtx.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Acquired In-Process Research and Development and Other Arrangements", "menuCat": "Notes", "order": "11", "role": "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangements", "shortName": "Acquired In-Process Research and Development and Other Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Earnings Per Share", "menuCat": "Notes", "order": "12", "role": "http://www.vrtx.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "13", "role": "http://www.vrtx.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Marketable Securities and Equity Investments", "menuCat": "Notes", "order": "14", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments", "shortName": "Marketable Securities and Equity Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "menuCat": "Notes", "order": "15", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss", "shortName": "Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Hedging", "menuCat": "Notes", "order": "16", "role": "http://www.vrtx.com/role/Hedging", "shortName": "Hedging", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Inventories", "menuCat": "Notes", "order": "17", "role": "http://www.vrtx.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs", "menuCat": "Notes", "order": "18", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "19", "role": "http://www.vrtx.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Statements of Income", "menuCat": "Statements", "order": "2", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "shortName": "Condensed Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "20", "role": "http://www.vrtx.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Additional Cash Flow Information", "menuCat": "Notes", "order": "21", "role": "http://www.vrtx.com/role/AdditionalCashFlowInformation", "shortName": "Additional Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Basis of Presentation and Accounting Policies (Policies)", "menuCat": "Policies", "order": "22", "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Revenue Recognition (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.vrtx.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Earnings Per Share (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.vrtx.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.vrtx.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Marketable Securities and Equity Investments (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables", "shortName": "Marketable Securities and Equity Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Hedging (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.vrtx.com/role/HedgingTables", "shortName": "Hedging (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Inventories (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.vrtx.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income", "menuCat": "Statements", "order": "3", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.vrtx.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Additional Cash Flow Information (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.vrtx.com/role/AdditionalCashFlowInformationTables", "shortName": "Additional Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Basis of Presentation and Accounting Policies (Details)", "menuCat": "Details", "order": "33", "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails", "shortName": "Basis of Presentation and Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)", "menuCat": "Details", "order": "34", "role": "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i42ba7520aa3742e08869dd02bc97113c_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Revenue Recognition - Additional Information (Details)", "menuCat": "Details", "order": "35", "role": "http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails", "shortName": "Revenue Recognition - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentInProcess", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)", "menuCat": "Details", "order": "36", "role": "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "shortName": "Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "id96f32d9bccb4f5ba68093ece409879a_D20190101-20191231", "decimals": "INF", "lang": "en-US", "name": "vrtx:CollaborativeArrangementRightToLicenseNumberOfTargets", "reportCount": 1, "unique": true, "unitRef": "target", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Earnings Per Share - Schedule of Computation (Details)", "menuCat": "Details", "order": "37", "role": "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "shortName": "Earnings Per Share - Schedule of Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i308dad806e734f57ae8103ccbe049621_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details)", "menuCat": "Details", "order": "38", "role": "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "shortName": "Earnings Per Share - Anti-dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i308dad806e734f57ae8103ccbe049621_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Fair Value Measurements - Additional Information (Details)", "menuCat": "Details", "order": "39", "role": "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i0a7cd8e256674846a711534e9b618407_I20230331", "decimals": "-5", "lang": "en-US", "name": "vrtx:BusinessCombinationRemainingMilestonePayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "menuCat": "Statements", "order": "4", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "ibb59fbd9724a4ceca9f28e9783d88ddd_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "menuCat": "Details", "order": "40", "role": "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "shortName": "Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "ibb59fbd9724a4ceca9f28e9783d88ddd_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i108d7bd86abe4e58838391cedbbc7af4_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "menuCat": "Details", "order": "41", "role": "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails", "shortName": "Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i108d7bd86abe4e58838391cedbbc7af4_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details)", "menuCat": "Details", "order": "42", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "shortName": "Marketable Securities and Equity Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "vrtx:CashEquivalentsAndDebtSecuritiesAvailableForSale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "menuCat": "Details", "order": "43", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails", "shortName": "Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "vrtx:CashEquivalentsAndDebtSecuritiesAvailableForSale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "menuCat": "Details", "order": "44", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "menuCat": "Details", "order": "45", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details)", "menuCat": "Details", "order": "46", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsNetUnrealizedGainsLossesDetails", "shortName": "Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i108d7bd86abe4e58838391cedbbc7af4_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "menuCat": "Details", "order": "47", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i23fe0afde1cd458bb33f64f4dd947b25_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Hedging - Additional Information (Details)", "menuCat": "Details", "order": "48", "role": "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "shortName": "Hedging - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i23fe0afde1cd458bb33f64f4dd947b25_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i3d8da6988daf4ab5a3cc36305fd391d2_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Hedging - Notional Amount (Details)", "menuCat": "Details", "order": "49", "role": "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "shortName": "Hedging - Notional Amount (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i3d8da6988daf4ab5a3cc36305fd391d2_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "5", "role": "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details)", "menuCat": "Details", "order": "50", "role": "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "shortName": "Hedging - Cash Flow Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "iac4a35b6dee84645b2e1cba9306d6c09_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i3d8da6988daf4ab5a3cc36305fd391d2_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Hedging - Derivative Fair Value (Details)", "menuCat": "Details", "order": "51", "role": "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "shortName": "Hedging - Derivative Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i45dea239c6874c28ae70eafc6d0b2044_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i3d8da6988daf4ab5a3cc36305fd391d2_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Hedging - Offsetting Derivatives (Details)", "menuCat": "Details", "order": "52", "role": "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "shortName": "Hedging - Offsetting Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i3d8da6988daf4ab5a3cc36305fd391d2_I20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeAssetFairValueGrossLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Inventories (Details)", "menuCat": "Details", "order": "53", "role": "http://www.vrtx.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details)", "menuCat": "Details", "order": "54", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i31e9bb0a22cd4e68b09b3fbafbd81752_I20230228", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details)", "menuCat": "Details", "order": "55", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i31e9bb0a22cd4e68b09b3fbafbd81752_I20230228", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "56", "role": "http://www.vrtx.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:IndemnificationClaims", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "57", "role": "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:IndemnificationClaims", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Additional Cash Flow Information (Details)", "menuCat": "Details", "order": "58", "role": "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "shortName": "Additional Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "ic1af14e7def84e3590f8cdcf9d63aa32_I20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i184cf5afd6cd4fa685060fb920896ba9_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "ie9644a4268654e9c8ac1040d8f7e79c9_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "menuCat": "Statements", "order": "7", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "ie9644a4268654e9c8ac1040d8f7e79c9_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "8", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Basis of Presentation and Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies", "shortName": "Basis of Presentation and Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20230331.htm", "contextRef": "i92c3c9bfd59749f283eff9b369a6a244_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 68, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "currency_AUD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Australia, Dollars", "terseLabel": "Australian dollar" } } }, "localname": "AUD", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Canada, Dollars", "terseLabel": "Canadian dollar" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Switzerland, Francs", "terseLabel": "Swiss Franc" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "British pound sterling" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by currency.", "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "stringItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r263", "r264", "r265", "r266", "r303", "r430", "r446", "r469", "r470", "r498", "r509", "r514", "r555", "r571", "r572", "r573", "r574", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r263", "r264", "r265", "r266", "r303", "r430", "r446", "r469", "r470", "r498", "r509", "r514", "r555", "r571", "r572", "r573", "r574", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r223", "r431", "r499", "r512", "r550", "r551", "r556", "r579" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r223", "r431", "r499", "r512", "r550", "r551", "r556", "r579" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r263", "r264", "r265", "r266", "r296", "r303", "r331", "r332", "r333", "r406", "r430", "r446", "r469", "r470", "r498", "r509", "r514", "r549", "r555", "r572", "r573", "r574", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r263", "r264", "r265", "r266", "r296", "r303", "r331", "r332", "r333", "r406", "r430", "r446", "r469", "r470", "r498", "r509", "r514", "r549", "r555", "r572", "r573", "r574", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": { "auth_ref": [ "r534", "r588" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.", "label": "Condensed Cash Flow Statement [Table Text Block]", "terseLabel": "Schedule of Additional Cash Flow Information" } } }, "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r224", "r225", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r471", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r500", "r513", "r556" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r224", "r225", "r456", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r471", "r472", "r500", "r513", "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r11", "r511" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r227", "r228" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r154", "r161", "r162", "r369", "r489", "r526" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "verboseLabel": "On Foreign Currency Forward Contracts" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r149", "r150", "r151", "r154", "r161", "r162", "r526" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "On Available-For-Sale Debt Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r28", "r29", "r30", "r141", "r440", "r451", "r452" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r160", "r161", "r389", "r390", "r391", "r392", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r27", "r30", "r86", "r399", "r447", "r448", "r526", "r527", "r528", "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "verboseLabel": "Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r26", "r30", "r86", "r161", "r162", "r390", "r391", "r392", "r393", "r394", "r526" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment", "verboseLabel": "Foreign Currency Forward Contract" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Additional Cash Flow Information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r3" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r341", "r342", "r343", "r535", "r536", "r537", "r562" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Common stock withheld for employee tax obligations" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r76", "r77", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r336" ], "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense included in costs and expenses" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, after Tax", "totalLabel": "Total stock-based compensation expense, net of tax" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r506", "r540" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-Backed Securities [Member]", "terseLabel": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r113", "r123", "r139", "r174", "r214", "r217", "r221", "r242", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r367", "r370", "r387", "r511", "r553", "r554", "r569" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r134", "r143", "r174", "r242", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r367", "r370", "r387", "r511", "r553", "r554", "r569" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r108" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Financial instruments carried at fair value (asset positions):" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r63" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r64" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r230", "r249" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": 1.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]", "terseLabel": "Total marketable debt securities" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r65", "r233", "r439" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Matures after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r65", "r232", "r438" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Matures within one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r62", "r229", "r249", "r433" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "totalLabel": "Total", "verboseLabel": "Debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r95", "r99" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Time deposits" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r363", "r531" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "netLabel": "Decrease in fair value of contingent consideration", "terseLabel": "Decrease in fair value of contingent payments", "verboseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r80", "r81", "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Balance at March 31, 2023", "periodStartLabel": "Balance at December 31, 2022" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r80", "r82" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "negatedLabel": "Other current liabilities, contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, measurement input (as a percent)" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r80", "r82" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 4.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "negatedTerseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r453", "r454", "r511", "r524" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r50", "r136", "r481" ], "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash equivalents:", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Marketable Securities and Equity Investments" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r45", "r50", "r52" ], "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r45", "r109" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "verboseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Acquired In-Process Research and Development and Other Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r557", "r564" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r17", "r115", "r127" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r70", "r261", "r262", "r459", "r552" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r535", "r536", "r562" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r2", "r72" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r2", "r511" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value; 500,000,000 shares authorized, 257,509,761 and 257,011,628 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r31", "r157", "r159", "r164", "r435", "r442" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r40", "r163", "r434", "r441" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r281", "r282", "r293" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r506", "r508", "r580" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r36", "r431" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r35" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (as a percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r231", "r249", "r254", "r255" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Allowance for credit loss for available-for-sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r237", "r252", "r494" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Unrealized loss position for greater than twelve months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r236", "r250", "r494" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Debt securities fair value, unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r345", "r346" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r48", "r212" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r19", "r25", "r97" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset", "negatedTerseLabel": "Gross Amounts Offset" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r21", "r23" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Legal Offset" } } }, "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r20", "r23", "r146" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "negatedTerseLabel": "Gross Amounts Not Offset" } } }, "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r145", "r148", "r386", "r488" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "totalLabel": "Gross Amounts Presented" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r145" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivative asset current, foreign currency forward contracts" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsNoncurrent": { "auth_ref": [ "r145" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Noncurrent", "terseLabel": "Other assets, foreign currency forward contracts" } } }, "localname": "DerivativeAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r24", "r97", "r110", "r144", "r488" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Gross Amounts Recognized", "verboseLabel": "Total assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r24", "r97", "r110", "r144", "r488" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "negatedLabel": "Total liabilities", "negatedTerseLabel": "Gross Amounts Recognized" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r96", "r98", "r101", "r102", "r488" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r107", "r373" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Hedging" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/Hedging" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r93", "r96", "r101" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r93", "r96", "r101", "r102", "r105", "r106", "r372" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r145", "r148", "r386", "r488" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "negatedTotalLabel": "Gross Amounts Presented" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r145" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "negatedTerseLabel": "Other current liabilities, foreign currency forward contracts" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r145" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "negatedTerseLabel": "Other long-term liabilities, foreign currency forward contracts" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "auth_ref": [ "r19", "r25", "r97", "r487" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset", "terseLabel": "Gross Amounts Offset" } } }, "localname": "DerivativeLiabilityFairValueGrossAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r21", "r23" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "negatedTotalLabel": "Legal Offset" } } }, "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r20", "r23", "r146" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "terseLabel": "Gross Amounts Not Offset" } } }, "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r559", "r560" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount of foreign currency forward contract" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r88", "r90", "r91", "r93", "r94", "r100", "r101", "r103", "r104", "r106", "r373" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Derivative term" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedging instruments", "verboseLabel": "Designated as Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r292", "r499", "r500", "r501", "r502", "r503", "r504", "r505" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r308", "r338", "r339", "r340", "r344", "r510" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation Expense and Share Repurchase Programs" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r165", "r182", "r183", "r184", "r185", "r186", "r190", "r192", "r197", "r198", "r199", "r203", "r375", "r376", "r436", "r443", "r491" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income per common share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r165", "r182", "r183", "r184", "r185", "r186", "r192", "r197", "r198", "r199", "r203", "r375", "r376", "r436", "r443", "r491" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per common share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r200", "r201", "r202", "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r388" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of changes in exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "negatedTerseLabel": "Stock-based compensation expense related to inventories" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r336" ], "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "negatedTerseLabel": "Income tax effect" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP share issuances" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r72", "r132", "r160", "r161", "r162", "r177", "r178", "r179", "r181", "r187", "r189", "r205", "r243", "r280", "r341", "r342", "r343", "r353", "r354", "r374", "r389", "r390", "r391", "r392", "r393", "r394", "r399", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r140", "r385", "r483" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Fair Value" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]", "terseLabel": "Corporate equity securities" } } }, "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity Securities, FV-NI, Cost", "terseLabel": "Amortized Cost" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r444", "r544" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedTerseLabel": "(Gains) losses on equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "auth_ref": [ "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Loss", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "EquitySecuritiesFvNiUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r66", "r122", "r515", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Corporate equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "verboseLabel": "Equity securities without readily determinable fair value, amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r377", "r378", "r383" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r276", "r297", "r298", "r299", "r300", "r301", "r302", "r378", "r403", "r404", "r405", "r496", "r497", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r377", "r378", "r380", "r381", "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Fair Value by Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r276", "r297", "r302", "r378", "r403", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r276", "r297", "r302", "r378", "r404", "r496", "r497", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r276", "r297", "r298", "r299", "r300", "r301", "r302", "r378", "r405", "r496", "r497", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r276", "r297", "r298", "r299", "r300", "r301", "r302", "r403", "r404", "r405", "r496", "r497", "r506", "r507", "r508" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r382", "r384" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring Basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r396" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r397", "r398" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments on finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r234", "r235", "r244", "r245", "r246", "r247", "r248", "r251", "r253", "r256", "r277", "r279", "r373", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r494", "r541", "r542", "r543", "r581", "r582", "r583", "r584", "r585", "r586", "r587" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "negatedTotalLabel": "Total financial liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign currency forward contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r137", "r258", "r432", "r495", "r511", "r546", "r547" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r93", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r33", "r111", "r117", "r129", "r214", "r216", "r220", "r222", "r437", "r493" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before provision for income taxes", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "verboseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "verboseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r175", "r349", "r351", "r352", "r355", "r357", "r359", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r176", "r188", "r189", "r213", "r347", "r356", "r358", "r445" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r531" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements": { "auth_ref": [ "r193", "r194", "r199" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements", "terseLabel": "Employee stock purchase program (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r193", "r194", "r195", "r199", "r307" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Share-based payment arrangements (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r68", "r69" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r119" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r169", "r172", "r173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r67", "r484" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r142", "r482", "r511" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vrtx.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r67", "r486" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r67", "r485" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r38" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letters of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r13", "r174", "r242", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r368", "r370", "r371", "r387", "r492", "r553", "r569", "r570" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r7", "r114", "r126", "r511", "r533", "r545", "r565" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r15", "r135", "r174", "r242", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r368", "r370", "r371", "r387", "r511", "r553", "r569", "r570" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Financial instruments carried at fair value (liability positions):" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r12", "r532" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r116" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "terseLabel": "Marketable securities:" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Long-term marketable securities" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r171" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r171" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r45", "r46", "r49" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r34", "r49", "r118", "r128", "r133", "r155", "r158", "r162", "r174", "r180", "r182", "r183", "r184", "r185", "r188", "r189", "r196", "r214", "r216", "r220", "r222", "r242", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r376", "r387", "r493", "r553" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net income", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Total product revenues outside of the United States" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not designated as hedging instruments", "verboseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r30", "r32" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsTableTextBlock": { "auth_ref": [ "r22", "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Assets [Table Text Block]", "terseLabel": "Schedule of Offsetting Assets" } } }, "localname": "OffsettingAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OffsettingDerivativeAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offsetting Derivative Assets [Abstract]", "terseLabel": "Offsetting Derivative Assets [Abstract]" } } }, "localname": "OffsettingDerivativeAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offsetting Derivative Liabilities [Abstract]", "terseLabel": "Offsetting Derivative Liabilities [Abstract]" } } }, "localname": "OffsettingDerivativeLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "auth_ref": [ "r22", "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Liabilities [Table Text Block]", "terseLabel": "Schedule of Offsetting Liabilities" } } }, "localname": "OffsettingLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r214", "r216", "r220", "r222", "r493" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r396" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r395" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r53", "r54", "r59", "r87" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r95", "r105" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets", "verboseLabel": "Other Assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r138" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r83", "r84", "r85" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized holding gains (losses) on marketable securities, net of tax of $(0.8) and zero, respectively" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r83", "r84", "r85" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "auth_ref": [ "r149", "r150", "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax", "terseLabel": "Unrealized holding gains (losses) on marketable securities, tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r152" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Unrealized (losses) gains on foreign currency forward contracts, net of tax of $7.4 and $(2.2), respectively" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "auth_ref": [ "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "terseLabel": "Unrealized gains (losses) on foreign currency forward contracts, tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r83", "r84", "r85", "r156", "r159" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss, net of tax", "totalLabel": "Total other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r14", "r511" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r49" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "verboseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r44" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r168" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Payments in connection with common stock withheld for employee tax obligations" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r41", "r61", "r166" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchases of available-for-sale debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": { "auth_ref": [ "r170", "r239" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.", "label": "Payments to Acquire Equity Securities, FV-NI", "negatedLabel": "Investment in equity securities" } } }, "localname": "PaymentsToAcquireEquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r42" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r1", "r278" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r1", "r278" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r1", "r511" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r525" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r43", "r75" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "terseLabel": "Issuances of common stock under benefit plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r61", "r166", "r167" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "terseLabel": "Maturities of available-for-sale debt securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r529", "r530" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r548", "r568" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r30", "r32" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r78", "r131", "r577" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r78" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Acquired in-process research and development expenses" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r50", "r52", "r112", "r124", "r136" ], "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r130", "r455", "r457", "r458" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "terseLabel": "Investments with restrictions" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "verboseLabel": "Restricted stock units (including PSUs)" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units (including PSUs)", "verboseLabel": "Unvested restricted stock units (including PSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r4", "r73", "r125", "r450", "r452", "r511" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r132", "r177", "r178", "r179", "r181", "r187", "r189", "r243", "r341", "r342", "r343", "r353", "r354", "r374", "r447", "r449" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r210", "r211", "r215", "r218", "r219", "r223", "r224", "r226", "r291", "r292", "r431" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Product revenues, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r30", "r566", "r567" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potential Gross Common Equivalent Shares" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "verboseLabel": "Schedule of Fair Value of Our Contingent Consideration Liabilities" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Schedule of Cash Equivalents and Marketable Securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Provision for (Benefits from) Income Taxes and Effective Tax rates" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-based Compensation Expense by Line Item" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r377", "r378" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets Subject to Fair Value Measurements" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "terseLabel": "Schedule of Foreign Exchange Contracts" } } }, "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r0", "r8", "r9", "r10" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories by Type" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedging Instruments" } } }, "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r304", "r306", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR Loan" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r37" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r335" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "terseLabel": "Total stock-based compensation expense included in \u201cTotal costs and expenses\u201d" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Common stock withheld for employee tax obligations (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r18", "r72", "r132", "r160", "r161", "r162", "r177", "r178", "r179", "r181", "r187", "r189", "r205", "r243", "r280", "r341", "r342", "r343", "r353", "r354", "r374", "r389", "r390", "r391", "r392", "r393", "r394", "r399", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]", "verboseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "verboseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r177", "r178", "r179", "r205", "r431" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "terseLabel": "Issuance of common stock under benefit plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "terseLabel": "Issuance of common stock under benefit plans" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Number of shares authorized to be repurchased" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock repurchase program, remaining amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r1", "r2", "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchase of common stock (in shares)", "terseLabel": "Shares repurchased (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r1", "r2", "r72", "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchase of common stock", "verboseLabel": "Value of shares repurchased" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r2", "r5", "r6", "r60", "r511", "r533", "r545", "r565" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r234", "r235", "r277", "r279", "r373", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r541", "r542", "r543", "r581", "r582", "r583", "r584", "r585", "r586", "r587" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r557", "r578" ], "lang": { "en-us": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "terseLabel": "Government-sponsored enterprise securities", "verboseLabel": "Government-sponsored enterprise securities" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r490", "r506", "r508", "r578" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "terseLabel": "Net unrealized gains (losses)" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsNetUnrealizedGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "terseLabel": "Schedule of Company's Net Unrealized Gains (Losses) on Corporate Equity Securities" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Net unrecognized tax benefits which would affect the tax rate if recognized" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r56", "r57", "r58", "r206", "r207", "r208", "r209" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]", "terseLabel": "Effect of potentially dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r191", "r199" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Shares used in per share calculations:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r190", "r199" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted-average common shares outstanding (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "vrtx_BusinessCombinationRemainingMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Remaining Milestone Payment", "label": "Business Combination, Remaining Milestone Payment", "terseLabel": "Remaining milestone payment" } } }, "localname": "BusinessCombinationRemainingMilestonePayment", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CRISPRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR", "label": "CRISPR [Member]", "terseLabel": "CRISPR" } } }, "localname": "CRISPRMember", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CRISPRT1DMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR T1D", "label": "CRISPR T1D [Member]", "terseLabel": "CRISPR T1D" } } }, "localname": "CRISPRT1DMember", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CRISPRTherapeuticsAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR Therapeutics AG", "label": "CRISPR Therapeutics AG [Member]", "terseLabel": "CRISPR Therapeutics" } } }, "localname": "CRISPRTherapeuticsAGMember", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CRSIPRJDCAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR Amended and restated the Original CTX001 JDCA", "label": "CRSIPR JDCA [Member]", "terseLabel": "CRISPR JDCA" } } }, "localname": "CRSIPRJDCAMember", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CashEquivalentsAndDebtSecuritiesAvailableForSale": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash Equivalents And Debt Securities, Available for Sale", "label": "Cash Equivalents And Debt Securities, Available for Sale", "totalLabel": "Amortized Cost" } } }, "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSale", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "vrtx_CashEquivalentsAndDebtSecuritiesAvailableForSale", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash Equivalents And Debt Securities, Available for Sale, Fair Value Disclosure", "label": "Cash Equivalents And Debt Securities, Available for Sale, Fair Value Disclosure", "terseLabel": "Fair Value" } } }, "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CashEquivalentsAndDebtSecuritiesAvailableForSaleGrossUnrealizedGains": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "vrtx_CashEquivalentsAndDebtSecuritiesAvailableForSale", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash Equivalents And Debt Securities, Available for Sale, Gross Unrealized Gains", "label": "Cash Equivalents And Debt Securities, Available for Sale, Gross Unrealized Gains", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleGrossUnrealizedGains", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent", "label": "Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent", "terseLabel": "Allocation of net profits and net losses, percent" } } }, "localname": "CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vrtx_CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized.", "label": "Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum", "terseLabel": "Collaborative arrangement, development and regulatory potential milestone payments maximum" } } }, "localname": "CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementRightToLicenseNumberOfTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Right To License, Number Of Targets", "label": "Collaborative Arrangement, Right To License, Number Of Targets", "terseLabel": "Collaborative arrangement, right to exclusively license, number of targets" } } }, "localname": "CollaborativeArrangementRightToLicenseNumberOfTargets", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrtx_CollaborativeArrangementUpFrontLicenseFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement Up-front License Fee", "label": "Collaborative Arrangement Up-front License Fee", "terseLabel": "Up-front payment" } } }, "localname": "CollaborativeArrangementUpFrontLicenseFee", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementsByAgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant terms of collaboration arrangements, by individual agreement.", "label": "Collaborative Arrangements by Agreement [Axis]", "terseLabel": "Collaborative Arrangements by Agreement [Axis]" } } }, "localname": "CollaborativeArrangementsByAgreementAxis", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vrtx_CollaborativeArrangementsByAgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements by Agreement [Domain]", "label": "Collaborative Arrangements by Agreement [Domain]", "terseLabel": "Collaborative Arrangements by Agreement [Domain]" } } }, "localname": "CollaborativeArrangementsByAgreementDomain", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_ContingentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent Liabilities", "label": "Contingent Liabilities", "terseLabel": "Contingent liabilities" } } }, "localname": "ContingentLiabilities", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtCovenantConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants.", "label": "Debt Covenant, Consolidated Leverage Ratio", "terseLabel": "Debt covenant, consolidated leverage ratio" } } }, "localname": "DebtCovenantConsolidatedLeverageRatio", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtCovenantIncreaseInConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant, Increase In Consolidated Leverage Ratio", "label": "Debt Covenant, Increase In Consolidated Leverage Ratio", "terseLabel": "Debt covenant, increase in consolidated leverage ratio" } } }, "localname": "DebtCovenantIncreaseInConsolidatedLeverageRatio", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtandEquitySecuritiesCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Cost", "label": "Debt and Equity Securities, Cost", "totalLabel": "Amortized Cost" } } }, "localname": "DebtandEquitySecuritiesCost", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesFairValue": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Fair Value", "label": "Debt and Equity Securities, Fair Value", "terseLabel": "Fair Value" } } }, "localname": "DebtandEquitySecuritiesFairValue", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesUnrealizedGain": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Unrealized Gain", "label": "Debt and Equity Securities, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "DebtandEquitySecuritiesUnrealizedGain", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesUnrealizedLoss": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Unrealized Loss", "label": "Debt and Equity Securities, Unrealized Loss", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "DebtandEquitySecuritiesUnrealizedLoss", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_EntradaTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entrada Therapeutics", "label": "Entrada Therapeutics [Member]", "terseLabel": "Entrada Therapeutics" } } }, "localname": "EntradaTherapeuticsMember", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_IndemnificationClaims": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of indemnification claims currently outstanding", "label": "Indemnification Claims", "terseLabel": "Indemnification claims" } } }, "localname": "IndemnificationClaims", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_KalydecoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KALYDECO inventories, net", "label": "KALYDECO [Member]", "terseLabel": "KALYDECO" } } }, "localname": "KalydecoMember", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increased borrowing capacity available in the future.", "label": "Line Of Credit Facility Additional Borrowing Capacity", "terseLabel": "Line of credit facility additional borrowing capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_MarketableSecuritiesAndOtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable Securities And Other Noncurrent Assets", "label": "Marketable Securities And Other Noncurrent Assets [Member]", "terseLabel": "Total marketable debt securities" } } }, "localname": "MarketableSecuritiesAndOtherNoncurrentAssetsMember", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable Securities [Member]", "label": "Marketable Securities [Member]", "verboseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_MarketableSecuritiesNoncurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable Securities, Noncurrent", "label": "Marketable Securities, Noncurrent [Member]", "terseLabel": "Long-term marketable securities" } } }, "localname": "MarketableSecuritiesNoncurrentMember", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_ORKAMBIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ORKAMBI [Member]", "label": "ORKAMBI [Member]", "terseLabel": "ORKAMBI" } } }, "localname": "ORKAMBIMember", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_OtherNonU.S.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other, Non U.S. [Member]", "label": "Other, Non U.S. [Member]", "terseLabel": "Other" } } }, "localname": "OtherNonU.S.Member", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_PaymentToAcquireCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment To Acquire Common Stock", "label": "Payment To Acquire Common Stock", "terseLabel": "Purchase of common stock" } } }, "localname": "PaymentToAcquireCommonStock", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_SYMDEKOSYMKEVIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SYMDEKO/SYMKEVI [Member]", "label": "SYMDEKO/SYMKEVI [Member]", "terseLabel": "SYMDEKO/SYMKEVI" } } }, "localname": "SYMDEKOSYMKEVIMember", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items]", "terseLabel": "Summary of cash, cash equivalents and marketable securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of the cash and cash equivalents and available-for-sale investments held by the entity.", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]", "terseLabel": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_ShareBasedCompensationAllocationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Share-based Compensation Allocation [Abstract]", "terseLabel": "Stock-based compensation expense:" } } }, "localname": "ShareBasedCompensationAllocationAbstract", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "vrtx_TRIKAFTAKAFTRIOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TRIKAFTA/KAFTRIO [Member]", "label": "TRIKAFTA/KAFTRIO [Member]", "terseLabel": "TRIKAFTA/KAFTRIO" } } }, "localname": "TRIKAFTAKAFTRIOMember", "nsuri": "http://www.vrtx.com/20230331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(ii)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(i)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Footnote 11(c)))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r519": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r521": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r522": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r523": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 77 0000875320-23-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-23-000012-xbrl.zip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end